
<html lang="en"     class="pb-page"  data-request-id="4259cf5f-f2ee-4b16-b2d3-4bc6a8f8451d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2015.58.issue-10;article:article:10.1021/acs.jmedchem.5b00067;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells" /></meta><meta name="dc.Creator" content="James R.  Henry" /></meta><meta name="dc.Creator" content="Michael D.  Kaufman" /></meta><meta name="dc.Creator" content="Sheng-Bin  Peng" /></meta><meta name="dc.Creator" content="Yu Mi  Ahn" /></meta><meta name="dc.Creator" content="Timothy M.  Caldwell" /></meta><meta name="dc.Creator" content="Lakshminarayana  Vogeti" /></meta><meta name="dc.Creator" content="Hanumaiah  Telikepalli" /></meta><meta name="dc.Creator" content="Wei-Ping  Lu" /></meta><meta name="dc.Creator" content="Molly M.  Hood" /></meta><meta name="dc.Creator" content="Thomas J.  Rutkoski" /></meta><meta name="dc.Creator" content="Bryan D.  Smith" /></meta><meta name="dc.Creator" content="Subha  Vogeti" /></meta><meta name="dc.Creator" content="David  Miller" /></meta><meta name="dc.Creator" content="Scott C.  Wise" /></meta><meta name="dc.Creator" content="Lawrence  Chun" /></meta><meta name="dc.Creator" content="Xiaoyi  Zhang" /></meta><meta name="dc.Creator" content="Youyan  Zhang" /></meta><meta name="dc.Creator" content="Lisa  Kays" /></meta><meta name="dc.Creator" content="Philip A.  Hipskind" /></meta><meta name="dc.Creator" content="Aaron D.  Wrobleski" /></meta><meta name="dc.Creator" content="Karen L.  Lobb" /></meta><meta name="dc.Creator" content="Julia M.  Clay" /></meta><meta name="dc.Creator" content="Jeffrey D.  Cohen" /></meta><meta name="dc.Creator" content="Jennie L.  Walgren" /></meta><meta name="dc.Creator" content="Denis  McCann" /></meta><meta name="dc.Creator" content="Phenil  Patel" /></meta><meta name="dc.Creator" content="David K.  Clawson" /></meta><meta name="dc.Creator" content="Sherry  Guo" /></meta><meta name="dc.Creator" content="Danalyn  Manglicmot" /></meta><meta name="dc.Creator" content="Chris  Groshong" /></meta><meta name="dc.Creator" content="Cheyenne  Logan" /></meta><meta name="dc.Creator" content="James J.  Starling" /></meta><meta name="dc.Creator" content="Daniel L.  Flynn" /></meta><meta name="dc.Description" content="The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. The kinase inhibitors vemurafenib and dabrafenib, which target onc..." /></meta><meta name="Description" content="The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. The kinase inhibitors vemurafenib and dabrafenib, which target onc..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 12, 2015" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b00067" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00067" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b00067" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b00067" /></link>
        
    
    

<title>Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b00067" /></meta><meta property="og:title" content="Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0016.jpeg" /></meta><meta property="og:description" content="The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic BRAF V600E, have shown significant clinical efficacy in melanoma patients harboring this mutation. Because of paradoxical pathway activation, both agents were demonstrated to promote growth and metastasis of tumor cells with RAS mutations in preclinical models and are contraindicated for treatment of cancer patients with BRAF WT background, including patients with KRAS or NRAS mutations. In order to eliminate the issues associated with paradoxical MAPK pathway activation and to provide therapeutic benefit to patients with RAS mutant cancers, we sought to identify a compound not only active against BRAF V600E but also wild type BRAF and CRAF. On the basis of its superior in vitro and in vivo profile, compound 13 was selected for further development and is currently being evaluated in phase I clinical studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b00067"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b00067">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b00067&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b00067&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b00067&amp;href=/doi/10.1021/acs.jmedchem.5b00067" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4165-4179</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm5013227" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/jm501702q" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+R.++Henry">James R. Henry</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+D.++Kaufman">Michael D. Kaufman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sheng-Bin++Peng">Sheng-Bin Peng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yu+Mi++Ahn">Yu Mi Ahn</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+M.++Caldwell">Timothy M. Caldwell</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lakshminarayana++Vogeti">Lakshminarayana Vogeti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hanumaiah++Telikepalli">Hanumaiah Telikepalli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wei-Ping++Lu">Wei-Ping Lu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Molly+M.++Hood">Molly M. Hood</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+J.++Rutkoski">Thomas J. Rutkoski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bryan+D.++Smith">Bryan D. Smith</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Subha++Vogeti">Subha Vogeti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Miller">David Miller</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott+C.++Wise">Scott C. Wise</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lawrence++Chun">Lawrence Chun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoyi++Zhang">Xiaoyi Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Youyan++Zhang">Youyan Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Kays">Lisa Kays</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip+A.++Hipskind">Philip A. Hipskind</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Aaron+D.++Wrobleski">Aaron D. Wrobleski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karen+L.++Lobb">Karen L. Lobb</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julia+M.++Clay">Julia M. Clay</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+D.++Cohen">Jeffrey D. Cohen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennie+L.++Walgren">Jennie L. Walgren</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Denis++McCann">Denis McCann</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Phenil++Patel">Phenil Patel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+K.++Clawson">David K. Clawson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sherry++Guo">Sherry Guo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Danalyn++Manglicmot">Danalyn Manglicmot</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chris++Groshong">Chris Groshong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cheyenne++Logan">Cheyenne Logan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+J.++Starling">James J. Starling</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+L.++Flynn">Daniel L. Flynn</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Eli Lilly and Company, Indianapolis, Indiana 46285, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Emerald Biostructures, Bainbridge Island, Washington 98110, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 317-433-4392. E-mail: <a href="/cdn-cgi/l/email-protection#b0dac2d8d5dec2c9f0dcd9dcdcc99ed3dfdd"><span class="__cf_email__" data-cfemail="eb8199838e859992ab8782878792c5888486">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00067&amp;href=/doi/10.1021%2Facs.jmedchem.5b00067" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4165–4179</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 12, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 January 2015</li><li><span class="item_label"><b>Published</b> online</span>12 May 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 May 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b00067" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00067</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4165%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJames%2BR.%2BHenry%252C%2BMichael%2BD.%2BKaufman%252C%2BSheng-Bin%2BPeng%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D10%26contentID%3Dacs.jmedchem.5b00067%26title%3DDiscovery%2Bof%2B1-%25283%252C3-Dimethylbutyl%2529-3-%25282-fluoro-4-methyl-5-%25287-methyl-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-6-yl%2529phenyl%2529urea%2B%2528LY3009120%2529%2Bas%2Ba%2BPan-RAF%2BInhibitor%2Bwith%2BMinimal%2BParadoxical%2BActivation%2Band%2BActivity%2Bagainst%2BBRAF%2Bor%2BRAS%2BMutant%2BTumor%2BCells%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4179%26publicationDate%3DMay%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b00067"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6223</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">50</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b00067" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;R. Henry&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;D. Kaufman&quot;},{&quot;first_name&quot;:&quot;Sheng-Bin&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Mi Ahn&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;M. Caldwell&quot;},{&quot;first_name&quot;:&quot;Lakshminarayana&quot;,&quot;last_name&quot;:&quot;Vogeti&quot;},{&quot;first_name&quot;:&quot;Hanumaiah&quot;,&quot;last_name&quot;:&quot;Telikepalli&quot;},{&quot;first_name&quot;:&quot;Wei-Ping&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Molly&quot;,&quot;last_name&quot;:&quot;M. Hood&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;J. Rutkoski&quot;},{&quot;first_name&quot;:&quot;Bryan&quot;,&quot;last_name&quot;:&quot;D. Smith&quot;},{&quot;first_name&quot;:&quot;Subha&quot;,&quot;last_name&quot;:&quot;Vogeti&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Miller&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;C. Wise&quot;},{&quot;first_name&quot;:&quot;Lawrence&quot;,&quot;last_name&quot;:&quot;Chun&quot;},{&quot;first_name&quot;:&quot;Xiaoyi&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Youyan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Kays&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;A. Hipskind&quot;},{&quot;first_name&quot;:&quot;Aaron&quot;,&quot;last_name&quot;:&quot;D. Wrobleski&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;L. Lobb&quot;},{&quot;first_name&quot;:&quot;Julia&quot;,&quot;last_name&quot;:&quot;M. Clay&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;D. Cohen&quot;},{&quot;first_name&quot;:&quot;Jennie&quot;,&quot;last_name&quot;:&quot;L. Walgren&quot;},{&quot;first_name&quot;:&quot;Denis&quot;,&quot;last_name&quot;:&quot;McCann&quot;},{&quot;first_name&quot;:&quot;Phenil&quot;,&quot;last_name&quot;:&quot;Patel&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;K. Clawson&quot;},{&quot;first_name&quot;:&quot;Sherry&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Danalyn&quot;,&quot;last_name&quot;:&quot;Manglicmot&quot;},{&quot;first_name&quot;:&quot;Chris&quot;,&quot;last_name&quot;:&quot;Groshong&quot;},{&quot;first_name&quot;:&quot;Cheyenne&quot;,&quot;last_name&quot;:&quot;Logan&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;J. Starling&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;L. Flynn&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;4165-4179&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b00067&quot;},&quot;abstract&quot;:&quot;The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic BRAF V600E, have shown significant clinical efficacy in melanoma patients harboring this mutation. Because of paradoxical pathway activation, both agents were demonstrated to promote growth and metastasis of tumor cells with RAS mutations in preclinical models and are contraindicated for treatment of cancer patients with BRAF WT background, including patients with KRAS or NRAS mutations. In order to eliminate the issues associated with paradoxical MAPK pathway activation and to provide therapeutic benefit to patients with RAS mutant cancers, we sought to identify a compound not only active against BRAF V600E but also wild type BRAF and CRAF. On the basis of its superior in vitro and in vivo profile, compound 13 was selected for further development and is currently being evaluated in phase I clinical studies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00067&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00067" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00067&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00067" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b00067&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00067" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b00067&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b00067&amp;href=/doi/10.1021/acs.jmedchem.5b00067" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b00067" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b00067" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b00067%26sid%3Dliteratum%253Aachs%26pmid%3D25965804%26genre%3Darticle%26aulast%3DHenry%26date%3D2015%26atitle%3DDiscovery%2Bof%2B1-%25283%252C3-Dimethylbutyl%2529-3-%25282-fluoro-4-methyl-5-%25287-methyl-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-6-yl%2529phenyl%2529urea%2B%2528LY3009120%2529%2Bas%2Ba%2BPan-RAF%2BInhibitor%2Bwith%2BMinimal%2BParadoxical%2BActivation%2Band%2BActivity%2Bagainst%2BBRAF%2Bor%2BRAS%2BMutant%2BTumor%2BCells%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D10%26spage%3D4165%26epage%3D4179%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=290769" title="Suspensions">Suspensions</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/jmcmar.2015.58.issue-10/20150528/jmcmar.2015.58.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic BRAF V600E, have shown significant clinical efficacy in melanoma patients harboring this mutation. Because of paradoxical pathway activation, both agents were demonstrated to promote growth and metastasis of tumor cells with <i>RAS</i> mutations in preclinical models and are contraindicated for treatment of cancer patients with <i>BRAF</i> WT background, including patients with <i>KRAS</i> or <i>NRAS</i> mutations. In order to eliminate the issues associated with paradoxical MAPK pathway activation and to provide therapeutic benefit to patients with <i>RAS</i> mutant cancers, we sought to identify a compound not only active against BRAF V600E but also wild type BRAF and CRAF. On the basis of its superior in vitro and in vivo profile, compound <b>13</b> was selected for further development and is currently being evaluated in phase I clinical studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors. Mutations that lead to constitutive activation of the MAPK pathway are among the most common mutations in human cancers.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> The kinase inhibitors vemurafenib (<b>1</b>) and dabrafenib (<b>2</b>), which target oncogenic BRAF V600E, have shown significant clinical efficacy in melanoma patients harboring this mutation (Chart <a class="ref internalNav" href="#cht1" aria-label="1">1</a>).<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3-5)</a> However, both vemurafenib and dabrafenib have been shown to induce dimerization of RAF proteins and promote paradoxical pathway activation in <i>BRAF</i> wild type (WT) cells.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6-8)</a> Clinically, paradoxical activation promotes drug induced skin lesions including karatoacanthomas and squamous cell carcinoma.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Because of paradoxical pathway activation, both vemurafenib and dabrafenib were demonstrated to promote growth and metastasis of tumor cells with <i>RAS</i> mutations in preclinical models and are contraindicated for treatment of cancer patients with <i>BRAF</i> WT background, including patients with <i>KRAS</i> or <i>NRAS</i> mutations.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> The precise mechanism of paradoxical activation is still unclear, but compound induced RAF dimerization appears to be an essential first step. In one model, it is hypothesized that a BRAF selective inhibitor triggers a RAS dependent BRAF-CRAF heterodimer. Paradoxical activation then follows when the BRAF selective inhibitor is not able to effectively inhibit both partners of the dimer, leaving the unoccupied CRAF protomer activated for signaling. In another model, paradoxical activation of RAF proteins can be explained by transactivation. A drug binding to one member of the RAF homodimer or heterodimer inhibits one partner but results in transactivation of the second drug-free partner likely due to a conformational change.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Therefore, effective inhibition of the transactivated partner is required for minimalizing the paradoxical activation. According to either model, a pan-RAF inhibitor with true cellular activities against all RAF isoforms is hypothesized to be essential for minimizing paradoxical activation.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Moreover, mutant <i>RAS</i>-driven cancers account for approximately one-third of all human cancers, and RAS-driven tumor cells have been shown to signal through RAF homodimers/heterodimers.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> In order to eliminate the issues associated with paradoxical MAPK pathway activation and to provide therapeutic benefit to patients with <i>RAS</i> mutant cancers, we sought to identify a compound not only active against BRAF V600E but also wild type BRAF and CRAF.</div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11402" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11402" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In general, compounds were evaluated for their ability to inhibit recombinant BRAF V600E in a biochemical assay monitoring ADP formation via the coupled pyruvate kinase/lactate dehydrogenase system. Wild type BRAF, CRAF, and MEK biochemical assays were run with recombinant protein in a filter binding format. Cellular profiling consisted of monitoring the change in phospho-ERK in the BRAF V600E driven melanoma cell line A375 as well as antiproliferative activity in the same line upon compound treatment for 72 h. Further cellular profiling was performed in the KRAS G13D mutant (<i>BRAF</i> WT) cell line HCT116, again measuring both impact on phospho-ERK and proliferation upon compound treatment.</div><div class="NLM_p">Our program began with the observation that <b>3</b> is a potent inhibitor of BRAF V600E (IC<sub>50</sub> = 1 nM) and CRAF (IC<sub>50</sub> = 3.1 nM) as determined in biochemical assays. Cellular potency was demonstrated in the BRAF V600E driven A375 cell line (IC<sub>50</sub> = 6.8 nM) and also in the CRAF driven KRAS mutant HCT116 cell line (IC<sub>50</sub> = 57 nM) as determined by inhibition of cellular phospho-ERK respectively (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Further, compound <b>3</b> showed an antiproliferative effect in A375 cells of 6 nM and in HCT116 cells of 32 nM.</div><div class="NLM_p">On the basis of the promising in vitro profile, a cocrystal X-ray structure of <b>3</b> was obtained bound to the BRAF V600E protein (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). The structure reveals a type II binding mode within the protein wherein the methylamino naphthyridone heterocycle forms a bidentate hydrogen bond with the Cys-532 hinge residue. Phe-595 of the DFG motif (activation loop) is displaced by the <i>tert</i>-butylisoxazole and adopts the DFG-out or inactive conformation of the kinase. The urea then makes hydrogen bond interactions with α-C helix Glu-501 residue and the activation loop Asp-594 residue, while the tetrahydrofuran is oriented toward solvent. This binding mode is in contrast to that of vemurafenib which binds in a so-called type IIb binding mode with the DFG motif in the active conformation and the α-C helix out.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a></div><div class="NLM_p">We next turned our attention to evaluating <b>3</b> in vivo. Despite measured clearances less than hepatic blood flow in rats and dogs, 50 and 6 mL min<sup>–1</sup> kg<sup>–1</sup>, respectively, when dosed as a suspension, the compound showed very poor bioavailability in both species of less than 10%, suggesting an issue with oral absorption. Further study revealed the compound to have very low solubility in simulated fed (FedSIF) and fasted intestinal fluid (FasSIF) of only 0.002 and 0.001 mg/mL, respectively.</div><div class="NLM_p">Further optimization of <b>3</b> led to <b>4</b> which maintained potent BRAF V600E activity in our biochemical assay of 1.2 nM, phospho-ERK inhibition in A375 cells of 96 nM, and antiproliferative activity of 56 nM. Importantly, no compounds in this study showed potent inhibition of MEK in a biochemical assay, as MEK inhibition would impact phospho-ERK measurements (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In contrast to <b>3</b> however, <b>4</b> showed marked improvement in solubility measures with FedSIF of 0.31 mg/mL and FasSIF of 0.041 mg/mL. When dosed orally as a suspension, the compound showed desirable clearance profiles of 13 mL min<sup>–1</sup> kg<sup>–1</sup> in rat and 14 mL min<sup>–1</sup> kg<sup>–1</sup> in dog while showing considerable improvement in oral bioavailabilities of 28% and 69% in rat and dog, respectively.</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. X-ray crystal structure of <b>3</b> bound to BRAF V600E.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Activities of RAF Inhibitors<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0014.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">BRAF V600E IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">BRAF WT IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">CRAF WT IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">A375 pERK IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">HCT116 pERK IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">KDR IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">A375 proliferation IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">HCT116 proliferation IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">MEK IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">0.0061</td><td class="colsep0 rowsep0" align="left">0.034</td><td class="colsep0 rowsep0" align="left">0.41</td><td class="colsep0 rowsep0" align="left">0.15</td><td class="colsep0 rowsep0" align="left">16.6</td><td class="colsep0 rowsep0" align="left">0.36</td><td class="colsep0 rowsep0" align="left">0.17</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">0.0097</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">0.011</td><td class="colsep0 rowsep0" align="left">5.88</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">0.0010</td><td class="colsep0 rowsep0" align="left">0.018</td><td class="colsep0 rowsep0" align="left">0.0031</td><td class="colsep0 rowsep0" align="left">0.0068</td><td class="colsep0 rowsep0" align="left">0.057</td><td class="colsep0 rowsep0" align="left">0.00046</td><td class="colsep0 rowsep0" align="left">0.0061</td><td class="colsep0 rowsep0" align="left">0.032</td><td class="colsep0 rowsep0" align="left">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">0.0012</td><td class="colsep0 rowsep0" align="left">0.010</td><td class="colsep0 rowsep0" align="left">0.0029</td><td class="colsep0 rowsep0" align="left">0.096</td><td class="colsep0 rowsep0" align="left">0.091</td><td class="colsep0 rowsep0" align="left">0.0019</td><td class="colsep0 rowsep0" align="left">0.056</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left">4.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">NA is not available.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Average of triplicate determinations.</p></div></div></div><div class="NLM_p">We next moved to study the effects of <b>4</b> on in vivo target inhibition (IVTI) based on phospho-ERK activity. A375 cells were implanted on the flank of nu/nu mice and allowed to grow to a size of 300 mm<sup>3</sup>. The test compound was dosed orally, and after 2 h, the mice were sacrificed and tumor samples were evaluated for phospho-ERK inhibition (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Compound <b>4</b> required a dose of 10.4 mg/kg to inhibit phospho-ERK at 50%, while a dose of 20.5 mg/kg inhibited phospho-ERK at 80%. A corresponding increase of exposure from 0.35 μM (167 ng/mL) to 1.8 μM (843 ng/mL) was observed between the ED<sub>50</sub> and ED<sub>80</sub> doses.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. IVTI dose–response with compound <b>4</b> in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With IVTI data in hand, <b>4</b> was next evaluated in an HT-29 (<i>BRAF</i> V600E) xenograft efficacy model. At doses corresponding to the ED<sub>50</sub> and ED<sub>80</sub> for phospho-ERK in the IVTI model, <b>4</b> showed a dose responsive efficacy in HT-29 tumors when dosed for 28 days without significant weight loss. Analysis of the tumors via Western blot after dosing confirmed significant phospho-ERK inhibition (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Xenograft efficacy of <b>4</b> in HT-29 tumors implanted in mice: (A) xenograft growth curve; (B) individual animal phospho-ERK Western blot tumor analysis after dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With a link between in vitro and in vivo target inhibition and in vivo efficacy in <i>BRAF</i> V600E tumors now established, we turned to the toxicological evaluation of <b>4</b> in rats and dogs. A number of dose-limiting toxicities were observed including profound inflammation, hyperbilirubinemia, skeletal muscle degeneration, and marked bone marrow hypocellularity. While some of the effects could be at least partially attributed to exaggerated pharmacology from RAF inhibition, other potential drivers for the undesirable toxicology profile of <b>4</b> were not clear, and the team embarked on further SAR study. The goal was to maintain desired BRAF V600E, CRAF activity, and in vivo pharmacokinetic properties while aiming to improve or modify overall kinase selectivity. As a surrogate sentinel for overall selectivity, we chose to routinely monitor activity against the tyrosine kinase KDR.</div><div class="NLM_p">Work to optimize <b>4</b> led to compound <b>5</b> where the <i>tert</i>-butylisoxazole had been modified to a <i>tert</i>-butylethylurea. Surprisingly, this change maintained all of the desired activity against BRAF V600E (IC<sub>50</sub> = 4 nM) and CRAF (IC<sub>50</sub> = 5 nM) while providing a significant decrease in KDR activity (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). While these new data were encouraging, compound <b>5</b> suffered from poor oral exposure in mice (data not shown) and required further optimization.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure–Activity Relationship of RAF Inhibitors<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0015.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">R<sub>4</sub></th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">BRAF V600E IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">BRAF WT IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">CRAF WT IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">A375 pERK IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">HCT116 pERK IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">KDR IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">A375 proliferation IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">HCT116 proliferation IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">MEK IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.0042</td><td class="colsep0 rowsep0" align="left">0.011</td><td class="colsep0 rowsep0" align="left">0.0052</td><td class="colsep0 rowsep0" align="left">0.040</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.025</td><td class="colsep0 rowsep0" align="left">0.034</td><td class="colsep0 rowsep0" align="left">0.13</td><td class="colsep0 rowsep0" align="left">2.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0.0077</td><td class="colsep0 rowsep0" align="left">0.039</td><td class="colsep0 rowsep0" align="left">0.0072</td><td class="colsep0 rowsep0" align="left">0.022</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left">0.75</td><td class="colsep0 rowsep0" align="left">0.010</td><td class="colsep0 rowsep0" align="left">0.174</td><td class="colsep0 rowsep0" align="left">15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.0043</td><td class="colsep0 rowsep0" align="left">0.027</td><td class="colsep0 rowsep0" align="left">0.0067</td><td class="colsep0 rowsep0" align="left">0.14</td><td class="colsep0 rowsep0" align="left">0.27</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">0.035</td><td class="colsep0 rowsep0" align="left">0.51</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">0.0076</td><td class="colsep0 rowsep0" align="left">0.018</td><td class="colsep0 rowsep0" align="left">0.0028</td><td class="colsep0 rowsep0" align="left">0.11</td><td class="colsep0 rowsep0" align="left">0.048</td><td class="colsep0 rowsep0" align="left">0.75</td><td class="colsep0 rowsep0" align="left">0.026</td><td class="colsep0 rowsep0" align="left">0.28</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.0030</td><td class="colsep0 rowsep0" align="left">0.0084</td><td class="colsep0 rowsep0" align="left">0.0016</td><td class="colsep0 rowsep0" align="left">0.082</td><td class="colsep0 rowsep0" align="left">0.046</td><td class="colsep0 rowsep0" align="left">0.033</td><td class="colsep0 rowsep0" align="left">0.040</td><td class="colsep0 rowsep0" align="left">0.16</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH</td><td class="colsep0 rowsep0" align="left">0.018</td><td class="colsep0 rowsep0" align="left">0.028</td><td class="colsep0 rowsep0" align="left">0.0056</td><td class="colsep0 rowsep0" align="left">0.047</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.17</td><td class="colsep0 rowsep0" align="left">0.011</td><td class="colsep0 rowsep0" align="left">0.32</td><td class="colsep0 rowsep0" align="left">5.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">0.0079</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">0.54</td><td class="colsep0 rowsep0" align="left">0.033</td><td class="colsep0 rowsep0" align="left">0.19</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">0.002</td><td class="colsep0 rowsep0" align="left">0.0044</td><td class="colsep0 rowsep0" align="left">0.0012</td><td class="colsep0 rowsep0" align="left">0.027</td><td class="colsep0 rowsep0" align="left">0.016</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">0.018</td><td class="colsep0 rowsep0" align="left">0.11</td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left">0.0058</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="left">0.0043</td><td class="colsep0 rowsep0" align="left">0.037</td><td class="colsep0 rowsep0" align="left">0.15</td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left">0.0092</td><td class="colsep0 rowsep0" align="left">0.22</td><td class="colsep0 rowsep0" align="left">>20</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">NA is not available.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Average of triplicate determinations.</p></div></div></div><div class="NLM_p">Turning our attention to the hinge binding moiety of the inhibitor, it was discovered that the naphthyridone of <b>5</b> could be replaced with a naphthyridine to give <b>10</b>. This change maintained the desirable in vitro BRAF and CRAF profile of <b>5</b> while unexpectedly providing an additional improvement in selectivity vs KDR (IC<sub>50</sub> = 172 nM). Further, this compound showed a significant improvement in in vivo parameters in rat with bioavailability of 30% when dosed as a suspension and an iv clearance of 3.36 mL min<sup>–1</sup> kg<sup>–1</sup>. Compound <b>6</b> was also found to have interesting properties, demonstrating improvement in KDR activity over <b>10</b>, to 0.75 μM while maintaining very desirable BRAF and CRAF activities. Removal of the R<sub>2</sub> methyl group of <b>10</b> gave compound <b>9</b>, resulting in a 2-fold loss in activity in the A375 phospho-ERK IC<sub>50</sub> and also a drop in activity in the cell proliferation assay. Further, this change drove an undesirable 5-fold increase in KDR activity. Removal of the fluorine from the central phenyl ring of <b>10</b> afforded <b>7</b>. Compound <b>7</b> exhibited a loss of desired BRAF cellular potency of nearly 3-fold compared to <b>10</b> (140 nM vs 47 nM) and 2 fold loss in CRAF cellular potency (267 nM vs 122 nM).</div><div class="NLM_p">Further modification of the hinge binder led to the pyridopyrimidine LY3009120 (<b>13</b>, Deciphera Pharmaceuticals ID DP-4978).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> While this structural change had little impact on BRAF and CRAF activity relative to <b>10</b>, the KDR selectivity was improved by greater than 20-fold to 3.9 μM. As seen in the naphthyridine SAR, removal of the methyl group from the central phenyl ring to give <b>8</b> results in an increase in KDR activity of 5-fold to 0.75 μM. Removal of either the <i>N</i>-methyl group of <b>13</b> to give <b>11</b> or the 5-methyl group of the pyridopyrimidine to give <b>12</b> has little impact on the desired in vitro biology, although <b>11</b> does show more potent KDR activity. In each case, however, removal of the methyl group has a negative impact on in vivo performance, resulting in high iv clearance and poor oral bioavailability.</div><div class="NLM_p">On the basis of their promising in vitro profiles, cocrystal X-ray structures of <b>6</b> and <b>13</b> were obtained bound to the BRAF V600E protein (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Similar to <b>3</b>, the structures reveal a type II binding mode wherein the methylamino napthyridine or methylamino pyridopyrimidine warheads form a bidentate hydrogen bond with Cys-532 hinge residue. Phe-595 of the DFG motif is displaced by the <i>tert</i>-butylethyl group and adopts the DFG-out or inactive conformation of the kinase. The urea then makes hydrogen bond interactions with Glu-501 and Asp-594. In compound <b>6</b>, the hydroxyl group seems to make an additional interaction with a binding site water. As shown with <b>8</b> vs <b>13</b>, the methyl substituent at R<sub>2</sub> plays an important role for KDR selectivity (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). The central phenyl ring bearing R<sub>2</sub> occupies the region near gatekeeper Thr-529 with a nearly orthogonal orientation to the heterocyclic warhead. The gatekeeper residue in KDR is valine compared to threonine in BRAF. The impact of the R<sub>2</sub> methyl substituent on KDR selectivity may be driven by differences in gatekeeper residues, but it is also possible that through reinforcement of the orthogonal conformation, selectivity is achieved.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) X-ray crystal structure of <b>6</b> bound to BRAF V600E. (B) X-ray crystal structure of <b>13</b> bound to BRAF V600E.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next tested our hypothesis that pan-RAF inhibition would prevent paradoxical activation. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>, evaluation of phospho-ERK in the <i>BRAF</i> WT cell line HCT116 shows that while <b>1</b> (vemurafenib) produces significant paradoxical activation as doses increase, pan-RAF inhibitors <b>6</b> and <b>13</b> give only very minor activation at very low doses, with near complete inhibition of phospho-ERK at concentrations above 100 nM. We believe this difference in behavior is driven by the pan-RAF activity of <b>6</b> and <b>13</b> and in particular the potent inhibition of CRAF. Indeed, the IC<sub>50</sub> value for biochemical inhibition of CRAF is 7 and 15 nM for <b>6</b> and <b>13</b>, respectively, compared to 414 nM for <b>1</b> in our assay conditions. Thus, the ability to inhibit all isoforms of RAF appears to be critical to avoid paradoxical activation and inhibit signaling through phospho-ERK in <i>RAF</i> WT cell lines.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Paradoxical activation of RAS-RAF-MEK signaling by vemurafenib (<b>1</b>), compound <b>6</b>, and <b>13</b> in <i>BRAF</i> WT HCT-116 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To confirm compound <b>13</b> as a pan-RAF inhibitor, it was evaluated in a whole cell-based KiNativ assay developed by ActivX Biosciences Inc. Compound <b>13</b> was incubated with A375 whole cell lysate for 15 min, and the binding affinities of over 170 kinases were determined by direct competitive binding with an ATP analog. Among the kinases measured, six proteins have binding affinities equal to or less than 100 nM, and eight targets have binding affinity between 290 and 1000 nM. The remaining kinases (over 150 examined) are inactive at 1 μM (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). As summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, <b>13</b> bound ARAF, BRAF, and CRAF native proteins with IC<sub>50</sub> values of 44, 31–47, and 42 nM, respectively. Vemurafenib was able to bind to BRAF and ARAF with IC<sub>50</sub> values of 260–360 and 950 nM, respectively; however, its binding affinity to CRAF was greater than 10,000 nM. Dabrafenib bound BRAF and ARAF potently with IC<sub>50</sub> values of 6 and 26 nM, respectively, while binding to CRAF was mild with an IC<sub>50</sub> of 150 nM, about 25-fold less than its binding affinity to BRAF.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. General KiNativ Profiling of <b>13</b> in A375 Cells<a class="ref internalNav" href="#tbl3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EphA2</td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ZAK</td><td class="colsep0 rowsep0" align="left">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p38</td><td class="colsep0 rowsep0" align="left">61–97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FYN</td><td class="colsep0 rowsep0" align="left">91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAP3K1</td><td class="colsep0 rowsep0" align="left">98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EphB4</td><td class="colsep0 rowsep0" align="left">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CSK</td><td class="colsep0 rowsep0" align="left">290–400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABL</td><td class="colsep0 rowsep0" align="left">380–520</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IRAK1</td><td class="colsep0 rowsep0" align="left">390</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GCN2</td><td class="colsep0 rowsep0" align="left">450–480</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JNK</td><td class="colsep0 rowsep0" align="left">470</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MAP2K5</td><td class="colsep0 rowsep0" align="left">800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KHS1</td><td class="colsep0 rowsep0" align="left">970</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="left">310 to >1000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl3-fn1"><div class="footnote" id="tbl3-fn1"><sup>a</sup><p class="last">The remaining kinases (>150) have IC<sub>50</sub> values of >1μM.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. RAF KiNativ Data in A375 Cells</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">ARAF</th><th class="colsep0 rowsep0" align="center">BRAF</th><th class="colsep0 rowsep0" align="center">CRAF</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">31–47</td><td class="colsep0 rowsep0" align="left">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">950</td><td class="colsep0 rowsep0" align="left">260–360</td><td class="colsep0 rowsep0" align="left">>10,000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">150</td></tr></tbody></table></div></div><div class="NLM_p">On the basis of its superior in vitro profile, <b>6</b> was moved into <i>BRAF</i>V600E A375 xenograft IVTI studies in mice. As illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>, a single dose oral treatment of mice from 3 to 50 mg/kg showed a dose dependent inhibition of phospho-MEK and phospho-ERK, and the calculated dose for 50% inhibition of phospho-ERK (EC<sub>50</sub>) was 1.7 mg/kg (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A), with a plasma concentration to achieve 50% inhibition of phospho-ERK (EC<sub>50</sub>) of 1347 ng/mL or 3.1 μM (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B). Similarly, <b>13</b> was evaluated in nude rats bearing A375 xenograft tumors. Single dose oral treatment with <b>13</b> from 3 to 50 mg/kg showed a dose dependent inhibition of phospho-ERK, with a calculated dose for 50% inhibition of phospho-ERK (EC<sub>50</sub>) of 4.36 mg/kg, with plasma concentration to achieve 50% inhibition of phospho-ERK (EC<sub>50</sub>) of 68.9 ng/mL or 165 nM, significantly lower than the EC<sub>50</sub> for compound <b>6</b>.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">On the basis of the in vivo target inhibition data for <b>6</b>, we initiated efficacy studies in A375 and HCT116 xenografts (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). As shown, <b>6</b> produced regressions in the A375 model when dosed at 20 and 30 mg/kg b.i.d. while also demonstrating significant efficacy in the <i>KRAS</i> mutant HCT116 xenograft at 40 mg/kg b.i.d. In both studies the compound was dosed for 15 days and was well tolerated with no significant weight loss in any group.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0008.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Mouse IVTI of <b>6</b> in A375 xenograft: (A) phospho-ERK dose response; (B) phospho-ERK concentration response; (C) Western blot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0009.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>6</b> in vivo efficacy in mice dosed b.i.d. for 15 days in (A) A375 <i>BRAF</i> V600E and (B) HCT116 xenograft tumors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We next evaluated <b>13</b> in xenograft efficacy models. Upon oral treatment of rats bearing <i>BRAF</i> V600E ST019VR PDX tumors with 15 or 30 mg/kg b.i.d. of <b>13</b>, a dose-dependent tumor growth inhibition was observed (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). Additional efficacy for <b>13</b> in <i>BRAF</i>, <i>NRAS</i>, and <i>KRAS</i> mutant xenograft models has also been demonstrated.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Altogether, these in vivo efficacy studies suggest that the pan-RAF inhibitors <b>6</b> and <b>13</b> are effective in inhibiting tumor growth with <i>BRAF</i>, <i>KRAS</i>, or <i>NRAS</i> mutations.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0010.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>13</b> in vivo efficacy in rat BRAF V600E ST019VR PDX model. Compound was dosed at 15 and 30 mg/kg b.i.d., respectively, for 28 days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Pharmacokinetic parameters for compound <b>13</b> have been determined in rat, dog, and monkey and are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. In each species the compound was dosed as a 1 mg/kg solution in the iv arm and a 10 mg/kg formulation in the oral arm. In each species, iv clearance was moderate at 30–55% of hepatic blood flow and volumes of distribution between 0.84 and 1.78 L/kg. The oral bioavailability was dependent on the formulation used. In rat and dog, HEC suspension of API in capsule gave very low oral exposure. Compound <b>13</b> is a weak base with a p<i>K</i><sub>a</sub> of 4.52, and the solubility is very low across the physiologically relevant pH range, as well as in simulated gastric and intestinal fluids. Solubility in water is <0.001 mg/mL and is 0.002 mg/mL in simulated gastric and intestinal (both fasted and fed) fluids, and the measured log <i>P</i> value was determined to be 4.29. Measured MDCK-MDR1 permeability is high (47 × 10<sup>–6</sup> cm/s, with an estimated human effective permeability of 4.48 × 10<sup>–4</sup> cm/s). In initial experiments, <b>13</b> demonstrated low bioavailability, likely due to its poor solubility,<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> and it became clear this compound would require use of enabling formulation technology to achieve target exposures. Use of a salt form was not considered because of the low p<i>K</i><sub>a</sub> (4.52) of the molecule. Insufficient solubility observed in liquid vehicles during preliminary solubility screens ruled out the possibility of liquid or semisolid formulations. Complexation approaches using cyclodextrins were also evaluated but were not pursued because of an inability to achieve a solubility that would support high drug dose. Evaluation of solid dispersion technologies was next pursued where the drug is dispersed in an inert polymeric matrix and rendered in an amorphous form which results in faster dissolution rate and/or higher extent and duration of supersaturation leading to enhanced oral bioavailability relative to the crystalline drug.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> Various polymers were evaluated with PVP-VA (Kollidon VA-64), resulting in a solid dispersion that was both chemically and physically stable under accelerated stability testing, as well as long-term storage under ambient conditions. Pharmacokinetic studies in dogs and pilot toxicology studies contained spray dried solid dispersion with <b>13</b>/PVP-VA in ratio of 20:80, with added 2% sodium lauryl sulfate. Further evaluations of physical stability and in vivo pharmacokinetics in dogs were done, followed by GLP toxicology studies using higher drug/polymer ratio (40:60) and 1% added sodium lauryl sulfate. For human studies the solid dispersion containing <b>13</b>/PVP-VA (40:60) was used. Dosing the molecule as an enabled formulation of 20% cyclodextrin in rat and monkey or solid dispersion in dog led to significantly improved oral exposure and bioavailability.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Parameters for Compound <b>13</b> across Species</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">species</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">SD rat: male, fasted, crossover (<i>n</i> = 3)</th><th class="rowsep1 colsep0" colspan="2" align="center">dog: male, fasted, crossover (<i>n</i> = 4)</th><th class="rowsep1 colsep0" align="center">monkey: male, fasted</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (po) (mg/kg):</th><th class="colsep0 rowsep0" align="center">10 (1% HEC suspension)</th><th class="colsep0 rowsep0" align="center">10 (20% cyclodextrin, suspension)</th><th class="colsep0 rowsep0" align="center">10 (API capsule)</th><th class="colsep0 rowsep0" align="center">10 (solid dispersion)</th><th class="colsep0 rowsep0" align="center">10 (20% cyclodextrin, suspension)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–24</sub> (ng·h/mL)</td><td class="colsep0 rowsep0" align="left">169 ± 138</td><td class="colsep0 rowsep0" align="left">1667 ± 717</td><td class="colsep0 rowsep0" align="left">20.5 ± 8.6</td><td class="colsep0 rowsep0" align="left">2093 ± 1229</td><td class="colsep0 rowsep0" align="left">1260 ± 141</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">34.4 ± 37.1</td><td class="colsep0 rowsep0" align="left">396 ± 142</td><td class="colsep0 rowsep0" align="left">2.8 ± 0.3</td><td class="colsep0 rowsep0" align="left">511 ± 36</td><td class="colsep0 rowsep0" align="left">492 ± 68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">half-life (h)</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="left">7.6 ± 4.4</td><td class="colsep0 rowsep0" align="left">7.9 ± 8.5</td><td class="colsep0 rowsep0" align="left">3.5 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bioavailability (%)</td><td class="colsep0 rowsep0" align="left">3.6 ± 2.8</td><td class="colsep0 rowsep0" align="left">31.7 ± 7.6</td><td class="colsep0 rowsep0" align="left">0.2 ± 0.1</td><td class="colsep0 rowsep0" align="left">16.7 ± 10.0</td><td class="colsep0 rowsep0" align="left">20 ± 0</td></tr></tbody></table><table class="table" border="0"><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">species</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">SD rat: male, fasted, crossover (<i>n</i> = 3)</th><th class="rowsep1 colsep0" colspan="2" align="center">dog: male, fasted, crossover (<i>n</i> = 4)</th><th class="rowsep1 colsep0" align="center">monkey: male, fasted</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (iv) (mg/kg):</th><th class="colsep0 rowsep0" colspan="2" align="center">1 (20% cyclodextrin solution)</th><th class="colsep0 rowsep0" colspan="2" align="center">1 (20% cyclodextrin solution)</th><th class="colsep0 rowsep0" align="center">1 (20% cyclodextrin solution)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">half-life (h)</td><td class="colsep0 rowsep0" colspan="2">1.1 ± 0.4</td><td class="colsep0 rowsep0">1.8 ± 0.1</td><td class="colsep0 rowsep0">2.1 ± 0.4</td><td class="colsep0 rowsep0">1.0 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">clearance (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" colspan="2">34.1 ± 8.5</td><td class="colsep0 rowsep0">16.1 ± 3.0</td><td class="colsep0 rowsep0">14.6 ± 1.3</td><td class="colsep0 rowsep0">25.9 ± 1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><i>Q</i><sub>h</sub> (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" colspan="2">55.2</td><td class="colsep0 rowsep0" colspan="2">30.9</td><td class="colsep0 rowsep0">43.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">vol. of dist. (L/kg)</td><td class="colsep0 rowsep0" colspan="2">1.08 ± 0.02</td><td class="colsep0 rowsep0">1.78 ± 0.33</td><td class="colsep0 rowsep0">1.53 ± 0.14</td><td class="colsep0 rowsep0">0.84 ± 0.42</td></tr></tbody></table></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60645" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60645" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compounds <b>3</b>, <b>4</b>, and <b>5</b> were prepared in a manor analogous to previous reports.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Compounds <b>6</b>, <b>7</b>, <b>9</b>, and <b>10</b> were prepared by the general methods illustrated in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In general, compound <b>18</b> is reacted with compound <b>22</b> (for <b>7</b>, <b>9</b>, and <b>10</b>) or <b>23</b> (for <b>6</b>) to provide <b>24</b> or <b>25</b>, respectively. Further treatment of <b>24</b> or <b>25</b> with ispropenyl chloroformate under Schotten–Baumann conditions provides <b>26</b> and <b>27</b>, respectively. Further reaction of <b>26</b> or <b>27</b> with the appropriate amine in the presence of a base followed by removal of the PMB group as necessary gives the products. In turn, two routes to compound <b>18</b> were employed. Compound <b>14</b> reacts with acetic anhydride in the presence of 1-methylimidazole to provide <b>15</b>. Nitro compound <b>15</b> is reduced to provide amine <b>16</b> which is condensed with aldehyde <b>17</b> in the presence of potassium hydroxide to yield naphthyridine <b>18</b>. Alternatively, compound <b>18</b> can be synthesized via Pd(PPh<sub>3</sub>)<sub>4</sub>-mediated coupling of boronate <b>21</b> with triflate <b>19</b> or bromide <b>20</b>.</div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) For <b>6</b>, <b>9</b>, <b>10</b>: rt, 16 h, 52%; (b) EtOAc, Pd/C (10%), H<sub>2</sub> 1 atm, 16 h, 75%; (c) EtOH, KOH, 60 °C, 1 h, 60%. (d) For <b>7</b>: dioxane, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 60 °C, 1 h, 84%. (e) <b>22</b>: NMP, 185 °C, 64 h, 43%. <b>23</b>: CH<sub>3</sub>NH<sub>2</sub> 30% EtOH, 120 °C microwave, 24 h, 98%; (f) EtOAc, H<sub>2</sub>0, rt, 1 h, 95%. (g) <b>26</b>: dioxane, RNH<sub>2</sub>, 60 °C, 4 h, carried on crude. <b>27</b>: dioxane, NMP, 80 °C, 16 h, 89%; (h) <b>26</b>, TFA, rt, 1 h, 53%.</p></p></figure><figure id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) acetone, KOH, rt, 10 min, carried on crude; (b) methylamine (33% in EtOH), 110 °C, 16 h, 65%, 2 steps; (c) MeCN, NBS, 0–5 °C 4 days, 31%; (d) NaOH, H<sub>2</sub>O, rt, 16 h, 56%; (e) pyridine, trifluoromethanesulfonic anhydride, 0 °C, 2 h, 70%; (f) DMF, glacial acetic acid, bleach, then methylamine (2.0 M in THF) 0 °C to rt, 2 h, 73%; (g) bis(pinacolato)diboron, KOAc, dioxane, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)–dichloromethane complex, 100 °C, 16 h, 85%; (h) EtOAC, aq NaHCO<sub>3</sub>, isopropenyl chloroformate, rt, 6 h, carried on crude; (i) 3,3-dimethylbutan-1-amine, NMP, dioxane, 75 °C, 16 h, 88% 2 steps. (j) From <b>34</b>: dioxane, NaHCO<sub>3</sub>, <b>38</b>, H<sub>2</sub>O, tetrakis(triphenylphosphine)palladium, 50 °C, 16 h, 77%.</p></p></figure><div class="NLM_p">Compounds <b>8</b> and <b>13</b> are prepared as described in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Compound <b>28</b> is reacted with acetone and potassium hydroxide to provide compound <b>29</b>, which is further reacted with methylamine to provide <b>30</b>. Compound <b>30</b> is then converted to bromide <b>31</b> with <i>N</i>-bromosuccinimide. Compound <b>28</b> can also be reacted with 1-hydroxypropan-2-one and potassium hydroxide to provide compound <b>32</b>, which can be converted to triflate <b>33</b> with trifluoromethanesulfonic anhydride. Compound <b>33</b> is then reacted with bleach followed by methylamine to provide compound <b>34</b>. Compound <b>35</b> is reacted with bis(pinacolato)diboron and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)–dichloromethane complex to give compound <b>36</b> which is treated with isopropenyl chloroformate to give compound <b>37</b>, which is further reacted with a suitable amine to produce compound <b>38</b>. Palladium coupling of boronate <b>38</b> with either bromide <b>31</b> or triflate <b>34</b> provided the desired final compounds.</div><figure id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0013.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeCN, TEA, 180 °C microwave, 15 min, 24%; (b) <b>41</b>, dioxane, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, Pd(PPh<sub>3</sub>)<sub>4</sub>, 60 °C, 3 h, 80%; (c) isopropenyl chloroformate, EtOAc, aq NaHCO<sub>3</sub>, rt, 2 h, 99%; (d) NMP, THF, 65 °C, 4 h, 75%; (e) TFA, 0 °C to rt, 16 h, 81%.</p></p></figure><div class="NLM_p last">Compound <b>12</b> is prepared as described in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Aldehyde <b>39</b> and protected <i>N</i>-methylguanidine are reacted to give <b>40</b>. Compounds <b>40</b> and <b>41</b> are reacted under palladium coupling conditions to provide compound <b>42</b>, which is further reacted with isopropenyl chloroformate to give compound <b>43</b>. Compound <b>43</b> was then converted to desired compound <b>12</b> as described above.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Discussion/Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37053" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37053" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have identified a series of compounds that are shown to be type II pan-RAF kinase inhibitors both biochemically and in cell based assays. Unlike more selective BRAF inhibitors, compounds <b>6</b> and <b>13</b> show minimal paradoxical pathway activation in RAF WT cell lines. Interestingly, as reported by others, we see an apparent increase in dimerization upon compound treatment.<a onclick="showRef(event, 'ref12 ref15 ref23'); return false;" href="javascript:void(0);" class="ref ref12 ref15 ref23">(12, 15, 23)</a> As proposed by others, our data suggest that even when compound induced dimerization of RAF proteins occurs, effective inhibition of dimer partners can still function to prevent significant paradoxical activation provided that both the BRAF and CRAF protomers are inhibitor-occupied.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Compounds <b>1</b> and <b>2</b> have both been shown to bind with the DFG-in and αC-helix-out. This change in conformation of the αC-helix likely negatively impacts dimerization, explaining the increased dimer seen with type II inhibitors. However, this same required αC-helix movement likely explains the inability of compounds <b>1</b> and <b>2</b> to inhibit signaling once dimerization has occurred.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Importantly, pan-RAF inhibition has also been shown to provide in vivo efficacy against a variety of BRAF, NRAS, and KRAS mutant tumors. We drove our SAR predominantly using RAF dependent assays in BRAF and KRAS mutant cells and KDR as a surrogate marker to improve overall selectivity which was also followed by a significant improvement in the toxicity profile of compound <b>13</b> over the initial leading compound <b>5</b>. On the basis of its superior in vitro and in vivo profile, compound <b>13</b> was selected for further development and is currently being evaluated in phase I clinical studies.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Experimentals</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61872" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61872" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> General</h3><div class="NLM_p">All commercial chemicals and solvents are reagent grade and were used without further purification unless otherwise noted.</div><div class="NLM_p last">All liquid chromatography (LC) analyses were performed using an Agilent 1100 LC system, consisting of a 1100 HiP degasser, 1100 binary pump, 1100 autosampler, 1100 thermostated column compartment, and a 1100 diode array detector (G4212B) coupled to an Agilent 1956 single quadrupole mass spectrometry (MS) detector. The injection volume was set to 1 μL by default. The UV (DAD) acquisition was performed at 80 Hz, with a scan range of 200–400 nm (by 2 nm step). The MS instrument was operated with an electrospray ionization source (ESI) in both positive and negative ion modes. The nebulizer pressure was set to 50 psi, and the drying gas temperature and flow were set to 350 °C and 12.0 L/min, respectively. The capillary voltages used were 4000 V in positive mode and 3500 V in negative mode. The MS acquisition range was set to 120–500 <i>m</i>/<i>z</i> with a step size of 0.25 <i>m</i>/<i>z</i> in both polarity modes. Fragmentor voltage was set to 80 (ESI+) or 80 (ESI−), gain to 1.00 (ESI+) or 1.00 (ESI−), and the ion count threshold to 100 (ESI+) or 100 (ESI−). The overall MS scan cycle time was 0.83 s/cycle. Data acquisition was performed with Agilent Chemstation software. Analyses were carried out on a Phenomenex Gemini-NX C18 column of 50 mm length, 2.1 mm internal diameter, and 3 μm particle size. The mobile phase used was A2 = water with 10 mM ammonium bicarbonate, pH = 9, B2 = acetonitrile. The run was performed at a temperature of 50 °C and a flow rate of 1.0 mL/min, with a gradient elution from 5% to 95% (B1) over 3.0 min followed by a 0.4 min hold at 95% (B1) and a total run time of 3.75 min. The second mobile phase used was A1 = water with 0.1% formic acid, B1 = acetonitrile with 0.1% formic acid. The run was performed at a temperature of 50 °C and a flow rate of 1.0 mL/min, with a gradient elution from 5% to 95% (B1) over 3.0 min followed by a 0.4 min hold at 95% (B1) and a total run time of 3.75 min. All final compounds were analyzed using one of these analytical methods and were at least 95% pure.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> 5-Bromo-2-fluoro-4-methylaniline <b>35</b>, R<sub>1</sub> = CH<sub>3</sub></h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Method A</h4><div class="NLM_p">Combine 1-bromo-4-fluoro-2-methylbenzene (30.0 g, 159 mmol) in concentrated sulfuric acid (100 mL), cool to about −5 °C, and treat dropwise with nitric acid (11.00 mL, 174 mmol) over 20 min. Allow reaction mixture to warm to rt and stir for 30 min. Pour onto crushed ice with stirring and partition with <i>tert</i>-butyl methyl ether (MTBE) (200 mL). Separate the aqueous layer and extract with MTBE (2 × 50 mL). Combine organic layers, dry, and concentrate under reduced pressure to provide 1-bromo-4-fluoro-2-methyl-5-nitrobenzene as an orange-colored viscous oil (39.0 g).</div><div class="NLM_p last">Combine crude 1-bromo-4-fluoro-2-methyl-5-nitrobenzene (32.4 g, 138 mmol), ethanol (100 mL), and Raney nickel (1.00 g, 17.04 mmol) in a shaker flask. Charge the flask with hydrogen (275 kPa) and agitate until the absorption of hydrogen ceases. Depressurize the reaction vessel, remove the catalyst by filtration, and evaporate the filtrate to dryness. Add MTBE, then filter again and evaporate the filtrate. Stir residue in hexanes. Collect the solids by filtration, wash with cold hexanes, and dry in vacuo to provide the title compound (17.8 g, 63% yield) as a dark solid. MS (<i>m</i>/<i>z</i>): 204.0 (M + 1)/206.0 (M + 3).</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Method B</h4><div class="NLM_p">To a four-necked round-bottom flask equipped with mechanical agitation, thermometer, ice bath, and N<sub>2</sub> inlet were added 1-bromo-4-fluoro-2-methylbenzene (1.4 kg, 7.4 mol), then concentrated H<sub>2</sub>SO<sub>4</sub> (6.3 kg) at 0–10 °C. After stirring for 10–20 min, the mixture was cooled to −10 to 0 °C, and KNO<sub>3</sub> (0.82 kg, 7.8 mol, 1.05 equiv) was added in portions in about 6 h while maintaining the temperature at −10 to 0 °C. After the addition, the reaction mixture was warmed to 10–20 °C and monitored by TLC (EA/PE = 1:20) and HPLC until the content of 1-bromo-4-fluoro-2-methylbenzene was <0.5%. The mixture was poured into ice/water mixture (11.2 kg, ice/water = 1:1) and extracted twice with MTBE (4.7 and 1.9 L). The organic layers were combined, washed with saturated brine (5.6 kg), and concentrated to 1.5–2 V below 45 °C under reduce pressure. The residue was diluted with EtOAc (5.6L) and the resulting solution used directly in the next step (1.22 kg (wt % corrected), 70.5% yield, and 68.3% purity detected by UV absorption at 210 nm). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.35 (s, <i>J</i> = 7.1 Hz, 1H), 7.29 (d, <i>J</i> = 11.3 Hz, 1H), 2.59 (d, <i>J</i> = 6.8 Hz, 3H).</div><div class="NLM_p last">To a four-necked round-bottom flask equipped with mechanical agitation, thermometer, and N<sub>2</sub> inlet were added a solution of 1-bromo-4-fluoro-2-methyl-5-nitrobenzene (1.16 kg, 4.96 mol) in EtOAc (5L) and 36% HCl solution (4.9 kg, 49.6 mol, 10.0 equiv). After stirring for 5–10 min at 20–30 °C, Fe powder (1.34 kg, 24.0 mol, 4.8 equiv) was added in portions while maintaining the temperature at 20–30 °C. The reaction was monitored by TLC (EA/PE = 1:10). After the completion of the reaction, the pH value was adjusted to 2–3 using NaHCO<sub>3</sub>, and Celite (0.56 kg) was added. The mixture was stirred for 0.5–1 h and filtered. The solid was washed with toluene (2 × 2.6 L). The filtrates were combined and stirred for another 0.5–1 h before separation of the layers. The aqueous layer was extracted with toluene (2.6 L). The organic layers were combined, washed with brine (3 L), and filtered through a silica gel pad (2–3 cm). The filtrate was concentrated to 2–2.5 L and the residue mixed with <i>n</i>-heptane (3.3 L). After concentration to 2–2.5 L again, <i>n</i>-heptane (1.65L) was added. The mixture was cooled to −10 to ∼0 °C and stirred for 1 h. The precipitate was collected by filtration, washed with <i>n</i>-heptane (0.5 L, precooled to −10 to 0 °C), and dried to afford the crude product of the title compound as a brown solid. Recrystallization of crude product with <i>n</i>-heptane (3.3L) gave off-white to brown solid of the title compound (527 g, 52% yield, and 98% purity detected by UV absorption at 210 nm). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 6.97 (m, 2H), 5.18 (s, 2H), 2.16 (s, 3H). <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>): δ 21.41, 116.60, 118.30, 119.66, 127.22, 132.88, (149.37,151.12). <sup>19</sup>F NMR (400 MHz, CDCl<sub>3</sub>): δ 151.14</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> 2-Fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline <b>36</b>, R<sub>1</sub> = CH<sub>3</sub></h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> Method A</h4><div class="NLM_p last">Combine 5-bromo-2-fluoro-4-methylaniline (3.1 g, 15.2 mmol), bis(pinacolato)diboron (4.24 g, 16.7 mmol), and potassium acetate (4.47 g, 45.6 mmol) in dioxane (40 mL) and sparge with argon. Add [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)–dichloromethane complex (0.620 g, 0.760 mmol). Sparge again with argon, and heat at 100 °C overnight. Filter the reaction mixture and concentrate in vacuo. Purify by silica gel chromatography (0–50% EtOAc/hexanes) to give the title compound (3.24 g, 85% yield). MS (<i>m</i>/<i>z</i>): 252.1 (M + 1).</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Method B</h4><div class="NLM_p last">To a four-necked round-bottom flask equipped with mechanical agitation, thermometer, and N<sub>2</sub> inlet were added 5-bromo-2-fluoro-4-methylaniline (200g, 0.98 mol), CH<sub>3</sub>COOK (192 g, 1.95 mol, 2.0 equiv), bis(pinacolato)diboron (248 g, 0.98 mol, 1.0 equiv), and IPAC (3 L). After degassing with N<sub>2</sub> for 30 min, the mixture was warmed to 50 °C and Pd(dppf)Cl<sub>2</sub> (8g, 4 wt %) was added. The reaction mixture was heated under reflux for at least 10 h until the content of starting material was ≤2% (GC). The mixture was cooled to 20–30 °C, filtered through a pad of Celite, and rinsed with IPAC (1 L). The filtrate was concentrated to 400–500 mL. The residue was mixed with <i>n</i>-heptane (700 mL), filtered through a SiO<sub>2</sub> pad, and eluted with IPAC/<i>n</i>-heptane (1/5 first, ∼2 L, and then 2/5, ∼3 L). The filtrate was concentrated to 350–400 mL. <i>n</i>-Heptane (300 mL) was added and the mixture was again concentrated to 350–400 mL. The residue (suspension) was cooled to −10 to −20 °C and filtered after stirring for 2–5 h. The crude product was dissolved in MeOH (200 mL) at 30–40 °C. Then slowly add H<sub>2</sub>O (600 mL) dropwise in 0.5–1 h. The suspension was cooled to 20–30 °C and filtered after stirring for 1–2 h.The solid was dried under high vacuum to afford the title compound as off-white solid (183g, 74% yield, and 99% purity detected by UV absorption at 210 nm. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.42 (d, <i>J</i> = 10.2 Hz, 1H), 7.01 (d, <i>J</i> = 12.4 Hz, 1H), 3.76 (s, 2H), 2.64 (s, 3H), 1.55 (s, 12H). <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>): δ 20.66, 20.67, 24.40, 82.93, 116.20, 124.37, 130.64, 135.02, (151.93,153.37). <sup>19</sup>F NMR (400 MHz, CDCl<sub>3</sub>): δ 145.72.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Prop-1-en-2-yl-2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylcarbamate <b>37</b>, R<sub>1</sub> = CH<sub>3</sub></h3><div class="NLM_p last">Add 2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (5.0 g, 19.91 mmol) and isopropenyl chloroformate (2.40 mL, 21.90 mmol) in EtOAc (60 mL) and saturated aqueous NaHCO<sub>3</sub> (60 mL) and stir at rt for 6 h. Separate the layers, extract the aqueous layer with EtOAc (2×), wash the combined organics with brine, dry over Na<sub>2</sub>SO<sub>4</sub>, and concentrate to obtain the title compound. Use for the next reaction without further purification (assuming 100% yield). MS (<i>m</i>/<i>z</i>): 336.2 (M + 1).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 3,3-Dimethylbutan-1-amine Hydrochloride</h3><div class="NLM_p">To a four-necked round-bottom flask equipped with mechanical agitation, thermometer, and N<sub>2</sub> inlet was added 3,3-dimethylbutanal (200g, 2.0 mol). Then 1-phenylmethanamine (214 g, 2.0 mol, 1.0 equiv) was added dropwise. The reaction mixture was stirred at 20–30 °C for 2–5 h until greater than 99% conversion by GC. NaCl (4 g) was added, and the aqueous phase was discarded. THF (800 mL) was added, and the mixture was concentrated to 400 mL. This operation was repeated until the KF of the residue was less than 0.2%. THF (800 mL) and <i>t</i>-BuOK (44.8 g, 0.4 mol, 0.2eq) were added. The mixture was warmed to 60–65 °C and stirred until the content of <i>N</i>-benzyl-3,3-dimethylbutan-1-imine was less than 1% by GC. After cooling to 10–20 °C, water (1500 mL) was added and the mixture was extracted with MTBE (2 × 1500 mL). The combined organic phase was washed with saturated NaCl (800 mL), sampled for water content analysis to ensure 1–2% KF content. The stream of <i>N</i>-(3,3-dimethylbutyl)-1-phenylmethanimine was used directly for the next step (83% purity by GC; GC–MS <i>m</i>/<i>z</i> 188.2 [M – H]<sup>+</sup>).</div><div class="NLM_p last">To a four-necked round-bottom flask equipped with mechanical agitation, thermometer, and N<sub>2</sub> inlet was added <i>N</i>-(3,3-dimethylbutyl)-1-phenylmethanimine solution obtained above (412g, 2.18 mol, 3.27 L of MTBE, 1.3 L of THF), and HCl/MTBE solution (16%, 398 g, 1.74 mol, 0.8 equiv) was added dropwise at 20–30 °C. White solid precipitated during the addition. After stirring for 1–2 h, an aliquot sample of the suspension was filtered. The mother liquor was checked by GC. If the content of <i>N</i>-(3,3-dimethylbutyl)-1-phenylmethanimine was greater than than 30%, an additional HCl/MTBE solution (45g, 0.10eq) was added until the content of <i>N</i>-(3,3-dimethylbutyl)-1-phenylmethanimine was between 20% and 30% by GC. The solid was collected by filtration, washed with MTBE (870 mL), and dried under N<sub>2</sub> to give the desired title compound as a white crystalline material (195g, 65% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.90 (s, 3H), 2.74 (m, 2H), 1.47 (m, 2H), 0.89 (s, 9H). <sup>13</sup>C NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 28.98, 29.31, 35.49, 40.34.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea <b>38</b>, R<sub>1</sub> = CH<sub>3</sub></h3><div id="sec5_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Method A</h4><div class="NLM_p last">Treat a solution of prop-1-en-2-yl 2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylcarbamate (6.67 g, 19.90 mmol) in dioxane (60 mL) with 3,3-dimethylbutan-1-amine (2.42 g, 23.9 mmol) and 1-methylpyrolidine (0.169 g, 1.99 mmol) and heat at 75 °C overnight. Cool the mixture to rt, collect the solid via filtration, and wash with diethyl ether to obtain the title compound (6.62 g, 88% yield over two steps). MS (<i>m</i>/<i>z</i>): 379.2 (M + 1).</div></div><div id="sec5_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Method B</h4><div class="NLM_p last">To a four-necked round-bottom flask equipped with mechanical agitation, thermometer, and N<sub>2</sub> inlet were added 2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (40g, 0.159 mol), THF (600 mL), and NaHCO<sub>3</sub> (16.0 g, 0.19 mol, 1.20 equiv). The mixture was cooled to 0–5 °C, and phenyl chloroformate (26.14 g, 0.167 mol, 1.05 equiv) was added dropwise. The reaction mixture was warmed to 60 °C and stirred until the content of 2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline was ≤2%. The mixture was filtered and the solid (salt) was washed with THF (120 mL). The filtrate was concentrated to 65–80 mL. To the residue, toluene (720 mL), 3,3-dimethylbutan-1-amine (HCl salt, 26.14 g, 0.19 mol, 1.2 equiv), and TEA (20.87 g, 0.21 mol, 1.3 equiv) were added. The resulting mixture was heated to 90 °C and stirred until the content of intermediate was ≤2%.The mixture was cooled to 15–20 °C, stirred for 2 h, and filtered. The solid was washed with toluene (120 mL), H<sub>2</sub>O (2 × 400 mL) and dried under high vacuum to afford the title compound as a white solid (54.9 g, 91.3% yield, and 99% purity detected by UV absorption at 210 nm). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.34 (d, <i>J</i> = 9.1 Hz, 1H), 8.08 (s, 1H), 6.98 (d, <i>J</i> = 12.3 Hz, 1H), 6.41 (s, 1H), 3.08 (s, 2H), 2.38 (s, 3H), 1.36 (m, 14H), 0.90 (s, 9H). <sup>13</sup>C NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 21.12,24.65,29.37,29.58, 35.65,43.50,83.25, 104.32116.09, 125.02, 128.19, 138.71, (152.40,154.34), 154.81. <sup>19</sup>F NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 136.34</div></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Ethyl 4-Amino-2-(methylthio)pyrimidine-5-carboxylate</h3><div id="sec5_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Method A</h4><div class="NLM_p last">Add concentrated ammonium hydroxide (335 mL, 8.60 mol) to a vigorously stirred suspension of ethyl 4-chloro-2-(methylthio)pyrimidine-5-carboxylate (200 g, 860 mmol) in ethanol (EtOH) (450 mL) and allow to stir overnight. Collect the solids by filtration, rinse with EtOH (2 × 100 mL) and H<sub>2</sub>O (3 × 200 mL), and dry in a vacuum oven (65–70 °C) overnight to afford the title compound (164.4 g, 90% yield) as a white solid. MS (<i>m</i>/<i>z</i>): 214.1(M + 1).</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Method B</h4><div class="NLM_p last">Charge reaction vessel with 1190 g of THF and 660 g of ethyl 4-chloro-2-(methylsulfanyl)pyrimidine-5-carboxylate (1.0 equiv, 2.84 mol). Stir at 10–20 °C for 20–30 min, and then add 907 g of NH<sub>3</sub>–H<sub>2</sub>O and 989 g of Et<sub>3</sub>N to the mixture. Heat to 45–55 °C, and stir for 2–6 h at 45–55 °C. After reaction was complete, cool to 8–12 °C and add 4000 g of water. Stir for 4–8 h at 8–12 °C, filter, and rinse with 200 g of water. Dry the cake in vacuum at 80 °C for 8–24 h to obtain the title compound (560 g; 98.8% purity in 92% yield; [M + 1] = 213.8. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 8.564 (s, 1H), 8.278 (s, 1H), 8.011 (s, 1H),7.649 (s, 1H), 4.293–4.240 (dd, <i>J</i><sub>1</sub> = 6.8, <i>J</i><sub>2</sub> = 14, 2H), 2.462 (s, 3H), 1.308–1.272 (m, 3H).</div></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 4-Amino-2-(methylthio)pyrimidin-5-yl)methanol</h3><div class="NLM_p last">Cool a solution of ethyl 4-amino-2-(methylthio)pyrimidine-5-carboxylate (72.3 g, 339 mmol) in tetrahydrofuran (THF) (900 mL) to 0 °C. Add a solution of LiAlH<sub>4</sub> (2 M in THF) (195 mL, 390 mmol) dropwise over 1 h. Stir for 2 h at 0 °C and allow the reaction to warm to rt overnight. Cool the mixture to 0 °C and cautiously quench by the sequential addition of water (15 mL), 20% aq KOH (15 mL), and water (30 mL). Stir the resulting mixture for 1 h. Dry over MgSO<sub>4</sub>, filter, concentrate under reduced pressure, and dry under vacuum to obtain the title compound (55.85 g, 96% yield). MS (<i>m</i>/<i>z</i>): 172.1 (M + 1).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-Amino-2-(methylthio)pyrimidine-5-carbaldehyde <b>28</b></h3><div id="sec5_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Method A</h4><div class="NLM_p last">Add MnO<sub>2</sub> (49.8 g, 572 mmol) to a suspension of 4-amino-2-(methylthio)pyrimidin-5-yl)methanol (28 g, 164 mmol) in chloroform (818 mL) and heat the reaction at 55 °C (measure internally) for 4 h. Filter the hot reaction mixture, and rinse the filter cake with hot chloroform and THF. Concentrate the combined filtrates under reduced pressure and dry under vacuum to afford the title compound (26.7 g, 96% yield) as a pale yellow solid MS (<i>m</i>/<i>z</i>): 170.1 (M + 1).</div></div><div id="sec5_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Method B</h4><div class="NLM_p last">Charge a reaction vessel with 450 g (2.08 mol, 1.0 equiv) of ethyl 4-amino-2-(methylthio)pyrimidine-5-carboxylate and 6750 mL (15.0 V) of THF. In a separate reaction vessel charge 88.1 g (1.1 equiv) of LiAlH<sub>4</sub> and 2250 g (5.0 V) of THF. Cool this LiAlH<sub>4</sub> mixture to −5 to 5 °C. Add the THF solution of ethyl 4-amino-2-(methylthio)pyrimidine-5-carboxylate dropwise to the LiAlH<sub>4</sub> mixture below 10 °C. After addition, stir the mixture at 5–15 °C for 2–3 h. Cool to −5 to 5 °C, and add 279 g (1.5 equiv) of EtOAc dropwise below 20 °C. Stir the mixture at 10–20 °C for 1–2 h. Add 450 g (0.66 equiv) of Na<sub>2</sub>SO<sub>4</sub>·10H<sub>2</sub>O in portions below 20 °C. Stir the mixture at 10–20 °C for 1–2 h. Filter the suspension through diatomaceous earth. Wash the cake with THF. Charge 734 g (4.0 equiv) of MnO<sub>2</sub> to the filtrate containing 4-amino-2-(methylthio)pyrimidin-5-yl)methanol solution. Heat the mixture to 40 °C. Stir the mixture at 40–45 °C for 6–8 h. Filter the suspension through diatomaceous earth. Wash cake with THF. Combine the filtrate, concentrate, and add 1530 g (5.0 V) of <i>n</i>-heptane dropwise. Stir the mixture at 10–20 °C for 3–4 h. Filter the suspension and wash the cake with heptane. Dry the filter cake under reduced pressure at 40–50 °C for 10–16 h to afford the title compound (276 g; 97.9% purity in 75% yield; [M + 1] = 171.8). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 7.887 (s, 1H), 6.704 (s, 2H), 5.066–5.042 (m, 1H), 4.292–4.280 (d, 2H), 2.392 (s, 3H). [M + 1] = 169.8. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ = 9.769 (s, 1H), 8.414 (s, 1H), 8.190 (s, 1H), 5.772 (s, 1H), 2.540 (s, 3H)).</div></div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 7-Methyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-6-ol <b>32</b></h3><div id="sec5_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> Method A</h4><div class="NLM_p last">Add 1-hydroxypropan-2-one (24.3 mL, 355 mmol) and 4-amino-2-(methylthio)pyrimidine-5-carbaldehyde (50 g, 296 mmol) to a solution of sodium hydroxide (23.64 g, 591 mmol) and water (200 mL). Add EtOH (600 mL) to the suspension, and stir at rt overnight. Slowly add a solution of concentrated HCl (50 mL) in water (350 mL). Add 1:1 EtOH/H<sub>2</sub>O (100 mL) and collect the solids by filtration. Wash the solids with 1:1 EtOH/H<sub>2</sub>O (250 mL), ice cold EtOH (4 × 25 mL), and hexanes (2 × 250 mL). Dry in the vacuum oven at 30–35 °C to provide the title compound as a tan solid (34 g, 56% yield). MS (<i>m</i>/<i>z</i>): 208.1 (M + 1).</div></div><div id="sec5_10_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> Method B</h4><div class="NLM_p last">Charge reaction vessel with 2400 g (8.0 V) of H<sub>2</sub>O and 177.3 g (2.5 equiv) of NaOH and 300.0 g (1.77 mol, 1.0 equiv) of 4-amino-2-(methylthio)pyrimidine-5-carbaldehyde and 157.6 g (1.2 equiv) of hydroxyacetone. Heat the mixture to 35–45 °C and stir for 10–20 h at 35–45 °C. Cool the mixture to 5–15 °C. Add 4500 mL of 1 N HCl dropwise and adjust pH to 3–4 below 15 °C. Stir for 1–2 h at 10–15 °C. Filter and rinse cake with 300 g of water. Dry the filter cake under reduced pressure at 50–60 °C for 16–24 h to provide the title compound (372 g of brown solid; 98.0% HPLC area (assay, 90.0%); 90% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 10.864 (s, 1H), 9.276 (s, 1H), 7.529 (s, 1H), 2.570 (s, 6 H)).</div></div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 7-Methyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-6-yl Trifluoromethanesulfonate <b>33</b></h3><div id="sec5_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Method A</h4><div class="NLM_p last">Combine 7-methyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-6-ol (25 g, 121 mmol), DCM (1100 mL), and pyridine (98 mL, 1206 mmol) and cool the mixture with an ice bath until the internal temperature is <3 °C. Add trifluoromethanesulfonic anhydride (24.5 mL, 145 mmol) slowly via syringe at such a rate that the internal temperature was maintained below 5 °C. Stir the reaction mixture at 0 °C for 2 h. Wash with water (3 × 300 mL) and brine (300 mL), dry over MgSO<sub>4</sub>, and filter. Concentrate the filtrate under reduced pressure (water bath temp of ∼35 °C) and dry under high vacuum for 2–3 h at rt. Dissolve the residue in DCM, and purify by silica gel chromatography (EtOAc/hexanes). Concentrate fractions to afford a semipure solid. Triturate the solid with 20% EtOAc/hexanes (100 mL), collect by filtration, rinse with 20% EtOAc/hexanes (2 × 10 mL), and dry under vacuum at rt to afford the title compound as a pale pink solid (28.6 g, 70% yield). MS (<i>m</i>/<i>z</i>): 340.0 (M + 1).</div></div><div id="sec5_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Method B</h4><div class="NLM_p last">Charge reaction vessel with 4000 mL (20.0 V) of DCM and 208 g (1.0 mol, 1.0 equiv) of 7-methyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-6-ol. Stir the mixture for 10–20 min. Charge 312 g (4.0 equiv) of pyridine below 20 °C. Cool to −5 to 0 °C, and add the solution of 416 g of trifluoromethanesulfonic anhydride (1.5 equiv) in DCM (2000 mL, 10.0 V) dropwise below 0 °C. After addition, stir at 0–5 °C for 2–3 h. Quench reaction with 2000 mL of 1 N HCl (2×). Wash with 500 mL of H<sub>2</sub>O twice. Add 100.0 g of silica gel and stir at 10–20 °C for 1–2 h. Filter the mixture through diatomaceous earth. Concentrate filtrate and add <i>n</i>-heptane 1000 mL (5.0 V) dropwise with stirring at 10–20 °C. Stir the mixture at 10–20 °C for 3–4 h. Filter and dry the cake under reduced pressure at 35–40 °C for 8–12 h to afford title compound (307 g of brown solid; 99.1% HPLC area (assay, 96.8%); 86% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ = 9.216 (s, 1H), 8.120 (s, 1H), 2.890 (s, 3H), 2.773 (s, 3H)).</div></div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 7-Methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl Trifluoromethanesulfonate <b>34</b></h3><div id="sec5_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Method A</h4><div class="NLM_p last">Heat a mixture 7-methyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-6-yl trifluoromethanesulfonate (28.6 g, 84 mmol), dimethylformamide (74 mL), and glacial acetic acid (9.61 mL, 169 mmol) to 45 °C and then add 6.15% aqueous NaOCl (bleach, 612 g, 506 mmol) dropwise over 2 h. Heat at 45–50 °C for 2 h, cool to rt, collect the solids by filtration, and wash with water (300 mL). Add DCM (200 mL) to the solids, cool the suspension in an ice–water bath, and treat with a solution of 2.0 M <i>N</i>-methylamine in THF (126 mL, 253 mmol). Allow the mixture to slowly warm to rt and stir for 2 h. Remove the solvent under reduced pressure, treat with methanol (MeOH) (50 mL), and stir at rt for 30 min. Collect the solid by filtration and wash with MeOH. Treat the solid with EtOAc (30 mL) and stir at rt for 30 min. Collect the solid by filtration and wash with EtOAc to obtain the title compound (19.82 g, 73% yield). MS (<i>m</i>/<i>z</i>): 323.0 (M + 1).</div></div><div id="sec5_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Method B</h4><div class="NLM_p last">Charge reaction vessel with 150 g (0.442 mol, 1.0  equiv, limited reagent) of 7-methyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidin-6-yl trifluoromethanesulfonate, add 3000 mL DCM to clear, cool the mixture to −5 to 5 °C. Add 105 g (0.442 mol, 1.0 equiv) of m-CPBA in portions below 5 °C. Stir the mixture at 0–5 °C for 3–4 h (E/A = 1%). Add 660 mL (1.326 mol, 3.0 equiv) of methylamine in 2 M THF dropwise below 10 °C, and stir the mixture at 0–10 °C for 3–4 h. Add 1500 mL DCM and 1000 mL H<sub>2</sub>O with stirring and separate the aqueous layer. Wash the organic layer with 500 mL of H<sub>2</sub>O four times and concentrate to 600 g below 40 °C. Solvent exchange with <i>n</i>-heptane twice and stir the mixture at 10–20 °C for 3–4 h. Filter the suspension. Rinse with 150 g of <i>n</i>-heptane and dry the filter cake under reduced pressure at 65–75 °C for 10–16 h to obtain the title compound (129.6 g, 96.5% purity in 82% yield; LC–MS (MS+ = 371.8). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ = 8.932 (s, 1H), 7.86 (m, 1H), 5.707 (s, 1H), 3.192–3.180 (d, 3H), 2.754 (s, 3H)).</div></div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N</i>,7-Dimethylpyrido[2,3-<i>d</i>]pyrimidin-2-amine <b>30</b></h3><div class="NLM_p last">Treat a solution of 4-amino-2-(methylthio)pyrimidine-5-carbaldehyde (10 g, 59.1 mmol) in acetone (100 mL) with KOH (3.32 g, 59.1 mmol), stir at rt for 10 min, then concentrate to dryness. Treat the residue with EtOAc, wash with saturated aqueous NaHCO<sub>3</sub>, then brine, dry over Na<sub>2</sub>SO<sub>4</sub>, and concentrate to obtain 7-methyl-2-(methylthio)pyrido[2,3-<i>d</i>]pyrimidine. MS (<i>m</i>/<i>z</i>): 192.1 (M + 1). Add a solution of methylamine in ethanol (33%, 80 mL) and heat at 110 °C overnight in a pressure tube. Remove the solvent under reduced pressure and purify the crude product by silica gel chromatography (50–100% EtOAc/hexanes) to obtain the title compound (6.73 g, 65%, over two steps). MS (<i>m</i>/<i>z</i>): 175.1 (M + 1).</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 6-Bromo-<i>N</i>,7-dimethylpyrido[2,3-<i>d</i>]pyrimidin-2-amine <b>31</b></h3><div class="NLM_p last">Cool a solution of <i>N</i>,7-dimethylpyrido[2,3-<i>d</i>]pyrimidin-2-amine (6.73 g, 38.6 mmol) in acetonitrile (160 mL) in an ice bath, and shield from light with aluminum foil. Add <i>N</i>-bromosuccinimide (6.88 g, 38.6 mmol) and stir at 0 °C for 2 h. Transfer the reaction to a 5 °C refrigerator for 4 days. Collect the solid by filtration. Wash the solid with DCM and concentrate the washings to obtain the title compound (3.0 g, 31% yield). MS (<i>m</i>/<i>z</i>): 253.0/255.0 (M + 1).</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea <b>13</b></h3><div id="sec5_15_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Method A</h4><div class="NLM_p last">Combine 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea (25.9 g, 68.5 mmol), 7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl trifluoromethanesulfonate (22.09 g, 68.5 mmol), and NaHCO<sub>3</sub> (17.28 g, 206 mmol) in 1,4-dioxane (500 mL) and water (125 mL) and sparge with argon for 20 min. Add tetrakis(triphenylphosphine)palladium (3.96 g, 3.43 mmol) and then heat under argon at 50 °C. Add additional portion of 7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl trifluoromethanesulfonate (300 mg, 0.55 mmol) and continue heating at 50 °C overnight. Cool the mixture to rt, collect the solid by filtration, and wash with water and then diethyl ether. Treat the solid with acetonitrile (50 mL) and heat the slurry at 80 °C for 30 min. Collect the solid by filtration, wash with acetonitrile, and dry under vacuum at 80 °C to obtain a pale yellow solid. Treat the solid with MeOH (50 mL), and heat the mixture at 80 °C for 1 h. Cool to rt, collect the solid via filtration, wash with MeOH (20 mL), and dry under vacuum to obtain the title compound (22.5 g, 77% yield) as a pale yellow solid. MS (<i>m</i>/<i>z</i>): 425.2 (M + 1).</div></div><div id="sec5_15_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Method B</h4><div class="NLM_p last">Sparge a suspension of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea (4.48 g, 11.8 mmol), 6-bromo-<i>N</i>,7-dimethylpyrido[2,3-<i>d</i>]pyrimidin-2-amine (3.0 g, 11.8 mmol), and K<sub>2</sub>CO<sub>3</sub> (4.91 g, 35.6 mmol) in dioxane (80 mL) and water (20 mL) with argon, treat with tetrakis(triphenylphosphine)palladium (0.685 g, 0.593 mmol), and heat at 85 °C overnight. Remove the dioxane under reduced pressure, treat the mixture with EtOAc and brine, separate the layers, dry the organics over Na<sub>2</sub>SO<sub>4</sub>, concentrate, and purify by silica gel chromatography (40–100% EtOAc/hexane, 100% EtOAc, 5% MeOH/EtOAc). Treat the material with CH<sub>3</sub>CN, heat at 80 °C for 1 h, cool to rt, and collect the solid via filtration to afford the title compound (3.52 g, 70% yield) as a pale yellow solid. MS (<i>m</i>/<i>z</i>): 425.2 (M + 1).</div></div><div id="sec5_15_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Method C</h4><div class="NLM_p last">Bubble with N<sub>2</sub> the mixture solvents 1,4-dioxane (1250 g) and water (200 g) in a reaction vessel. Heat the mixture to 80–85 °C. Charge 100 g (0.31 mol, 1.0  equiv of limited reagent) of 7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl trifluoromethanesulfonate, 117.4 g (0.31 mol, 1.0 equiv) of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)urea, 128.7 g (0.93 mol, 3.0 equiv) of K<sub>2</sub>CO<sub>3</sub>, and 6.81 g (0.0093 mol, 0.03 equiv) of Pd(dppf)Cl<sub>2</sub> under nitrogen. Stir the mixture at 80–90 °C for 4–6 h. Cool the mixture to 40–50 °C. Concentrate and add 2000 g of water dropwise below 30 °C. After addition, stir the mixture at 10–30 °C for 6–8 h. Filter and rinse with 200 g of water, then wash the cake. Dry the filter cake under reduced pressure at 60–70 °C for 14–16 h to obtain Tech grade API of title compound (158g, 90.4% pure, assay, 63.4%, KF 5–6%). Dissolve the Tech grade API of title compound in 1000 mL of DCM and 1000 mL of EtOH at 10–30 °C. Add 50 g of silica gel, 80 g of Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>·5H<sub>2</sub>O, and 10 g of active carbon. Heat the mixture to 40–50 °C and stir for 3–5 h and cool to 10–30 °C. Filter and wash the cake with 200 g of DCM/EtOH (1:1). Stir with 5 g of silica thiol at 40–50 °C and filter. Solvent-exchange with 390.0 g of EtOH twice. Concentrate and filter the suspension, then wash the cake with 39.0 g of EtOH. Dry the filter cake under reduced pressure at 65–75 °C for 14–16 h to obtain API of title compound (61 g, 98.5% pure, assay, 97.5%, 65% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ = 9.077 (s, 1H), 8.278 (s, 1H), 7.968–7.947 (d, 1H), 7.893 (s, 1H), 7.680 (s, 1H), 7.193–7.162 (d, 1H), 6.512–6.485 (m, 1H), 3.088–3.035 (m, 2H), 2.924–2.914 (d, 3H), 2.296 (s, 3H), 1.955(s, 3H), 1.344–1.304 (m, 2H), 0.875 (s, 9 H). HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>29</sub>FN<sub>6</sub>O 424.2387, found 424.2377.)</div></div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Cell Lines, Antibodies, and Reagents</h3><div class="NLM_p last">All cell lines were cultured in conditions recommended by sources where the cell lines were purchased (ATCC, JCRB, SIBS, ECACC, RIKEN). Cell density was optimized and growth curves were determined for all cell lines to identify drug testing conditions for a duration based on two average population doublings. Prior to testing, cell lines were tested for mycoplasma and identity was confirmed by STR-based DNA fingerprinting and multiplex PCR (IDEXX-Radil). Antibodies against ERK1/2, phospho-ERK1/2 (no. 9101), phospho-Akt1 (S473) (no. 4060), ARAF (no. 4432), B-RAF (no. 9434), C-RAF (no. 9422), phospho-MEK1/2 (no. 9154) and Akt (no. 9272), cleaved PARP (no. 5625), Myc-tag (no. 2272), and actin (no. 4970) were obtained from Cell Signaling Technology. Anti-tubulin (ab7291, Abcam), anti-pRSK (ab32413, Abcam), and anti-RAS (Upstate) antibodies were obtained from the indicated companies. Cell lysate preparation, Western blot, and flow cytometry analyses were described previously.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a></div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Enzymatic Kinase Assays</h3><div class="NLM_p last">The enzymatic assays of BRAF, CRAF, and BRAF mutations evaluate a property of RAF and MEK1 complex, which in the presence of ATP catalyzes an enhanced ATP hydrolysis (Rominger et al., 2007). The ADP formed was monitored by the well-known coupled PK/LDH (pyruvate kinase/lactate dehydrogenase) system in the form of NADH oxidation, which can be monitored at 340 nm. In the BRAF WT enzymatic assay, the reaction mixture contains 1.2 nM BRAF, 30 nM MEK1, 1000 μM ATP, 3.5 units (per 100 μL) of PK, 5 units (per 100 μL) of LDH, 1 mM PEP, and 280 μM NADH. In the CRAF assay, the reaction mixture contains 0.6 nM CRAF, 26 nM MEK1, 2000 μM ATP, and the same amount of PK, LDH, PEP, and NADH as above. In the BRAF V600E assay, the reaction mixture contains 1.6 μM BRAF V600E, 26 nM MEK1, 200 μM ATP, and the same amount of PK, LDH, PEP, and NADH as above. In the BRAFV600E + T529I assay, the reaction mixture contains 6.2 nM BRAF V600E + T529I, 30 nM MEK1, 200 μM ATP, and the same amount of PK, LDH, PEP, and NADH as above. In the B-RAF V600E + G468A assay, the reaction mixture contains 3.5 nM B-RAF, 30 nM MEK1, 200 μM ATP, and the same amount of PK, LDH, PEP, and NADH as above. All assays were started by mixing the above mixture with test compound and monitored at 340 nm continuously for approximately 5 h. Reaction data at the 3 to 4 h time frame were collected to calculate IC<sub>50</sub>.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> CellTiter-Blue Cell Proliferation and Viability Assay</h3><div id="sec5_18_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> A375 Cell Proliferation Assay</h4><div class="NLM_p last">A375 cells (catalog no. CRL-1619) were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Briefly, cells were grown in DMEM high glucose supplemented with 10% characterized fetal bovine serum (Invitrogen, Carlsbad, CA) and 1% penicillin/streptomycin/<span class="smallcaps smallerCapital">l</span>-glutamine at 37 °C, 5% CO<sub>2</sub>, and 95% humidity. Cells were allowed to expand until 70–95% confluency at which point they were subcultured or harvested for assay use. A serial dilution of test compound was dispensed into a 384-well black clear bottom plate in triplicate. Six-hundred-twenty-five cells were added per well in 50 μL of complete growth medium in the 384-well plate. Plates were incubated for 67 h at 37 °C, 5% CO<sub>2</sub>, and 95% humidity. At the end of the incubation period, 10 μL of a 440 μM solution of resazurin (Sigma, St. Louis, MO) in PBS was added to each well of the plate and plates were incubated for an additional 5 h at 37 °C, 5% CO<sub>2</sub>, and 95% humidity. Plates were read on a Synergy2 reader (Biotek, Winooski, VT) using an excitation of 540 nm and an emission of 600 nm. Data were analyzed using Prism software (GraphPad, San Diego, CA) to calculate IC<sub>50</sub> values.</div></div><div id="sec5_18_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> HCT-116 Cell Proliferation Assay</h4><div class="NLM_p last">HCT-116 cells (catalog no. CCL-247) were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Briefly, cells were grown in McCoy’s 5A supplemented with 10% characterized fetal bovine serum (Invitrogen, Carlsbad, CA) and 1% penicillin/streptomycin/<span class="smallcaps smallerCapital">l</span>-glutamine at 37 °C, 5% CO<sub>2</sub>, and 95% humidity. Cells were allowed to expand until 75–90% confluency at which point they were subcultured or harvested for assay use. A serial dilution of test compound was dispensed into a 384-well black clear bottom plate in triplicate. Six-hundred-twenty-five cells were added per well in 50 μL of complete growth medium in the 384-well plate. Plates were incubated for 67 h at 37 °C, 5% CO<sub>2</sub>, and 95% humidity. At the end of the incubation period, 10 μL of a 440 μM solution of resazurin (Sigma, St. Louis, MO) in PBS was added to each well of the plate and plates were incubated for an additional 5 h at 37 °C, 5% CO<sub>2</sub>, and 95% humidity. Plates were read on a Synergy2 reader (Biotek, Winooski, VT) using an excitation of 540 nm and an emission of 600 nm. Data were analyzed using Prism software (GraphPad, San Diego, CA) to calculate IC<sub>50</sub> values.</div></div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Kinase Activity Measurement Using KiNativ Assays of ActivX Biosciences Inc</h3><div class="NLM_p last">Whole cell KiNativ assays were developed by ActivX Biosciences Inc. using whole cell lysates of A375 cells as described.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Animal Studies</h3><div class="NLM_p last">To evaluate in vivo efficacy, multiple xenograft tumor models were utilized. Briefly, (5–10) × 10<sup>6</sup> tumor cells in a 1:1 Matrigel mix (0.2 mL total volume) were injected subcutaneously into the right hind flank of female NIH nude rats, or female athymic nude mice (Taconic Biosciences). After allowing tumors to reach a desired size of approximately 500 mm<sup>3</sup> (rats) or 300 mm<sup>3</sup> (mice), animals were randomized into either groups of 8 for efficacy studies or groups of 3−4 for PK/PD studies. All procedures and techniques were performed in accordance with American Association for Laboratory Animal Care institutional guidelines and monitored by the Eli Lilly and Company Animal Care and Use Committee. Treatment was either vehicle (20% cyclodextrin, 25 mM phosphate, pH2.0) or <b>13</b> administered via oral gavage (po) at 0.6 mL per animal twice daily. Tumor growth and body weight were monitored over time to evaluate efficacy and signs of toxicity as described.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> MSD ELISA Analysis of Phospho-ERK Activity</h3><div class="NLM_p last">The ELISA analysis of phospho-ERK activity was determined with Meso Scale Discovery (MSD) ERK1 and ERK2 Duplex V.2 MD6000 4 Spot Plate and assay kit (catalog no. N41CB-1) per manufacturer’s instructions.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i53"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00067">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10070" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10070" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Synthetic procedures and analytical data for all compounds except for <b>13</b>. The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b00067" class="ext-link">10.1021/acs.jmedchem.5b00067</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00067/suppl_file/jm5b00067_si_001.pdf">jm5b00067_si_001.pdf (461.79 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b00067" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24757" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24757" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James R. Henry</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6208100a070c101b220e0b0e0e1b4c010d0f"><span class="__cf_email__" data-cfemail="6309110b060d111a230f0a0f0f1a4d000c0e">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael D. Kaufman</span> - <span class="hlFld-Affiliation affiliation">Deciphera
Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sheng-Bin Peng</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Mi Ahn</span> - <span class="hlFld-Affiliation affiliation">Deciphera
Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy M. Caldwell</span> - <span class="hlFld-Affiliation affiliation">Deciphera
Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lakshminarayana Vogeti</span> - <span class="hlFld-Affiliation affiliation">Deciphera
Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hanumaiah Telikepalli</span> - <span class="hlFld-Affiliation affiliation">Deciphera
Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei-Ping Lu</span> - <span class="hlFld-Affiliation affiliation">Deciphera
Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Molly M. Hood</span> - <span class="hlFld-Affiliation affiliation">Deciphera
Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas J. Rutkoski</span> - <span class="hlFld-Affiliation affiliation">Deciphera
Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bryan D. Smith</span> - <span class="hlFld-Affiliation affiliation">Deciphera
Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Subha Vogeti</span> - <span class="hlFld-Affiliation affiliation">Deciphera
Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Miller</span> - <span class="hlFld-Affiliation affiliation">Deciphera
Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott C. Wise</span> - <span class="hlFld-Affiliation affiliation">Deciphera
Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lawrence Chun</span> - <span class="hlFld-Affiliation affiliation">Emerald
Biostructures, Bainbridge Island, Washington 98110, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoyi Zhang</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Youyan Zhang</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Kays</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip A. Hipskind</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aaron D. Wrobleski</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen L. Lobb</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julia M. Clay</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey D. Cohen</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennie L. Walgren</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Denis McCann</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Phenil Patel</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David K. Clawson</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sherry Guo</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Danalyn Manglicmot</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chris Groshong</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheyenne Logan</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James J. Starling</span> - <span class="hlFld-Affiliation affiliation">Eli
Lilly and Company, Indianapolis, Indiana 46285, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel L. Flynn</span> - <span class="hlFld-Affiliation affiliation">Deciphera
Pharmaceuticals, LLC, Waltham, Massachusetts 02451, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d894e3881-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70582" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70582" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Oscar DeFrutos and Carlos Gutierrez for their critical chemistry contributions. This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract DE-AC02-06CH11357. Use of the Lilly Research Laboratories Collaborative Access Team (LRL-CAT) beamline at Sector 31 of the Advanced Photon Source was provided by Eli Lilly Company, which operates the facility.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i55" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i55"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i56" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i56"> Abbreviations Used</h2><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen activated protein kinase</p></td></tr><tr><td class="NLM_term">ADP</td><td class="NLM_def"><p class="first last">adenosine diphosphate</p></td></tr><tr><td class="NLM_term">IVTI</td><td class="NLM_def"><p class="first last">in vivo target inhibition</p></td></tr><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">aspartic acid–phenylalanine–glycine</p></td></tr><tr><td class="NLM_term">ED<sub>50</sub></td><td class="NLM_def"><p class="first last">effective dose giving 50% target inhibition</p></td></tr><tr><td class="NLM_term">ED<sub>80</sub></td><td class="NLM_def"><p class="first last">effective dose giving 80% target inhibition</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">b.i.d.</td><td class="NLM_def"><p class="first last">twice daily</p></td></tr><tr><td class="NLM_term">API</td><td class="NLM_def"><p class="first last">active pharmaceutical ingredient</p></td></tr><tr><td class="NLM_term">GLP</td><td class="NLM_def"><p class="first last">good laboratory practice</p></td></tr><tr><td class="NLM_term">PMB</td><td class="NLM_def"><p class="first last">para-methoxy benzyl</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80667" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80667" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 27 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Vigil, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherfils, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossman, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">RAS superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">842</span><span class="NLM_x">–</span> <span class="NLM_lpage">857</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1038%2Fnrc2960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=21102635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=842-857&author=D.+Vigilauthor=J.+Cherfilsauthor=K.+L.+Rossmanauthor=C.+J.+Der&title=RAS+superfamily+GEFs+and+GAPs%3A+validated+and+tractable+targets+for+cancer+therapy%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?</span></div><div class="casAuthors">Vigil, Dominico; Cherfils, Jacqueline; Rossman, Kent L.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">842-857</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There is now considerable and increasing evidence for a causal role for aberrant activity of the Ras superfamily of small GTPases in human cancers.  These GTPases function as GDP-GTP-regulated binary switches that control many fundamental cellular processes.  A common mechanism of GTPase deregulation in cancer is the deregulated expression and/or activity of their regulatory proteins, guanine nucleotide exchange factors (GEFs) that promote formation of the active GTP-bound state and GTPase-activating proteins (GAPs) that return the GTPase to its GDP-bound inactive state.  In this Review, we assess the assocn. of GEFs and GAPs with cancer and their druggability for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwbf8B7sLmb7Vg90H21EOLACvtfcHk0lh4UD01E0wPKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsbrM&md5=b7ad81f2fe0f7f7eaa5f015188f62e85</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2960%26sid%3Dliteratum%253Aachs%26aulast%3DVigil%26aufirst%3DD.%26aulast%3DCherfils%26aufirst%3DJ.%26aulast%3DRossman%26aufirst%3DK.%2BL.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DRAS%2520superfamily%2520GEFs%2520and%2520GAPs%253A%2520validated%2520and%2520tractable%2520targets%2520for%2520cancer%2520therapy%253F%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D842%26epage%3D857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Pylayeva-Gupta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabocka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bar-Sagi, D.</span><span> </span><span class="NLM_article-title">RAS oncogenes: weaving a tumorigenic web</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1038%2Fnrc3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=21993244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSkur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=761-774&author=Y.+Pylayeva-Guptaauthor=E.+Grabockaauthor=D.+Bar-Sagi&title=RAS+oncogenes%3A+weaving+a+tumorigenic+web"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">RAS oncogenes: weaving a tumorigenic web</span></div><div class="casAuthors">Pylayeva-Gupta, Yuliya; Grabocka, Elda; Bar-Sagi, Dafna</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">761-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  RAS proteins are essential components of signalling pathways that emanate from cell surface receptors.  Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer.  A wealth of biochem. and genetic studies indicates that RAS proteins control a complex mol. circuitry that consists of a wide array of interconnecting pathways.  In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdHRt0jsiXtLVg90H21EOLACvtfcHk0lh4UD01E0wPKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSkur7K&md5=d1be47023ab43a30cb81e71cb92bc0aa</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3106%26sid%3Dliteratum%253Aachs%26aulast%3DPylayeva-Gupta%26aufirst%3DY.%26aulast%3DGrabocka%26aufirst%3DE.%26aulast%3DBar-Sagi%26aufirst%3DD.%26atitle%3DRAS%2520oncogenes%253A%2520weaving%2520a%2520tumorigenic%2520web%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D761%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of mutated, activated BRAF in metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+mutated%2C+activated+BRAF+in+metastatic+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0lhvWJGs2kIxiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520mutated%252C%2520activated%2520BRAF%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BRIM-3 Study Group.</span><span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthurauthor=BRIM-3+Study+Group.&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0lhvWJGs2kIxiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3D%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demidov, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutzmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. H.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaempgen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Algarra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaszewska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiarion-Sileni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haney, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirakhur, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guckert, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">380</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1016%2FS0140-6736%2812%2960868-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=22735384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=358-365&author=A.+Hauschildauthor=J.+J.+Grobauthor=L.+V.+Demidovauthor=T.+Jouaryauthor=R.+Gutzmerauthor=M.+Millwardauthor=P.+Rutkowskiauthor=C.+U.+Blankauthor=W.+H.+Millerauthor=E.+Kaempgenauthor=S.+Mart%C3%ADn-Algarraauthor=B.+Karaszewskaauthor=C.+Mauchauthor=V.+Chiarion-Sileniauthor=A.+M.+Martinauthor=S.+Swannauthor=P.+Haneyauthor=B.+Mirakhurauthor=M.+E.+Guckertauthor=V.+Goodmanauthor=P.+B.+Chapman&title=Dabrafenib+in+BRAF-mutated+metastatic+melanoma%3A+a+multicentre%2C+open-label%2C+phase+3+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span></div><div class="casAuthors">Hauschild, Axel; Grob, Jean-Jacques; Demidov, Lev V.; Jouary, Thomas; Gutzmer, Ralf; Millward, Michael; Rutkowski, Piotr; Blank, Christian U.; Miller, Wilson H.; Kaempgen, Eckhart; Martin-Algarra, Salvador; Karaszewska, Boguslawa; Mauch, Cornelia; Chiarion-Sileni, Vanna; Martin, Anne-Marie; Swann, Suzanne; Haney, Patricia; Mirakhur, Beloo; Guckert, Mary E.; Goodman, Vicki; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">9839</span>),
    <span class="NLM_cas:pages">358-365</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dabrafenib, an inhibitor of mutated BRAF, has clin. activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAFV600-mutated metastatic melanoma.  We studied the efficacy of dabrafenib in patients with BRAFV600E-mutated metastatic melanoma.We enrolled patients in this open-label phase 3 trial between Dec 23, 2010, and Sept 1, 2011.  This report is based on a data cutoff date of Dec 19, 2011.  Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAFV600E mutation-pos. melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m2 i.v. every 3 wk).  Patients were stratified according to American Joint Committee on Cancer stage (unresectable III+IVM1a+IVM1b vs IVM1c).  The primary endpoint was investigator-assessed progression-free survival and was analyzed by intention to treat; safety was assessed per protocol.  This study is registered with ClinicalTrials.gov, no. NCT01227889.Of the 733 patients screened, 250 were randomly assigned to receive either dabrafenib (187 patients) or dacarbazine (63 patients).  Median progression-free survival was 5·1 mo for dabrafenib and 2·7 mo for dacarbazine, with a hazard ratio (HR) of 0·30 (95% CI 0·18-0·51; p<0·0001).  At data cutoff, 107 (57%) patients in the dabrafenib group and 14 (22%) in the dacarbazine group remained on randomized treatment.  Treatment-related adverse events (grade 2 or higher) occurred in 100 (53%) of the 187 patients who received dabrafenib and in 26 (44%) of the 59 patients who received dacarbazine.  The most common adverse events with dabrafenib were skin-related toxic effects, fever, fatigue, arthralgia, and headache.  The most common adverse events with dacarbazine were nausea, vomiting, neutropenia, fatigue, and asthenia.  Grade 3-4 adverse events were uncommon in both groups.Dabrafenib significantly improved progression-free survival compared with dacarbazine.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEDYPJULE5c7Vg90H21EOLACvtfcHk0ljWEcXtTA3DEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D&md5=5e8699780f47bd37e075d39636e0d809</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960868-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960868-X%26sid%3Dliteratum%253Aachs%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DKaempgen%26aufirst%3DE.%26aulast%3DMart%25C3%25ADn-Algarra%26aufirst%3DS.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DMauch%26aufirst%3DC.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DHaney%26aufirst%3DP.%26aulast%3DMirakhur%26aufirst%3DB.%26aulast%3DGuckert%26aufirst%3DM.%2BE.%26aulast%3DGoodman%26aufirst%3DV.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DDabrafenib%2520in%2520BRAF-mutated%2520metastatic%2520melanoma%253A%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D358%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Heidorn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milagre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nourry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhomen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&author=S.+J.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+Niculescu-Duvasauthor=N.+Dhomenauthor=J.+Hussainauthor=J.+S.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-dead+BRAF+and+oncogenic+RAS+cooperate+to+drive+tumor+progression+through+CRAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0ljWEcXtTA3DEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescu-Duvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-dead%2520BRAF%2520and%2520oncogenic%2520RAS%2520cooperate%2520to%2520drive%2520tumor%2520progression%2520through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26spage%3D209%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Poulikakos, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1038%2Fnature08902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=20179705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=N.+Rosen&title=RAF+inhibitors+transactivate+RAF+dimers+and+ERK+signalling+in+cells+with+wild-type+BRAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Zhang, Chao; Bollag, Gideon; Shokat, Kevan M.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">427-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF are dependent on the RAF-MEK-ERK signaling pathway for their growth.  We found that ATP-competitive RAF inhibitors inhibit ERK signaling in cells with mutant BRAF, but unexpectedly enhance signaling in cells with wild-type BRAF.  Here we demonstrate the mechanistic basis for these findings.  We used chem. genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors.  Induction of ERK signaling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity.  Drug binding to one member of RAF homodimers (CRAF-CRAF) or heterodimers (CRAF-BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer.  In BRAF(V600E) tumors, RAS is not activated, thus transactivation is minimal and ERK signaling is inhibited in cells exposed to RAF inhibitors.  These results indicate that RAF inhibitors will be effective in tumors in which BRAF is mutated.  Furthermore, because RAF inhibitors do not inhibit ERK signaling in other cells, the model predicts that they would have a higher therapeutic index and greater antitumor activity than mitogen-activated protein kinase (MEK) inhibitors, but could also cause toxicity due to MEK/ERK activation.  These predictions have been borne out in a recent clin. trial of the RAF inhibitor PLX4032 (refs 4, 5).  The model indicates that promotion of RAF dimerization by elevation of wild-type RAF expression or RAS activity could lead to drug resistance in mutant BRAF tumors.  In agreement with this prediction, RAF inhibitors do not inhibit ERK signaling in cells that coexpress BRAF(V600E) and mutant RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlm9feupyNrVg90H21EOLACvtfcHk0ljWEcXtTA3DEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D&md5=8323a558886ccbb8f7d85b22b9bfbc15</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature08902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08902%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRAF%2520inhibitors%2520transactivate%2520RAF%2520dimers%2520and%2520ERK%2520signalling%2520in%2520cells%2520with%2520wild-type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D427%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaiswal, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0ljvFF6r2UfhGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D431%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Sanchez-Laorden, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saturno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turajlic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">ra30</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1126%2Fscisignal.2004815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=24667377" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=ra30&author=B.+Sanchez-Laordenauthor=A.+Virosauthor=M.+R.+Girottiauthor=M.+Pedersenauthor=G.+Saturnoauthor=A.+Zambonauthor=D.+Niculescu-Duvazauthor=S.+Turajlicauthor=A.+Hayesauthor=M.+Goreauthor=J.+Larkinauthor=P.+Loriganauthor=M.+Cookauthor=C.+Springerauthor=R.+Marais&title=BRAF+inhibitors+induce+metastasis+in+RAS+mutant+or+inhibitor-resistant+melanoma+cells+by+reactivating+MEK+and+ERK+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004815%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Laorden%26aufirst%3DB.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DGirotti%26aufirst%3DM.%2BR.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DTurajlic%26aufirst%3DS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DCook%26aufirst%3DM.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DBRAF%2520inhibitors%2520induce%2520metastasis%2520in%2520RAS%2520mutant%2520or%2520inhibitor-resistant%2520melanoma%2520cells%2520by%2520reactivating%2520MEK%2520and%2520ERK%2520signaling%26jtitle%3DSci.%2520Signaling%26date%3D2014%26volume%3D7%26spage%3Dra30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Blasco, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francoz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santamaria, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canamero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubus, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charron, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">C-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">652</span><span class="NLM_x">–</span> <span class="NLM_lpage">663</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=652-663&author=R.+B.+Blascoauthor=S.+Francozauthor=D.+Santamariaauthor=M.+Canameroauthor=P.+Dubusauthor=J.+Charronauthor=M.+Baccariniauthor=M.+Barbacid&title=C-Raf%2C+but+not+B-Raf%2C+is+essential+for+development+of+K-Ras+oncogene-driven+non-small+cell+lung+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlasco%26aufirst%3DR.%2BB.%26aulast%3DFrancoz%26aufirst%3DS.%26aulast%3DSantamaria%26aufirst%3DD.%26aulast%3DCanamero%26aufirst%3DM.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DCharron%26aufirst%3DJ.%26aulast%3DBaccarini%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DC-Raf%252C%2520but%2520not%2520B-Raf%252C%2520is%2520essential%2520for%2520development%2520of%2520K-Ras%2520oncogene-driven%2520non-small%2520cell%2520lung%2520carcinoma%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D652%26epage%3D663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Karreth, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frese, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeNicola, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span> </span><span class="NLM_article-title">C-Raf is required for the initiation of lung cancer by K-RasG12D</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=128-136&author=F.+A.+Karrethauthor=K.+K.+Freseauthor=G.+M.+DeNicolaauthor=M.+Baccariniauthor=D.+A.+Tuveson&title=C-Raf+is+required+for+the+initiation+of+lung+cancer+by+K-RasG12D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKarreth%26aufirst%3DF.%2BA.%26aulast%3DFrese%26aufirst%3DK.%2BK.%26aulast%3DDeNicola%26aufirst%3DG.%2BM.%26aulast%3DBaccarini%26aufirst%3DM.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26atitle%3DC-Raf%2520is%2520required%2520for%2520the%2520initiation%2520of%2520lung%2520cancer%2520by%2520K-RasG12D%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D128%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span> </span><span class="NLM_article-title">Conformation specific effects of Raf kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7332</span><span class="NLM_x">–</span> <span class="NLM_lpage">7341</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300613w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7332-7341&author=X.+Wangauthor=J.+Kim&title=Conformation+specific+effects+of+Raf+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm300613w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300613w%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DConformation%2520specific%2520effects%2520of%2520Raf%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7332%26epage%3D7341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Okaniwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchiyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tottori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span> </span><span class="NLM_article-title">Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6478</span><span class="NLM_x">–</span> <span class="NLM_lpage">6494</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400778d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2qsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6478-6494&author=M.+Okaniwaauthor=M.+Hiroseauthor=T.+Aritaauthor=M.+Yabukiauthor=A.+Nakamuraauthor=T.+Takagiauthor=T.+Kawamotoauthor=N.+Uchiyamaauthor=A.+Sumitaauthor=S.+Tsutsumiauthor=T.+Tottoriauthor=Y.+Inuiauthor=B.+C.+Sangauthor=J.+Yanoauthor=K.+Aertgeertsauthor=S.+Yoshidaauthor=T.+Ishikawa&title=Discovery+of+a+selective+kinase+inhibitor+%28TAK-632%29+targeting+pan-RAF+inhibition%3A+design%2C+synthesis%2C+and+biological+evaluation+of+C-7-substituted+1%2C3-benzothiazole+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives</span></div><div class="casAuthors">Okaniwa, Masanori; Hirose, Masaaki; Arita, Takeo; Yabuki, Masato; Nakamura, Akito; Takagi, Terufumi; Kawamoto, Tomohiro; Uchiyama, Noriko; Sumita, Akihiko; Tsutsumi, Shunichirou; Tottori, Tsuneaki; Inui, Yoshitaka; Sang, Bi-Ching; Yano, Jason; Aertgeerts, Kathleen; Yoshida, Sei; Ishikawa, Tomoyasu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6478-6494</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With the aim of discovering a selective kinase inhibitor targeting pan-RAF kinase inhibition, we designed novel 1,3-benzothiazole derivs. based on our thiazolo[5,4-b]pyridine class RAF/VEGFR2 inhibitor and developed a regioselective cyclization methodol. for the C-7-substituted 1,3-benzothiazole scaffold utilizing meta-substituted anilines.  Eventually, we selected 7-cyano deriv. I (TAK-632) as a development candidate and confirmed its binding mode by cocrystal structure with BRAF.  Accommodation of the 7-cyano group into the BRAF-selectivity pocket and the 3-(trifluoromethyl)phenyl acetamide moiety into the hydrophobic back pocket of BRAF in the DFG-out conformation contributed to enhanced RAF potency and selectivity vs VEGFR2.  Reflecting its potent pan-RAF inhibition and slow off-rate profile, I demonstrated significant cellular activity against mutated BRAF or mutated NRAS cancer cell lines.  Furthermore, in both A375 (BRAFV600E) and HMVII (NRASQ61K) xenograft models in rats, I demonstrated regressive antitumor efficacy by twice daily, 14-day repetitive administration without significant body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2jcxKx47lWLVg90H21EOLACvtfcHk0lhciKboAGzLJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2qsrzL&md5=60ccb75bcf7d7772cdf21468e26c141f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm400778d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400778d%26sid%3Dliteratum%253Aachs%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DHirose%26aufirst%3DM.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DSumita%26aufirst%3DA.%26aulast%3DTsutsumi%26aufirst%3DS.%26aulast%3DTottori%26aufirst%3DT.%26aulast%3DInui%26aufirst%3DY.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520kinase%2520inhibitor%2520%2528TAK-632%2529%2520targeting%2520pan-RAF%2520inhibition%253A%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520C-7-substituted%25201%252C3-benzothiazole%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6478%26epage%3D6494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Allgeier, M. C.; Flynn, D. L.; Kaufman, M. D.; Patel, P. J.; Wolfangel, C. D.</span><span> </span><span class="NLM_article-title">2-Amino, 6-phenyl substituted pyrido[2, 3-d]pyrimidine derivatives useful as raf kinase inhibitors</span>. WO2013134243,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+C.+Allgeier&author=D.+L.+Flynn&author=M.+D.+Kaufman&author=P.+J.+Patel&author=C.+D.+Wolfangel&title=2-Amino%2C+6-phenyl+substituted+pyrido%5B2%2C+3-d%5Dpyrimidine+derivatives+useful+as+raf+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllgeier%26aufirst%3DM.%2BC.%26atitle%3D2-Amino%252C%25206-phenyl%2520substituted%2520pyrido%255B2%252C%25203-d%255Dpyrimidine%2520derivatives%2520useful%2520as%2520raf%2520kinase%2520inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Peng, S.; Henry, J. R.; Kaufman, M. D.; Lu, W.; Smith, B. D.; Vogeti, S.; Wise, S.; Chun, L.; Buchanan, S.; Mochalkin, I.; Zhang, Y.; Van Horn, R.; Yin, T.; Zhang, X.; Yadav, V.; Chen, S.; Gong, X.; Ma, X.; Webster, Y.; Huber, L.; Kays, L.; Donoho, G.; Walgren, J.; McCann, D.; Patel, P.; Conti, I.; Plowman, G. D.; Starling, J. J.; Flynn, D. L.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Peng%2C+S.%3B+Henry%2C+J.+R.%3B+Kaufman%2C+M.+D.%3B+Lu%2C+W.%3B+Smith%2C+B.+D.%3B+Vogeti%2C+S.%3B+Wise%2C+S.%3B+Chun%2C+L.%3B+Buchanan%2C+S.%3B+Mochalkin%2C+I.%3B+Zhang%2C+Y.%3B+Van+Horn%2C+R.%3B+Yin%2C+T.%3B+Zhang%2C+X.%3B+Yadav%2C+V.%3B+Chen%2C+S.%3B+Gong%2C+X.%3B+Ma%2C+X.%3B+Webster%2C+Y.%3B+Huber%2C+L.%3B+Kays%2C+L.%3B+Donoho%2C+G.%3B+Walgren%2C+J.%3B+McCann%2C+D.%3B+Patel%2C+P.%3B+Conti%2C+I.%3B+Plowman%2C+G.+D.%3B+Starling%2C+J.+J.%3B+Flynn%2C+D.+L.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DS." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Rohrs, B. R.</span><span> </span><span class="NLM_article-title">Biopharmaceutics modeling and the role of dose and formulation on oral exposure</span>. In  <span class="citation_source-book">Optimizing the “Drug-like” Properties of Leads in Drug Discovery</span>; <span class="NLM_contrib-group">Borchardt, R. T.; Kerns, E. H.; Hageman, M. J.; Thakker, D. R.; Stevens, J. L.</span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">IV</span>, pp  <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1007%2F978-0-387-44961-6_7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=151-166&author=B.+R.+Rohrsauthor=R.+T.+Borchardt&author=E.+H.+Kerns&author=M.+J.+Hageman&author=D.+R.+Thakker&author=J.+L.+Stevens&title=Optimizing+the+%E2%80%9CDrug-like%E2%80%9D+Properties+of+Leads+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2F978-0-387-44961-6_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-0-387-44961-6_7%26sid%3Dliteratum%253Aachs%26aulast%3DRohrs%26aufirst%3DB.%2BR.%26atitle%3DBiopharmaceutics%2520modeling%2520and%2520the%2520role%2520of%2520dose%2520and%2520formulation%2520on%2520oral%2520exposure%26btitle%3DOptimizing%2520the%2520%25E2%2580%259CDrug-like%25E2%2580%259D%2520Properties%2520of%2520Leads%2520in%2520Drug%2520Discovery%26aulast%3DBorchardt%26aufirst%3DR.%2BT.%26pub%3DSpringer%26date%3D2006%26volume%3DIV%26spage%3D151%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Oh, D.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curl, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amidon, G. L.</span><span> </span><span class="NLM_article-title">Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1023%2FA%3A1018947113238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=8456075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1SmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=264-270&author=D.-M.+Ohauthor=R.+L.+Curlauthor=G.+L.+Amidon&title=Estimating+the+fraction+dose+absorbed+from+suspensions+of+poorly+soluble+compounds+in+humans%3A+a+mathematical+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model</span></div><div class="casAuthors">Oh, Doo Man; Curl, Rane L.; Amidon, Gordon L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">264-70</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">A microscopic mass balance approach has been developed to predict the fraction dose absorbed of suspensions of poorly sol. compds.  The math. model includes four fundamental dimensionless parameters to est. the fraction dose absorbed: initial satn. (Is), absorption no. (An), dose no. (Do), and dissoln. no. (Dn).  The fraction dose absorbed (F) increases with increasing Is, An, and Dn and with decreasing Do.  At higher Dn and lower Do, the fraction dose absorbed reaches the maximal F, which depends only on An.  The dissoln. no. limit on F can appear at both lower Do and lower Dn.  It is shown that the extent fo drug absorption is expected to be highly variable when Dn and Do are approx. one.  Furthermore, by calcg. these dimensionless groups for a given compd., a formulation scientists can est. not only the extent of drug absorption but also the effect, if any, of particle size redn. on the extent of drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopaxhSvKyLwrVg90H21EOLACvtfcHk0li9SJ2vANHHmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1SmsLw%253D&md5=a83a50cd018fc09bd4b3142305199fa9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018947113238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018947113238%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DD.-M.%26aulast%3DCurl%26aufirst%3DR.%2BL.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DEstimating%2520the%2520fraction%2520dose%2520absorbed%2520from%2520suspensions%2520of%2520poorly%2520soluble%2520compounds%2520in%2520humans%253A%2520a%2520mathematical%2520model%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26spage%3D264%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Leuner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dressman, J. B.</span><span> </span><span class="NLM_article-title">Improving drug solubility for oral delivery using solid dispersions</span> <span class="citation_source-journal">Eur. J. Pharm. Biopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1016%2FS0939-6411%2800%2900076-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10840192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjslyju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2000&pages=47-60&author=C.+Leunerauthor=J.+B.+Dressman&title=Improving+drug+solubility+for+oral+delivery+using+solid+dispersions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Improving drug solubility for oral delivery using solid dispersions</span></div><div class="casAuthors">Leuner, C.; Dressman, J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutics and Biopharmaceutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-60</span>CODEN:
                <span class="NLM_cas:coden">EJPBEL</span>;
        ISSN:<span class="NLM_cas:issn">0939-6411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 101 refs.  The soly. behavior of drugs remains one of the most challenging aspects in formulation development.  With the advent of combinatorial chem. and high throughput screening, the no. of poorly water sol. compds. has dramatically increased.  Although solid solns. have tremendous potential for improving drug soly., 40 yr of research have resulted in only a few marketed products using this approach.  With the introduction of new manufg. technologies such as hot melt extrusion, it should be possible to overcome problems in scale-up and for this reason solid solns. are enjoying a renaissance.  This article begins with an overview of the historical background and definitions of the various systems including eutectic mixts., solid dispersions and solid solns.  The remainder of the article is devoted to the prodn., the different carriers and the methods used for the characterization of solid dispersions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaO0ikKHQTgLVg90H21EOLACvtfcHk0li9SJ2vANHHmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjslyju7c%253D&md5=098a62ba5325f4cf33283bcec9421470</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0939-6411%2800%2900076-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0939-6411%252800%252900076-X%26sid%3Dliteratum%253Aachs%26aulast%3DLeuner%26aufirst%3DC.%26aulast%3DDressman%26aufirst%3DJ.%2BB.%26atitle%3DImproving%2520drug%2520solubility%2520for%2520oral%2520delivery%2520using%2520solid%2520dispersions%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2000%26volume%3D50%26spage%3D47%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Janssens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Mooter, G.</span><span> </span><span class="NLM_article-title">Review: Physical chemistry of solid dispersions</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1571</span><span class="NLM_x">–</span> <span class="NLM_lpage">1586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1211%2Fjpp.61.12.0001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=19958579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFGqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=1571-1586&author=S.+Janssensauthor=G.+Van+den+Mooter&title=Review%3A+Physical+chemistry+of+solid+dispersions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Review: physical chemistry of solid dispersions</span></div><div class="casAuthors">Janssens, Sandrien; Van den Mooter, Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1571-1586</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Press</span>)
        </div><div class="casAbstract">A review.  With poorly sol. drug candidates emerging in the drug discovery pipeline, the importance of the solid dispersion formulation approach is increasing.  This strategy includes complete removal of drug crystallinity, and mol. dispersion of the poorly sol. compd. in a hydrophilic polymeric carrier.  The potential of this technique to increase oral absorption and hence bioavailability is enormous.  Nevertheless, some issues have to be considered regarding thermodn. instability, as well in supersatd. solns. that are formed upon dissoln. as in the solid state.  After a brief discussion on the historical background of solid dispersions and their current role in formulation, an overview will be given on the phys. chem. and stability of glass solns. as they form supersatd. solns., and during their shelf life.  Thorough understanding of these aspects will elicit conscious evaluation of carrier properties and eventually facilitate rational excipient selection.  Thus, full exploitation of the solid dispersion strategy may provide an appropriate answer to drug attrition due to low aq. soly. in later stages of development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2x4xN6QffoLVg90H21EOLACvtfcHk0li9SJ2vANHHmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFGqsr4%253D&md5=7c8c3efd9cf1fcc162e208ff8ffda813</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1211%2Fjpp.61.12.0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252Fjpp.61.12.0001%26sid%3Dliteratum%253Aachs%26aulast%3DJanssens%26aufirst%3DS.%26aulast%3DVan%2Bden%2BMooter%26aufirst%3DG.%26atitle%3DReview%253A%2520Physical%2520chemistry%2520of%2520solid%2520dispersions%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2009%26volume%3D61%26spage%3D1571%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Flynn, D. L.; Kaufman, M. D.; Patt, W. C.; Petillo, P. A.</span><span> </span><span class="NLM_article-title">Kinase inhibitors useful for the treatment of proliferative diseases</span>. WO2008034008,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+L.+Flynn&author=M.+D.+Kaufman&author=W.+C.+Patt&author=P.+A.+Petillo&title=Kinase+inhibitors+useful+for+the+treatment+of+proliferative+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DKinase%2520inhibitors%2520useful%2520for%2520the%2520treatment%2520of%2520proliferative%2520diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Flynn, D. L.; Kaufman, M. D.; Vogeti, L.; Wise, S. C.; Lu, W.; Smith, B. D.; Caldwell, T. M.; Patt, W. C.; Henry, J. R.; Hipskind, P. A.; Peng, S.</span><span> </span><span class="NLM_article-title">Raf inhibitor compounds</span>. WO2013134298,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=D.+L.+Flynn&author=M.+D.+Kaufman&author=L.+Vogeti&author=S.+C.+Wise&author=W.+Lu&author=B.+D.+Smith&author=T.+M.+Caldwell&author=W.+C.+Patt&author=J.+R.+Henry&author=P.+A.+Hipskind&author=S.+Peng&title=Raf+inhibitor+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DRaf%2520inhibitor%2520compounds%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Flynn, D. L.; Henry, J. R.; Hipskind, P. A.; Kaufman, M. D.; Lu, W.; Peng, S.; Smith, B. D.; Vogeti, L.; Wise, S. C.</span><span> </span><span class="NLM_article-title">2-Amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors</span>. WO2013134252,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=D.+L.+Flynn&author=J.+R.+Henry&author=P.+A.+Hipskind&author=M.+D.+Kaufman&author=W.+Lu&author=S.+Peng&author=B.+D.+Smith&author=L.+Vogeti&author=S.+C.+Wise&title=2-Amino%2C+6-phenyl+substituted+pyrido+%5B2%2C+3+-+d%5D+pyrimidine+derivatives+useful+as+raf+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3D2-Amino%252C%25206-phenyl%2520substituted%2520pyrido%2520%255B2%252C%25203%2520-%2520d%255D%2520pyrimidine%2520derivatives%2520useful%2520as%2520raf%2520kinase%2520inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Lavoie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thevakumaran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavory, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padeganeh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiral, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchaine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouvier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicheri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therrien, M.</span><span> </span><span class="NLM_article-title">Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1038%2Fnchembio.1257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=23685672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=428-436&author=H.+Lavoieauthor=N.+Thevakumaranauthor=G.+Gavoryauthor=J.+J.+Liauthor=A.+Padeganehauthor=S.+Guiralauthor=J.+Duchaineauthor=D.+Y.+Maoauthor=M.+Bouvierauthor=F.+Sicheriauthor=M.+Therrien&title=Inhibitors+that+stabilize+a+closed+RAF+kinase+domain+conformation+induce+dimerization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</span></div><div class="casAuthors">Lavoie, Hugo; Thevakumaran, Neroshan; Gavory, Gwenaelle; Li, John J.; Padeganeh, Abbas; Guiral, Sebastien; Duchaine, Jean; Mao, Daniel Y. L.; Bouvier, Michel; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">428-436</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF kinases have a prominent role in cancer.  Their mode of activation is complex but critically requires dimerization of their kinase domains.  Unexpectedly, several ATP-competitive RAF inhibitors were recently found to promote dimerization and transactivation of RAF kinases in a RAS-dependent manner and, as a result, undesirably stimulate RAS/ERK pathway-mediated cell growth.  The mechanism by which these inhibitors induce RAF kinase domain dimerization remains unclear.  Here we describe bioluminescence resonance energy transfer-based biosensors for the extended RAF family that enable the detection of RAF dimerization in living cells.  Notably, we demonstrate the utility of these tools for profiling kinase inhibitors that selectively modulate RAF dimerization and for probing structural determinants of RAF dimerization in vivo.  Our findings, which seem generalizable to other kinase families allosterically regulated by kinase domain dimerization, suggest a model whereby ATP-competitive inhibitors mediate RAF dimerization by stabilizing a rigid closed conformation of the kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhEtTJvsZ1FrVg90H21EOLACvtfcHk0liiWmn7taohAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D&md5=f866ae6da93c5e2d7fec53b8dc0e6f2a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1257%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DGavory%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DPadeganeh%26aufirst%3DA.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DDuchaine%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DD.%2BY.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DInhibitors%2520that%2520stabilize%2520a%2520closed%2520RAF%2520kinase%2520domain%2520conformation%2520induce%2520dimerization%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D428%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Carnahan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babij, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonderfecht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagapudi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broome, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmontes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, T. L.</span><span> </span><span class="NLM_article-title">Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2399</span><span class="NLM_x">–</span> <span class="NLM_lpage">2410</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1158%2F1535-7163.MCT-10-0181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=20663930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2399-2410&author=J.+Carnahanauthor=P.+J.+Beltranauthor=C.+Babijauthor=Q.+Leauthor=M.+J.+Roseauthor=S.+Vonderfechtauthor=J.+L.+Kimauthor=A.+L.+Smithauthor=K.+Nagapudiauthor=M.+A.+Broomeauthor=M.+Fernandoauthor=H.+Khaauthor=B.+Belmontesauthor=R.+Radinskyauthor=R.+Kendallauthor=T.+L.+Burgess&title=Selective+and+potent+Raf+inhibitors+paradoxically+stimulate+normal+cell+proliferation+and+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth</span></div><div class="casAuthors">Carnahan, Josette; Beltran, Pedro J.; Babij, Carol; Le, Quynh; Rose, Mark J.; Vonderfecht, Steven; Kim, Joseph L.; Smith, Adrian L.; Nagapudi, Karthik; Broome, Martin A.; Fernando, Manory; Kha, Hue; Belmontes, Brian; Radinsky, Robert; Kendall, Richard; Burgess, Teresa L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2399-2410</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Raf inhibitors are under clin. investigation, specifically in patients with tumor types harboring frequent activating mutations in B-Raf.  Here, we show that cell lines and tumors harboring mutant B-Raf were sensitive to a novel series of Raf inhibitors (e.g., V600EB-Raf A375, IC50 on cells = 2 nmol/L; ED50 on tumor xenografts = 1.3 mg/kg).  However, in cells and tumors with wild-type B-Raf, exposure to Raf inhibitors resulted in a dose-dependent and sustained activation of mitogen-activated protein kinase signaling.  In some of these cell lines, Raf inhibition led to entry into the cell cycle, enhanced proliferation, and significantly stimulated tumor growth in vivo.  Inhibition with structurally distinct Raf inhibitors or isoform-specific small interfering RNA knockdown of Raf showed that these effects were mediated directly through Raf.  Either A-Raf or C-Raf mediated the Raf inhibitor-induced mitogen-activated protein kinase pathway activation in an inhibitor-specific manner.  These paradoxical effects of Raf inhibition were seen in malignant and normal cells in vitro and in vivo.  Hyperplasia of normal epithelial cells in the esophagus and the stomach was evident in mice with all efficacious Raf inhibitors (n = 8) tested.  An implication of these results is that Raf inhibitors may induce unexpected normal cell and tumor tissue proliferation in patients.  Mol Cancer Ther; 9(8); 2399-410.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN5Uws5uZF4rVg90H21EOLACvtfcHk0liiWmn7taohAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D&md5=c2958b3c22d623571dea9bedf6835834</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0181%26sid%3Dliteratum%253Aachs%26aulast%3DCarnahan%26aufirst%3DJ.%26aulast%3DBeltran%26aufirst%3DP.%2BJ.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DLe%26aufirst%3DQ.%26aulast%3DRose%26aufirst%3DM.%2BJ.%26aulast%3DVonderfecht%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DNagapudi%26aufirst%3DK.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DKha%26aufirst%3DH.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DBurgess%26aufirst%3DT.%2BL.%26atitle%3DSelective%2520and%2520potent%2520Raf%2520inhibitors%2520paradoxically%2520stimulate%2520normal%2520cell%2520proliferation%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2399%26epage%3D2410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Yadav, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Horn, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starling, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckmann, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. B.</span><span> </span><span class="NLM_article-title">The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2253</span><span class="NLM_x">–</span> <span class="NLM_lpage">2263</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1158%2F1535-7163.MCT-14-0257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=25122067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yisb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2253-2263&author=V.+Yadavauthor=T.+F.+Burkeauthor=L.+Huberauthor=R.+D.+Van+Hornauthor=Y.+Zhangauthor=S.+G.+Buchananauthor=E.+M.+Chanauthor=J.+J.+Starlingauthor=R.+P.+Beckmannauthor=S.+B.+Peng&title=The+CDK4%2F6+inhibitor+LY2835219+overcomes+vemurafenib+resistance+resulting+from+MAPK+reactivation+and+cyclin+D1+upregulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation</span></div><div class="casAuthors">Yadav, Vipin; Burke, Teresa F.; Huber, Lysiane; Van Horn, Robert D.; Zhang, Youyan; Buchanan, Sean G.; Chan, Edward M.; Starling, James J.; Beckmann, Richard P.; Peng, Sheng-Bin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2253-2263</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">B-RAF selective inhibitors, including vemurafenib, were recently developed as effective therapies for melanoma patients with B-RAF V600E mutation.  However, most patients treated with vemurafenib eventually develop resistance largely due to reactivation of MAPK signaling.  Inhibitors of MAPK signaling, including MEK1/2 inhibitor trametinib, failed to show significant clin. benefit in patients with acquired resistance to vemurafenib.  Here, we describe that cell lines with acquired resistance to vemurafenib show reactivation of MAPK signaling and upregulation of cyclin D1 and are sensitive to inhibition of LY2835219, a selective inhibitor of cyclin-dependent kinase (CDK) 4/6.  LY2835219 was demonstrated to inhibit growth of melanoma A375 tumor xenografts and delay tumor recurrence in combination with vemurafenib.  Furthermore, we developed an in vivo vemurafenib-resistant model by continuous administration of vemurafenib in A375 xenografts.  Consistently, we found that MAPK is reactivated and cyclin D1 is elevated in vemurafenib-resistant tumors, as well as in the resistant cell lines derived from these tumors.  Importantly, LY2835219 exhibited tumor growth regression in a vemurafenib-resistant model.  Mechanistic anal. revealed that LY2835219 induced apoptotic cell death in a concn.-dependent manner in vemurafenib-resistant cells whereas it primarily mediated cell-cycle G1 arrest in the parental cells.  Similarly, RNAi-mediated knockdown of cyclin D1 induced significantly higher rate of apoptosis in the resistant cells than in parental cells, suggesting that elevated cyclin D1 activity is important for the survival of vemurafenib-resistant cells.  Altogether, we propose that targeting cyclin D1-CDK4/6 signaling by LY2835219 is an effective strategy to overcome MAPK-mediated resistance to B-RAF inhibitors in B-RAF V600E melanoma.  Mol Cancer Ther; 13(10); 2253-63. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIfpmG0cDdI7Vg90H21EOLACvtfcHk0liiWmn7taohAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yisb7M&md5=1dc6e49913933e10f0d9a27875e68705</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0257%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DBurke%26aufirst%3DT.%2BF.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DChan%26aufirst%3DE.%2BM.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DBeckmann%26aufirst%3DR.%2BP.%26aulast%3DPeng%26aufirst%3DS.%2BB.%26atitle%3DThe%2520CDK4%252F6%2520inhibitor%2520LY2835219%2520overcomes%2520vemurafenib%2520resistance%2520resulting%2520from%2520MAPK%2520reactivation%2520and%2520cyclin%2520D1%2520upregulation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2253%26epage%3D2263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Yadav, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starling, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. B.</span><span> </span><span class="NLM_article-title">Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">28087</span><span class="NLM_x">–</span> <span class="NLM_lpage">28098</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=28087-28098&author=V.+Yadavauthor=X.+Zhangauthor=J.+Liuauthor=S.+Estremauthor=S.+Liauthor=X.+Q.+Gongauthor=S.+Buchananauthor=J.+R.+Henryauthor=J.+J.+Starlingauthor=S.+B.+Peng&title=Reactivation+of+mitogen-activated+protein+kinase+%28MAPK%29+pathway+by+FGF+receptor+3+%28FGFR3%29%2FRas+mediates+resistance+to+vemurafenib+in+human+B-RAF+V600E+mutant+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DEstrem%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DGong%26aufirst%3DX.%2BQ.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DPeng%26aufirst%3DS.%2BB.%26atitle%3DReactivation%2520of%2520mitogen-activated%2520protein%2520kinase%2520%2528MAPK%2529%2520pathway%2520by%2520FGF%2520receptor%25203%2520%2528FGFR3%2529%252FRas%2520mediates%2520resistance%2520to%2520vemurafenib%2520in%2520human%2520B-RAF%2520V600E%2520mutant%2520melanoma%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D28087%26epage%3D28098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Patricelli, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagannathan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okerberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herring, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarich, J. W.</span><span> </span><span class="NLM_article-title">In situ kinase profiling reveals functionally relevant properties of native kinases</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1016%2Fj.chembiol.2011.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=21700206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVejtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=699-710&author=M.+P.+Patricelliauthor=T.+K.+Nomanbhoyauthor=J.+Wuauthor=H.+Brownauthor=D.+Zhouauthor=J.+Zhangauthor=S.+Jagannathanauthor=A.+Abanauthor=E.+Okerbergauthor=C.+Herringauthor=B.+Nordinauthor=H.+Weissigauthor=Q.+Yangauthor=J.+D.+Leeauthor=N.+S.+Grayauthor=J.+W.+Kozarich&title=In+situ+kinase+profiling+reveals+functionally+relevant+properties+of+native+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases</span></div><div class="casAuthors">Patricelli, Matthew P.; Nomanbhoy, Tyzoon K.; Wu, Jiangyue; Brown, Heidi; Zhou, David; Zhang, Jianming; Jagannathan, Subadhra; Aban, Arwin; Okerberg, Eric; Herring, Chris; Nordin, Brian; Weissig, Helge; Yang, Qingkai; Lee, Jiing-Dwan; Gray, Nathanael S.; Kozarich, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">699-710</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Protein kinases are intensely studied mediators of cellular signaling, yet important questions remain regarding their regulation and in vivo properties.  Here, we use a probe-based chemoprotemics platform to profile several well studied kinase inhibitors against >200 kinases in native cell proteomes and reveal biol. targets for some of these inhibitors.  Several striking differences were identified between native and recombinant kinase inhibitory profiles, in particular, for the Raf kinases.  The native kinase binding profiles presented here closely mirror the cellular activity of these inhibitors, even when the inhibition profiles differ dramatically from recombinant assay results.  Addnl., Raf activation events could be detected on live cell treatment with inhibitors.  These studies highlight the complexities of protein kinase behavior in the cellular context and demonstrate that profiling with only recombinant/purified enzymes can be misleading.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopb21npuaC_rVg90H21EOLACvtfcHk0lhhs80dV6IMUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVejtbo%253D&md5=dda091b895850c95131f80c3aba9e8c7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJagannathan%26aufirst%3DS.%26aulast%3DAban%26aufirst%3DA.%26aulast%3DOkerberg%26aufirst%3DE.%26aulast%3DHerring%26aufirst%3DC.%26aulast%3DNordin%26aufirst%3DB.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BD.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26atitle%3DIn%2520situ%2520kinase%2520profiling%2520reveals%2520functionally%2520relevant%2520properties%2520of%2520native%2520kinases%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D699%26epage%3D710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 50 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Mohammed S. Abdel-Maksoud, Mohammed I. El-Gamal, Bong S. Lee, Mahmoud M. Gamal El-Din, Hong R. Jeon, Dow Kwon, Usama M. Ammar, Karim I. Mersal, Eslam M. H. Ali, Kyung-Tae Lee, Kyung Ho Yoo, Dong Keun Han, Jae Kyun Lee, Garam Kim, Hong Seok Choi, Young Jik Kwon, Kwan Hyi Lee, <span class="NLM_string-name hlFld-ContribAuthor">Chang Hyun Oh</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of New Imidazo[2,1-b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising In Vitro and In Vivo Anti-melanoma Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6877-6901. <a href="https://doi.org/10.1021/acs.jmedchem.1c00230" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00230</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00230%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNew%252BImidazo%25255B2%25252C1-b%25255Dthiazole%252BDerivatives%252Bas%252BPotent%252BPan-RAF%252BInhibitors%252Bwith%252BPromising%252BIn%252BVitro%252Band%252BIn%252BVivo%252BAnti-melanoma%252BActivity%26aulast%3DAbdel-Maksoud%26aufirst%3DMohammed%2BS.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D05022021%26date%3D17052021%26volume%3D64%26issue%3D10%26spage%3D6877%26epage%3D6901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Malcolm P. Huestis, Matthew R. Durk, Charles Eigenbrot, Paul Gibbons, Thomas L. Hunsaker, Hank La, Dennis H. Leung, Wendy Liu, Shiva Malek, Mark Merchant, John G. Moffat, Christine S. Muli, Christine J. Orr, Brendan T. Parr, Frances Shanahan, Christopher J. Sneeringer, Weiru Wang, Ivana Yen, Jianping Yin, Joachim Rudolph, <span class="NLM_string-name hlFld-ContribAuthor">Michael Siu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 791-797. <a href="https://doi.org/10.1021/acsmedchemlett.1c00063" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00063%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DTargeting%252BKRAS%252BMutant%252BCancers%252Bvia%252BCombination%252BTreatment%25253A%252BDiscovery%252Bof%252Ba%252BPyridopyridazinone%252Bpan-RAF%252BKinase%252BInhibitor%26aulast%3DHuestis%26aufirst%3DMalcolm%2BP.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D27012021%26date%3D31032021%26date%3D21042021%26volume%3D12%26issue%3D5%26spage%3D791%26epage%3D797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Malcolm P. Huestis, Darlene Dela Cruz, Antonio G. DiPasquale, Matthew R. Durk, Charles Eigenbrot, Paul Gibbons, Alberto Gobbi, Thomas L. Hunsaker, Hank La, Dennis H. Leung, Wendy Liu, Shiva Malek, Mark Merchant, John G. Moffat, Christine S. Muli, Christine J. Orr, Brendan T. Parr, Frances Shanahan, Christopher J. Sneeringer, Weiru Wang, Ivana Yen, Jianping Yin, Michael Siu, <span class="NLM_string-name hlFld-ContribAuthor">Joachim Rudolph</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3940-3955. <a href="https://doi.org/10.1021/acs.jmedchem.0c02085" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02085%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BKRAS%252BMutant%252BCancers%252Bvia%252BCombination%252BTreatment%25253A%252BDiscovery%252Bof%252Ba%252B5-Fluoro-4-%2525283H%252529-quinazolinone%252BAryl%252BUrea%252Bpan-RAF%252BKinase%252BInhibitor%26aulast%3DHuestis%26aufirst%3DMalcolm%2BP.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D01122020%26date%3D29032021%26volume%3D64%26issue%3D7%26spage%3D3940%26epage%3D3955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Arun K. Ghosh, <span class="NLM_string-name hlFld-ContribAuthor">Margherita Brindisi</span>. </span><span class="cited-content_cbyCitation_article-title">Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (6)
                                     , 2751-2788. <a href="https://doi.org/10.1021/acs.jmedchem.9b01541" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01541</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01541%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DUrea%252BDerivatives%252Bin%252BModern%252BDrug%252BDiscovery%252Band%252BMedicinal%252BChemistry%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D16092019%26date%3D02122019%26volume%3D63%26issue%3D6%26spage%3D2751%26epage%3D2788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bogos Agianian, <span class="NLM_string-name hlFld-ContribAuthor">Evripidis Gavathiotis</span>. </span><span class="cited-content_cbyCitation_article-title">Current Insights of BRAF Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (14)
                                     , 5775-5793. <a href="https://doi.org/10.1021/acs.jmedchem.7b01306" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01306</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01306%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252BInsights%252Bof%252BBRAF%252BInhibitors%252Bin%252BCancer%26aulast%3DAgianian%26aufirst%3DBogos%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D01092017%26date%3D06032018%26date%3D20022018%26volume%3D61%26issue%3D14%26spage%3D5775%26epage%3D5793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Gaoyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiang  Zhou</span>, <span class="hlFld-ContribAuthor ">Yadong  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, and <span class="hlFld-ContribAuthor ">Weifang  Tang</span>  . </span><span class="cited-content_cbyCitation_article-title">Potent Pan-Raf and Receptor Tyrosine Kinase Inhibitors Based on a Cyclopropyl Formamide Fragment Overcome Resistance. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (6)
                                     , 1439-1452. <a href="https://doi.org/10.1021/acs.jcim.6b00795" title="DOI URL">https://doi.org/10.1021/acs.jcim.6b00795</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.6b00795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.6b00795%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DPotent%252BPan-Raf%252Band%252BReceptor%252BTyrosine%252BKinase%252BInhibitors%252BBased%252Bon%252Ba%252BCyclopropyl%252BFormamide%252BFragment%252BOvercome%252BResistance%26aulast%3DZhang%26aufirst%3DYanmin%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D31122016%26date%3D19052017%26date%3D26062017%26date%3D09052017%26volume%3D57%26issue%3D6%26spage%3D1439%26epage%3D1452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lewis D.  Pennington</span> and <span class="hlFld-ContribAuthor ">Demetri T.  Moustakas</span>  . </span><span class="cited-content_cbyCitation_article-title">The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (9)
                                     , 3552-3579. <a href="https://doi.org/10.1021/acs.jmedchem.6b01807" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01807</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01807%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BNecessary%252BNitrogen%252BAtom%25253A%252BA%252BVersatile%252BHigh-Impact%252BDesign%252BElement%252Bfor%252BMultiparameter%252BOptimization%26aulast%3DPennington%26aufirst%3DLewis%2BD.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D09122016%26date%3D08022017%26date%3D11052017%26volume%3D60%26issue%3D9%26spage%3D3552%26epage%3D3579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony  Champiré</span>, <span class="hlFld-ContribAuthor ">Christine  Vala</span>, <span class="hlFld-ContribAuthor ">Achraf  Laabid</span>, <span class="hlFld-ContribAuthor ">Ahmed  Benharref</span>, <span class="hlFld-ContribAuthor ">Mathieu  Marchivie</span>, <span class="hlFld-ContribAuthor ">Karen  Plé</span>, and <span class="hlFld-ContribAuthor ">Sylvain  Routier</span>  . </span><span class="cited-content_cbyCitation_article-title">Controlled Dimroth Rearrangement in the Suzuki–Miyaura Cross Coupling of Triazolopyridopyrimidines. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (24)
                                     , 12506-12513. <a href="https://doi.org/10.1021/acs.joc.6b02357" title="DOI URL">https://doi.org/10.1021/acs.joc.6b02357</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b02357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b02357%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DControlled%252BDimroth%252BRearrangement%252Bin%252Bthe%252BSuzuki%2525E2%252580%252593Miyaura%252BCross%252BCoupling%252Bof%252BTriazolopyridopyrimidines%26aulast%3DChampir%25C3%25A9%26aufirst%3DAnthony%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D27092016%26date%3D05122016%26date%3D16122016%26date%3D15112016%26volume%3D81%26issue%3D24%26spage%3D12506%26epage%3D12513" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miriam  Pons</span>, <span class="hlFld-ContribAuthor ">Yanira  Zeyn</span>, <span class="hlFld-ContribAuthor ">Stella  Zahn</span>, <span class="hlFld-ContribAuthor ">Nisintha  Mahendrarajah</span>, <span class="hlFld-ContribAuthor ">Brent D. G.  Page</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Walburgis  Brenner</span>, <span class="hlFld-ContribAuthor ">Falk  Butter</span>, <span class="hlFld-ContribAuthor ">Oliver H.  Krämer</span>. </span><span class="cited-content_cbyCitation_article-title">Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (14)
                                     , 3464. <a href="https://doi.org/10.3390/cancers13143464" title="DOI URL">https://doi.org/10.3390/cancers13143464</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13143464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13143464%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DOncogenic%252BKinase%252BCascades%252BInduce%252BMolecular%252BMechanisms%252BThat%252BProtect%252BLeukemic%252BCell%252BModels%252Bfrom%252BLethal%252BEffects%252Bof%252BDe%252BNovo%252BdNTP%252BSynthesis%252BInhibition%26aulast%3DPons%26aufirst%3DMiriam%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D14%26spage%3D3464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rahim  Ullah</span>, <span class="hlFld-ContribAuthor ">Qing  Yin</span>, <span class="hlFld-ContribAuthor ">Aidan H.  Snell</span>, <span class="hlFld-ContribAuthor ">Lixin  Wan</span>. </span><span class="cited-content_cbyCitation_article-title">RAF-MEK-ERK pathway in cancer evolution and treatment. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2021,</strong> <em>84 </em><a href="https://doi.org/10.1016/j.semcancer.2021.05.010" title="DOI URL">https://doi.org/10.1016/j.semcancer.2021.05.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2021.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2021.05.010%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DRAF-MEK-ERK%252Bpathway%252Bin%252Bcancer%252Bevolution%252Band%252Btreatment%26aulast%3DUllah%26aufirst%3DRahim%26date%3D2021%26volume%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhe  Zhao</span>, <span class="hlFld-ContribAuthor ">Riku  Fagerlund</span>, <span class="hlFld-ContribAuthor ">Andreas S.  Baur</span>, <span class="hlFld-ContribAuthor ">Kalle  Saksela</span>, . </span><span class="cited-content_cbyCitation_article-title">HIV-1 Nef-Induced Secretion of the Proinflammatory Protease TACE into Extracellular Vesicles Is Mediated by Raf-1 and Can Be Suppressed by Clinical Protein Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Virology</span><span> <strong>2021,</strong> <em>95 </em>
                                    (9)
                                     <a href="https://doi.org/10.1128/JVI.00180-21" title="DOI URL">https://doi.org/10.1128/JVI.00180-21</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/JVI.00180-21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FJVI.00180-21%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Virology%26atitle%3DHIV-1%252BNef-Induced%252BSecretion%252Bof%252Bthe%252BProinflammatory%252BProtease%252BTACE%252Binto%252BExtracellular%252BVesicles%252BIs%252BMediated%252Bby%252BRaf-1%252Band%252BCan%252BBe%252BSuppressed%252Bby%252BClinical%252BProtein%252BKinase%252BInhibitors%26aulast%3DZhao%26aufirst%3DZhe%26date%3D2021%26volume%3D95%26issue%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valeria  Merz</span>, <span class="hlFld-ContribAuthor ">Marina  Gaule</span>, <span class="hlFld-ContribAuthor ">Camilla  Zecchetto</span>, <span class="hlFld-ContribAuthor ">Alessandro  Cavaliere</span>, <span class="hlFld-ContribAuthor ">Simona  Casalino</span>, <span class="hlFld-ContribAuthor ">Camilla  Pesoni</span>, <span class="hlFld-ContribAuthor ">Serena  Contarelli</span>, <span class="hlFld-ContribAuthor ">Fabio  Sabbadini</span>, <span class="hlFld-ContribAuthor ">Monica  Bertolini</span>, <span class="hlFld-ContribAuthor ">Domenico  Mangiameli</span>, <span class="hlFld-ContribAuthor ">Michele  Milella</span>, <span class="hlFld-ContribAuthor ">Vita  Fedele</span>, <span class="hlFld-ContribAuthor ">Davide  Melisi</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting KRAS: The Elephant in the Room of Epithelial Cancers. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fonc.2021.638360" title="DOI URL">https://doi.org/10.3389/fonc.2021.638360</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2021.638360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2021.638360%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DTargeting%252BKRAS%25253A%252BThe%252BElephant%252Bin%252Bthe%252BRoom%252Bof%252BEpithelial%252BCancers%26aulast%3DMerz%26aufirst%3DValeria%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pratibha  Yadav</span>, <span class="hlFld-ContribAuthor ">Kamal  Shah</span>. </span><span class="cited-content_cbyCitation_article-title">An overview on synthetic and pharmaceutical prospective of pyrido[2,3‐
              d
              ]pyrimidines scaffold. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>97 </em>
                                    (3)
                                     , 633-648. <a href="https://doi.org/10.1111/cbdd.13800" title="DOI URL">https://doi.org/10.1111/cbdd.13800</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13800%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DAn%252Boverview%252Bon%252Bsynthetic%252Band%252Bpharmaceutical%252Bprospective%252Bof%252Bpyrido%25255B2%25252C3%2525E2%252580%252590%252Bd%252B%25255Dpyrimidines%252Bscaffold%26aulast%3DYadav%26aufirst%3DPratibha%26date%3D2021%26date%3D2020%26volume%3D97%26issue%3D3%26spage%3D633%26epage%3D648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicolas  Dumaz</span>, <span class="hlFld-ContribAuthor ">Céleste  Lebbé</span>. </span><span class="cited-content_cbyCitation_article-title">New perspectives on targeting RAF, MEK and ERK in melanoma. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Oncology</span><span> <strong>2021,</strong> <em>33 </em>
                                    (2)
                                     , 120-126. <a href="https://doi.org/10.1097/CCO.0000000000000708" title="DOI URL">https://doi.org/10.1097/CCO.0000000000000708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/CCO.0000000000000708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FCCO.0000000000000708%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Oncology%26atitle%3DNew%252Bperspectives%252Bon%252Btargeting%252BRAF%25252C%252BMEK%252Band%252BERK%252Bin%252Bmelanoma%26aulast%3DDumaz%26aufirst%3DNicolas%26date%3D2021%26date%3D2020%26volume%3D33%26issue%3D2%26spage%3D120%26epage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jackson  Peterson</span>, <span class="hlFld-ContribAuthor ">Siqi  Li</span>, <span class="hlFld-ContribAuthor ">Erin  Kaltenbrun</span>, <span class="hlFld-ContribAuthor ">Ozgun  Erdogan</span>, <span class="hlFld-ContribAuthor ">Christopher M.  Counter</span>. </span><span class="cited-content_cbyCitation_article-title">Expression of transgenes enriched in rare codons is enhanced by the MAPK pathway. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-78453-5" title="DOI URL">https://doi.org/10.1038/s41598-020-78453-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-78453-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-78453-5%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DExpression%252Bof%252Btransgenes%252Benriched%252Bin%252Brare%252Bcodons%252Bis%252Benhanced%252Bby%252Bthe%252BMAPK%252Bpathway%26aulast%3DPeterson%26aufirst%3DJackson%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joseph D.  Khoury</span>, <span class="hlFld-ContribAuthor ">Mehrnoosh  Tashakori</span>, <span class="hlFld-ContribAuthor ">Hong  Yang</span>, <span class="hlFld-ContribAuthor ">Sanam  Loghavi</span>, <span class="hlFld-ContribAuthor ">Ying  Wang</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Sujan  Piya</span>, <span class="hlFld-ContribAuthor ">Gautam  Borthakur</span>. </span><span class="cited-content_cbyCitation_article-title">Pan-RAF Inhibition Shows Anti-Leukemic Activity in RAS-Mutant Acute Myeloid Leukemia Cells and Potentiates the Effect of Sorafenib in Cells with FLT3 Mutation. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (12)
                                     , 3511. <a href="https://doi.org/10.3390/cancers12123511" title="DOI URL">https://doi.org/10.3390/cancers12123511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12123511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12123511%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DPan-RAF%252BInhibition%252BShows%252BAnti-Leukemic%252BActivity%252Bin%252BRAS-Mutant%252BAcute%252BMyeloid%252BLeukemia%252BCells%252Band%252BPotentiates%252Bthe%252BEffect%252Bof%252BSorafenib%252Bin%252BCells%252Bwith%252BFLT3%252BMutation%26aulast%3DKhoury%26aufirst%3DJoseph%2BD.%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D12%26spage%3D3511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jaydeepsinh  Chavda</span>, <span class="hlFld-ContribAuthor ">Hardik  Bhatt</span>. </span><span class="cited-content_cbyCitation_article-title">Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>206 </em>, 112675. <a href="https://doi.org/10.1016/j.ejmech.2020.112675" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112675</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112675%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystemic%252Breview%252Bon%252BB-RafV600E%252Bmutation%252Bas%252Bpotential%252Btherapeutic%252Btarget%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DChavda%26aufirst%3DJaydeepsinh%26date%3D2020%26volume%3D206%26spage%3D112675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karel  Vališ</span>, <span class="hlFld-ContribAuthor ">Petr  Novák</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting ERK-Hippo Interplay in Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (9)
                                     , 3236. <a href="https://doi.org/10.3390/ijms21093236" title="DOI URL">https://doi.org/10.3390/ijms21093236</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21093236&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21093236%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DTargeting%252BERK-Hippo%252BInterplay%252Bin%252BCancer%252BTherapy%26aulast%3DVali%25C5%25A1%26aufirst%3DKarel%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D9%26spage%3D3236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shripad V.  Bhagwat</span>, <span class="hlFld-ContribAuthor ">William T.  McMillen</span>, <span class="hlFld-ContribAuthor ">Shufen  Cai</span>, <span class="hlFld-ContribAuthor ">Baohui  Zhao</span>, <span class="hlFld-ContribAuthor ">Matthew  Whitesell</span>, <span class="hlFld-ContribAuthor ">Weihua  Shen</span>, <span class="hlFld-ContribAuthor ">Lisa  Kindler</span>, <span class="hlFld-ContribAuthor ">Robert S.  Flack</span>, <span class="hlFld-ContribAuthor ">Wenjuan  Wu</span>, <span class="hlFld-ContribAuthor ">Bryan  Anderson</span>, <span class="hlFld-ContribAuthor ">Yan  Zhai</span>, <span class="hlFld-ContribAuthor ">Xiu-Juan  Yuan</span>, <span class="hlFld-ContribAuthor ">Meghann  Pogue</span>, <span class="hlFld-ContribAuthor ">Robert D.  Van Horn</span>, <span class="hlFld-ContribAuthor ">Xi  Rao</span>, <span class="hlFld-ContribAuthor ">Denis  McCann</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Dropsey</span>, <span class="hlFld-ContribAuthor ">Jason  Manro</span>, <span class="hlFld-ContribAuthor ">Jennie  Walgren</span>, <span class="hlFld-ContribAuthor ">Eunice  Yuen</span>, <span class="hlFld-ContribAuthor ">Michael J.  Rodriguez</span>, <span class="hlFld-ContribAuthor ">Gregory D.  Plowman</span>, <span class="hlFld-ContribAuthor ">Ramon V.  Tiu</span>, <span class="hlFld-ContribAuthor ">Sajan  Joseph</span>, <span class="hlFld-ContribAuthor ">Sheng-Bin  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (2)
                                     , 325-336. <a href="https://doi.org/10.1158/1535-7163.MCT-19-0183" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-0183</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-0183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-0183%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DERK%252BInhibitor%252BLY3214996%252BTargets%252BERK%252BPathway%2525E2%252580%252593Driven%252BCancers%25253A%252BA%252BTherapeutic%252BApproach%252BToward%252BPrecision%252BMedicine%26aulast%3DBhagwat%26aufirst%3DShripad%2BV.%26date%3D2020%26date%3D2019%26volume%3D19%26issue%3D2%26spage%3D325%26epage%3D336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan J.  Sullivan</span>, <span class="hlFld-ContribAuthor ">Antoine  Hollebecque</span>, <span class="hlFld-ContribAuthor ">Keith T.  Flaherty</span>, <span class="hlFld-ContribAuthor ">Geoffrey I.  Shapiro</span>, <span class="hlFld-ContribAuthor ">Jordi  Rodon Ahnert</span>, <span class="hlFld-ContribAuthor ">Michael J.  Millward</span>, <span class="hlFld-ContribAuthor ">Wei  Zhang</span>, <span class="hlFld-ContribAuthor ">Ling  Gao</span>, <span class="hlFld-ContribAuthor ">Amanda  Sykes</span>, <span class="hlFld-ContribAuthor ">Melinda D.  Willard</span>, <span class="hlFld-ContribAuthor ">Danni  Yu</span>, <span class="hlFld-ContribAuthor ">Andrew E.  Schade</span>, <span class="hlFld-ContribAuthor ">KrisAnne  Crowe</span>, <span class="hlFld-ContribAuthor ">Daniel L.  Flynn</span>, <span class="hlFld-ContribAuthor ">Michael D.  Kaufman</span>, <span class="hlFld-ContribAuthor ">James R.  Henry</span>, <span class="hlFld-ContribAuthor ">Sheng-Bin  Peng</span>, <span class="hlFld-ContribAuthor ">Karim A.  Benhadji</span>, <span class="hlFld-ContribAuthor ">Ilaria  Conti</span>, <span class="hlFld-ContribAuthor ">Michael S.  Gordon</span>, <span class="hlFld-ContribAuthor ">Ramon V.  Tiu</span>, <span class="hlFld-ContribAuthor ">David S.  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (2)
                                     , 460-467. <a href="https://doi.org/10.1158/1535-7163.MCT-19-0681" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-0681</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-0681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-0681%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DA%252BPhase%252BI%252BStudy%252Bof%252BLY3009120%25252C%252Ba%252BPan-RAF%252BInhibitor%25252C%252Bin%252BPatients%252Bwith%252BAdvanced%252Bor%252BMetastatic%252BCancer%26aulast%3DSullivan%26aufirst%3DRyan%2BJ.%26date%3D2020%26date%3D2019%26volume%3D19%26issue%3D2%26spage%3D460%26epage%3D467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Urvi H.  Gala</span>, <span class="hlFld-ContribAuthor ">Dave A.  Miller</span>, <span class="hlFld-ContribAuthor ">Robert O.  Williams</span>. </span><span class="cited-content_cbyCitation_article-title">Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Reviews on Cancer</span><span> <strong>2020,</strong> <em>1873 </em>
                                    (1)
                                     , 188319. <a href="https://doi.org/10.1016/j.bbcan.2019.188319" title="DOI URL">https://doi.org/10.1016/j.bbcan.2019.188319</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbcan.2019.188319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbcan.2019.188319%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Reviews%2520on%2520Cancer%26atitle%3DHarnessing%252Bthe%252Btherapeutic%252Bpotential%252Bof%252Banticancer%252Bdrugs%252Bthrough%252Bamorphous%252Bsolid%252Bdispersions%26aulast%3DGala%26aufirst%3DUrvi%2BH.%26date%3D2020%26volume%3D1873%26issue%3D1%26spage%3D188319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruo-Jun  Man</span>, <span class="hlFld-ContribAuthor ">Ya-Liang  Zhang</span>, <span class="hlFld-ContribAuthor ">Ai-Qin  Jiang</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">A patent review of RAF kinase inhibitors (2010–2018). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (9)
                                     , 675-688. <a href="https://doi.org/10.1080/13543776.2019.1651842" title="DOI URL">https://doi.org/10.1080/13543776.2019.1651842</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1651842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1651842%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DA%252Bpatent%252Breview%252Bof%252BRAF%252Bkinase%252Binhibitors%252B%2525282010%2525E2%252580%2525932018%252529%26aulast%3DMan%26aufirst%3DRuo-Jun%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D9%26spage%3D675%26epage%3D688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng-Fei  Wang</span>, <span class="hlFld-ContribAuthor ">Han-Yue  Qiu</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">A patent review of BRAF inhibitors: 2013-2018. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (8)
                                     , 595-603. <a href="https://doi.org/10.1080/13543776.2019.1640680" title="DOI URL">https://doi.org/10.1080/13543776.2019.1640680</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1640680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1640680%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DA%252Bpatent%252Breview%252Bof%252BBRAF%252Binhibitors%25253A%252B2013-2018%26aulast%3DWang%26aufirst%3DPeng-Fei%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D8%26spage%3D595%26epage%3D603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hengyu  Lu</span>, <span class="hlFld-ContribAuthor ">Chen  Liu</span>, <span class="hlFld-ContribAuthor ">Roberto  Velazquez</span>, <span class="hlFld-ContribAuthor ">Hongyun  Wang</span>, <span class="hlFld-ContribAuthor ">Lukas Manuel  Dunkl</span>, <span class="hlFld-ContribAuthor ">Malika  Kazic-Legueux</span>, <span class="hlFld-ContribAuthor ">Anne  Haberkorn</span>, <span class="hlFld-ContribAuthor ">Eric  Billy</span>, <span class="hlFld-ContribAuthor ">Eusebio  Manchado</span>, <span class="hlFld-ContribAuthor ">Saskia M.  Brachmann</span>, <span class="hlFld-ContribAuthor ">Susan E.  Moody</span>, <span class="hlFld-ContribAuthor ">Jeffrey A.  Engelman</span>, <span class="hlFld-ContribAuthor ">Peter S.  Hammerman</span>, <span class="hlFld-ContribAuthor ">Giordano  Caponigro</span>, <span class="hlFld-ContribAuthor ">Morvarid  Mohseni</span>, <span class="hlFld-ContribAuthor ">Huai-Xiang  Hao</span>. </span><span class="cited-content_cbyCitation_article-title">SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2019,</strong> <em>18 </em>
                                    (7)
                                     , 1323-1334. <a href="https://doi.org/10.1158/1535-7163.MCT-18-0852" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-18-0852</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-18-0852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-18-0852%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DSHP2%252BInhibition%252BOvercomes%252BRTK-Mediated%252BPathway%252BReactivation%252Bin%252BKRAS-Mutant%252BTumors%252BTreated%252Bwith%252BMEK%252BInhibitors%26aulast%3DLu%26aufirst%3DHengyu%26date%3D2019%26date%3D2019%26volume%3D18%26issue%3D7%26spage%3D1323%26epage%3D1334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Morana  Vojnic</span>, <span class="hlFld-ContribAuthor ">Daisuke  Kubota</span>, <span class="hlFld-ContribAuthor ">Christopher  Kurzatkowski</span>, <span class="hlFld-ContribAuthor ">Michael  Offin</span>, <span class="hlFld-ContribAuthor ">Ken  Suzawa</span>, <span class="hlFld-ContribAuthor ">Ryma  Benayed</span>, <span class="hlFld-ContribAuthor ">Adam J.  Schoenfeld</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Plodkowski</span>, <span class="hlFld-ContribAuthor ">John T.  Poirier</span>, <span class="hlFld-ContribAuthor ">Charles M.  Rudin</span>, <span class="hlFld-ContribAuthor ">Mark G.  Kris</span>, <span class="hlFld-ContribAuthor ">Neal X.  Rosen</span>, <span class="hlFld-ContribAuthor ">Helena A.  Yu</span>, <span class="hlFld-ContribAuthor ">Gregory J.  Riely</span>, <span class="hlFld-ContribAuthor ">Maria E.  Arcila</span>, <span class="hlFld-ContribAuthor ">Romel  Somwar</span>, <span class="hlFld-ContribAuthor ">Marc  Ladanyi</span>. </span><span class="cited-content_cbyCitation_article-title">Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (5)
                                     , 802-815. <a href="https://doi.org/10.1016/j.jtho.2018.12.038" title="DOI URL">https://doi.org/10.1016/j.jtho.2018.12.038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2018.12.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2018.12.038%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DAcquired%252BBRAF%252BRearrangements%252BInduce%252BSecondary%252BResistance%252Bto%252BEGFR%252Btherapy%252Bin%252BEGFR-Mutated%252BLung%252BCancers%26aulast%3DVojnic%26aufirst%3DMorana%26date%3D2019%26volume%3D14%26issue%3D5%26spage%3D802%26epage%3D815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gautham  Gampa</span>, <span class="hlFld-ContribAuthor ">Minjee  Kim</span>, <span class="hlFld-ContribAuthor ">Afroz S.  Mohammad</span>, <span class="hlFld-ContribAuthor ">Karen E.  Parrish</span>, <span class="hlFld-ContribAuthor ">Ann C.  Mladek</span>, <span class="hlFld-ContribAuthor ">Jann N.  Sarkaria</span>, <span class="hlFld-ContribAuthor ">William F.  Elmquist</span>. </span><span class="cited-content_cbyCitation_article-title">Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2019,</strong> <em>368 </em>
                                    (3)
                                     , 446-461. <a href="https://doi.org/10.1124/jpet.118.253708" title="DOI URL">https://doi.org/10.1124/jpet.118.253708</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.118.253708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.118.253708%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DBrain%252BDistribution%252Band%252BActive%252BEfflux%252Bof%252BThree%252BpanRAF%252BInhibitors%25253A%252BConsiderations%252Bin%252Bthe%252BTreatment%252Bof%252BMelanoma%252BBrain%252BMetastases%26aulast%3DGampa%26aufirst%3DGautham%26date%3D2019%26date%3D2019%26volume%3D368%26issue%3D3%26spage%3D446%26epage%3D461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Gaoyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Chunqi  Duan</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Weifang  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent Pan-Raf inhibitors with increased solubility to overcome drug resistance. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>163 </em>, 243-255. <a href="https://doi.org/10.1016/j.ejmech.2018.11.033" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.11.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.11.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.11.033%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252BPan-Raf%252Binhibitors%252Bwith%252Bincreased%252Bsolubility%252Bto%252Bovercome%252Bdrug%252Bresistance%26aulast%3DWang%26aufirst%3DLu%26date%3D2019%26volume%3D163%26spage%3D243%26epage%3D255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hitoshi  Sase</span>, <span class="hlFld-ContribAuthor ">Yoshito  Nakanishi</span>, <span class="hlFld-ContribAuthor ">Satoshi  Aida</span>, <span class="hlFld-ContribAuthor ">Kana  Horiguchi-Takei</span>, <span class="hlFld-ContribAuthor ">Nukinori  Akiyama</span>, <span class="hlFld-ContribAuthor ">Toshihiko  Fujii</span>, <span class="hlFld-ContribAuthor ">Kiyoaki  Sakata</span>, <span class="hlFld-ContribAuthor ">Toshiyuki  Mio</span>, <span class="hlFld-ContribAuthor ">Masahiro  Aoki</span>, <span class="hlFld-ContribAuthor ">Nobuya  Ishii</span>. </span><span class="cited-content_cbyCitation_article-title">Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in
              FGFR2
              -Amplified Gastric Cancer. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (10)
                                     , 2217-2225. <a href="https://doi.org/10.1158/1535-7163.MCT-17-1022" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-17-1022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-17-1022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-17-1022%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DAcquired%252BJHDM1D%2525E2%252580%252593BRAF%252BFusion%252BConfers%252BResistance%252Bto%252BFGFR%252BInhibition%252Bin%252BFGFR2%252B-Amplified%252BGastric%252BCancer%26aulast%3DSase%26aufirst%3DHitoshi%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D10%26spage%3D2217%26epage%3D2225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Su‑Min  Yang</span>, <span class="hlFld-ContribAuthor ">Yu‑Kyoung  Park</span>, <span class="hlFld-ContribAuthor ">Jee  Kim</span>, <span class="hlFld-ContribAuthor ">Yun‑Han  Lee</span>, <span class="hlFld-ContribAuthor ">Tae‑Yun  Lee</span>, <span class="hlFld-ContribAuthor ">Byeong‑Churl  Jang</span>. </span><span class="cited-content_cbyCitation_article-title">LY3009120, a pan-Raf kinase inhibitor, inhibits adipogenesis of 3T3-L1 cells by controlling the expression and phosphorylation of C/EBP-α, PPAR-γ, STAT‑3, FAS, ACC, perilipin�A, and AMPK. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Medicine</span><span> <strong>2018,</strong> <em> </em><a href="https://doi.org/10.3892/ijmm.2018.3890" title="DOI URL">https://doi.org/10.3892/ijmm.2018.3890</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/ijmm.2018.3890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fijmm.2018.3890%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Medicine%26atitle%3DLY3009120%25252C%252Ba%252Bpan-Raf%252Bkinase%252Binhibitor%25252C%252Binhibits%252Badipogenesis%252Bof%252B3T3-L1%252Bcells%252Bby%252Bcontrolling%252Bthe%252Bexpression%252Band%252Bphosphorylation%252Bof%252BC%25252FEBP-%2525CE%2525B1%25252C%252BPPAR-%2525CE%2525B3%25252C%252BSTAT%2525E2%252580%2525913%25252C%252BFAS%25252C%252BACC%25252C%252Bperilipin%2525EF%2525BF%2525BDA%25252C%252Band%252BAMPK%26aulast%3DYang%26aufirst%3DSu%25E2%2580%2591Min%26date%3D2018%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2018,</strong> <em>135 </em>, 239-258. <a href="https://doi.org/10.1016/j.phrs.2018.08.013" title="DOI URL">https://doi.org/10.1016/j.phrs.2018.08.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2018.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2018.08.013%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DTargeting%252Boncogenic%252BRaf%252Bprotein-serine%25252Fthreonine%252Bkinases%252Bin%252Bhuman%252Bcancers%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2018%26volume%3D135%26spage%3D239%26epage%3D258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew M.  Waters</span>, <span class="hlFld-ContribAuthor ">Channing J.  Der</span>. </span><span class="cited-content_cbyCitation_article-title">KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cold Spring Harbor Perspectives in Medicine</span><span> <strong>2018,</strong> <em>8 </em>
                                    (9)
                                     , a031435. <a href="https://doi.org/10.1101/cshperspect.a031435" title="DOI URL">https://doi.org/10.1101/cshperspect.a031435</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1101/cshperspect.a031435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1101%2Fcshperspect.a031435%26sid%3Dliteratum%253Aachs%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspectives%2520in%2520Medicine%26atitle%3DKRAS%25253A%252BThe%252BCritical%252BDriver%252Band%252BTherapeutic%252BTarget%252Bfor%252BPancreatic%252BCancer%26aulast%3DWaters%26aufirst%3DAndrew%2BM.%26date%3D2018%26date%3D2017%26volume%3D8%26issue%3D9%26spage%3Da031435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheng-Dong  Ji</span>, <span class="hlFld-ContribAuthor ">Yan-Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Dong-Fang  Xiang</span>, <span class="hlFld-ContribAuthor ">Qiang  Liu</span>, <span class="hlFld-ContribAuthor ">Zhi-Hua  Zhou</span>, <span class="hlFld-ContribAuthor ">Feng  Qian</span>, <span class="hlFld-ContribAuthor ">Lang  Yang</span>, <span class="hlFld-ContribAuthor ">Yong  Ren</span>, <span class="hlFld-ContribAuthor ">Wei  Cui</span>, <span class="hlFld-ContribAuthor ">Sen-Lin  Xu</span>, <span class="hlFld-ContribAuthor ">Xi-Long  Zhao</span>, <span class="hlFld-ContribAuthor ">Xia  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Peng  Zhang</span>, <span class="hlFld-ContribAuthor ">Ji-Ming  Wang</span>, <span class="hlFld-ContribAuthor ">You-Hong  Cui</span>, <span class="hlFld-ContribAuthor ">Xiu-Wu  Bian</span>. </span><span class="cited-content_cbyCitation_article-title">Kir2.1 Interaction with Stk38 Promotes Invasion and Metastasis of Human Gastric Cancer by Enhancing MEKK2–MEK1/2–ERK1/2 Signaling. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2018,</strong> <em>78 </em>
                                    (11)
                                     , 3041-3053. <a href="https://doi.org/10.1158/0008-5472.CAN-17-3776" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-17-3776</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-17-3776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-17-3776%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DKir2.1%252BInteraction%252Bwith%252BStk38%252BPromotes%252BInvasion%252Band%252BMetastasis%252Bof%252BHuman%252BGastric%252BCancer%252Bby%252BEnhancing%252BMEKK2%2525E2%252580%252593MEK1%25252F2%2525E2%252580%252593ERK1%25252F2%252BSignaling%26aulast%3DJi%26aufirst%3DCheng-Dong%26date%3D2018%26date%3D2018%26volume%3D78%26issue%3D11%26spage%3D3041%26epage%3D3053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S-H  Chen</span>, <span class="hlFld-ContribAuthor ">X  Gong</span>, <span class="hlFld-ContribAuthor ">Y  Zhang</span>, <span class="hlFld-ContribAuthor ">R D  Van Horn</span>, <span class="hlFld-ContribAuthor ">T  Yin</span>, <span class="hlFld-ContribAuthor ">L  Huber</span>, <span class="hlFld-ContribAuthor ">T F  Burke</span>, <span class="hlFld-ContribAuthor ">J  Manro</span>, <span class="hlFld-ContribAuthor ">P W  Iversen</span>, <span class="hlFld-ContribAuthor ">W  Wu</span>, <span class="hlFld-ContribAuthor ">S V  Bhagwat</span>, <span class="hlFld-ContribAuthor ">R P  Beckmann</span>, <span class="hlFld-ContribAuthor ">R V  Tiu</span>, <span class="hlFld-ContribAuthor ">S G  Buchanan</span>, <span class="hlFld-ContribAuthor ">S-B  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2018,</strong> <em>37 </em>
                                    (6)
                                     , 821-832. <a href="https://doi.org/10.1038/onc.2017.384" title="DOI URL">https://doi.org/10.1038/onc.2017.384</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/onc.2017.384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fonc.2017.384%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DRAF%252Binhibitor%252BLY3009120%252Bsensitizes%252BRAS%252Bor%252BBRAF%252Bmutant%252Bcancer%252Bto%252BCDK4%25252F6%252Binhibition%252Bby%252Babemaciclib%252Bvia%252Bsuperior%252Binhibition%252Bof%252Bphospho-RB%252Band%252Bsuppression%252Bof%252Bcyclin%252BD1%26aulast%3DChen%26aufirst%3DS-H%26date%3D2018%26date%3D2017%26volume%3D37%26issue%3D6%26spage%3D821%26epage%3D832" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ze-Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Peng-Fei  Wang</span>, <span class="hlFld-ContribAuthor ">Jun-Ting  Ma</span>, <span class="hlFld-ContribAuthor ">Ying-Zi  Chai</span>, <span class="hlFld-ContribAuthor ">Hui-Min  Hu</span>, <span class="hlFld-ContribAuthor ">Wen-Long  Gao</span>, <span class="hlFld-ContribAuthor ">Zhong-Chang  Wang</span>, <span class="hlFld-ContribAuthor ">Bao-Zhong  Wang</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design of potent B-Raf
              V600E
              inhibitors by multiple copy simulation search strategy. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2018,</strong> <em>91 </em>
                                    (2)
                                     , 567-574. <a href="https://doi.org/10.1111/cbdd.13121" title="DOI URL">https://doi.org/10.1111/cbdd.13121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13121%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DDesign%252Bof%252Bpotent%252BB-Raf%252BV600E%252Binhibitors%252Bby%252Bmultiple%252Bcopy%252Bsimulation%252Bsearch%252Bstrategy%26aulast%3DWang%26aufirst%3DZe-Feng%26date%3D2018%26date%3D2017%26volume%3D91%26issue%3D2%26spage%3D567%26epage%3D574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel C.  Kirouac</span>, <span class="hlFld-ContribAuthor ">Gabriele  Schaefer</span>, <span class="hlFld-ContribAuthor ">Jocelyn  Chan</span>, <span class="hlFld-ContribAuthor ">Mark  Merchant</span>, <span class="hlFld-ContribAuthor ">Christine  Orr</span>, <span class="hlFld-ContribAuthor ">Shih-Min A.  Huang</span>, <span class="hlFld-ContribAuthor ">John  Moffat</span>, <span class="hlFld-ContribAuthor ">Lichuan  Liu</span>, <span class="hlFld-ContribAuthor ">Kapil  Gadkar</span>, <span class="hlFld-ContribAuthor ">Saroja  Ramanujan</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model. </span><span class="cited-content_cbyCitation_journal-name">npj Systems Biology and Applications</span><span> <strong>2017,</strong> <em>3 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41540-017-0016-1" title="DOI URL">https://doi.org/10.1038/s41540-017-0016-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41540-017-0016-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41540-017-0016-1%26sid%3Dliteratum%253Aachs%26jtitle%3Dnpj%2520Systems%2520Biology%2520and%2520Applications%26atitle%3DClinical%252Bresponses%252Bto%252BERK%252Binhibition%252Bin%252BBRAF%252BV600E-mutant%252Bcolorectal%252Bcancer%252Bpredicted%252Busing%252Ba%252Bcomputational%252Bmodel%26aulast%3DKirouac%26aufirst%3DDaniel%2BC.%26date%3D2017%26date%3D2017%26volume%3D3%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zoi  Karoulia</span>, <span class="hlFld-ContribAuthor ">Evripidis  Gavathiotis</span>, <span class="hlFld-ContribAuthor ">Poulikos I.  Poulikakos</span>. </span><span class="cited-content_cbyCitation_article-title">New perspectives for targeting RAF kinase in human cancer. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Cancer</span><span> <strong>2017,</strong> <em>17 </em>
                                    (11)
                                     , 676-691. <a href="https://doi.org/10.1038/nrc.2017.79" title="DOI URL">https://doi.org/10.1038/nrc.2017.79</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrc.2017.79&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrc.2017.79%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Cancer%26atitle%3DNew%252Bperspectives%252Bfor%252Btargeting%252BRAF%252Bkinase%252Bin%252Bhuman%252Bcancer%26aulast%3DKaroulia%26aufirst%3DZoi%26date%3D2017%26date%3D2017%26volume%3D17%26issue%3D11%26spage%3D676%26epage%3D691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">P  Jain</span>, <span class="hlFld-ContribAuthor ">T M  Fierst</span>, <span class="hlFld-ContribAuthor ">H J  Han</span>, <span class="hlFld-ContribAuthor ">T E  Smith</span>, <span class="hlFld-ContribAuthor ">A  Vakil</span>, <span class="hlFld-ContribAuthor ">P B  Storm</span>, <span class="hlFld-ContribAuthor ">A C  Resnick</span>, <span class="hlFld-ContribAuthor ">A J  Waanders</span>. </span><span class="cited-content_cbyCitation_article-title">CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2017,</strong> <em>36 </em>
                                    (45)
                                     , 6348-6358. <a href="https://doi.org/10.1038/onc.2017.276" title="DOI URL">https://doi.org/10.1038/onc.2017.276</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/onc.2017.276&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fonc.2017.276%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DCRAF%252Bgene%252Bfusions%252Bin%252Bpediatric%252Blow-grade%252Bgliomas%252Bdefine%252Ba%252Bdistinct%252Bdrug%252Bresponse%252Bbased%252Bon%252Bdimerization%252Bprofiles%26aulast%3DJain%26aufirst%3DP%26date%3D2017%26date%3D2017%26volume%3D36%26issue%3D45%26spage%3D6348%26epage%3D6358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yung-mae M.  Yao</span>, <span class="hlFld-ContribAuthor ">Gregory P.  Donoho</span>, <span class="hlFld-ContribAuthor ">Philip W.  Iversen</span>, <span class="hlFld-ContribAuthor ">Youyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Robert D.  Van Horn</span>, <span class="hlFld-ContribAuthor ">Amelie  Forest</span>, <span class="hlFld-ContribAuthor ">Ruslan D.  Novosiadly</span>, <span class="hlFld-ContribAuthor ">Yue Wang  Webster</span>, <span class="hlFld-ContribAuthor ">Philip  Ebert</span>, <span class="hlFld-ContribAuthor ">Steven  Bray</span>, <span class="hlFld-ContribAuthor ">Jason C.  Ting</span>, <span class="hlFld-ContribAuthor ">Amit  Aggarwal</span>, <span class="hlFld-ContribAuthor ">James R.  Henry</span>, <span class="hlFld-ContribAuthor ">Ramon V.  Tiu</span>, <span class="hlFld-ContribAuthor ">Gregory D.  Plowman</span>, <span class="hlFld-ContribAuthor ">Sheng-Bin  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with
              BRAF
              or
              KRAS
              Mutations. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2017,</strong> <em>23 </em>
                                    (18)
                                     , 5547-5560. <a href="https://doi.org/10.1158/1078-0432.CCR-16-3250" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-16-3250</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-16-3250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-16-3250%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DMouse%252BPDX%252BTrial%252BSuggests%252BSynergy%252Bof%252BConcurrent%252BInhibition%252Bof%252BRAF%252Band%252BEGFR%252Bin%252BColorectal%252BCancer%252Bwith%252BBRAF%252Bor%252BKRAS%252BMutations%26aulast%3DYao%26aufirst%3DYung-mae%2BM.%26date%3D2017%26date%3D2017%26volume%3D23%26issue%3D18%26spage%3D5547%26epage%3D5560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peng-Fei  Wang</span>, <span class="hlFld-ContribAuthor ">Han-Yue  Qiu</span>, <span class="hlFld-ContribAuthor ">Ze-Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Yong-Jiao  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhong-Chang  Wang</span>, <span class="hlFld-ContribAuthor ">Dong-Dong  Li</span>, <span class="hlFld-ContribAuthor ">Hai-Liang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel B-RafV600E inhibitors employing FBDD strategy. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2017,</strong> <em>132 </em>, 63-76. <a href="https://doi.org/10.1016/j.bcp.2017.02.022" title="DOI URL">https://doi.org/10.1016/j.bcp.2017.02.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2017.02.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2017.02.022%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DIdentification%252Bof%252Bnovel%252BB-RafV600E%252Binhibitors%252Bemploying%252BFBDD%252Bstrategy%26aulast%3DWang%26aufirst%3DPeng-Fei%26date%3D2017%26volume%3D132%26spage%3D63%26epage%3D76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eliza  Vakana</span>, <span class="hlFld-ContribAuthor ">Susan  Pratt</span>, <span class="hlFld-ContribAuthor ">Wayne  Blosser</span>, <span class="hlFld-ContribAuthor ">Michele  Dowless</span>, <span class="hlFld-ContribAuthor ">Nicholas  Simpson</span>, <span class="hlFld-ContribAuthor ">Xiu-Juan  Yuan</span>, <span class="hlFld-ContribAuthor ">Susan  Jaken</span>, <span class="hlFld-ContribAuthor ">Jason  Manro</span>, <span class="hlFld-ContribAuthor ">Jennifer  Stephens</span>, <span class="hlFld-ContribAuthor ">Youyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Lysiane  Huber</span>, <span class="hlFld-ContribAuthor ">Sheng-Bin  Peng</span>, <span class="hlFld-ContribAuthor ">Louis F.  Stancato</span>. </span><span class="cited-content_cbyCitation_article-title">LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (6)
                                     , 9251-9266. <a href="https://doi.org/10.18632/oncotarget.14002" title="DOI URL">https://doi.org/10.18632/oncotarget.14002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.14002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.14002%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DLY3009120%25252C%252Ba%252BpanRAF%252Binhibitor%25252C%252Bhas%252Bsignificant%252Banti-tumor%252Bactivity%252Bin%252BBRAF%252Band%252BKRAS%252Bmutant%252Bpreclinical%252Bmodels%252Bof%252Bcolorectal%252Bcancer%26aulast%3DVakana%26aufirst%3DEliza%26date%3D2017%26date%3D2016%26volume%3D8%26issue%3D6%26spage%3D9251%26epage%3D9266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yin  Chen</span>, <span class="hlFld-ContribAuthor ">Yaxin  Zheng</span>, <span class="hlFld-ContribAuthor ">Qinglin  Jiang</span>, <span class="hlFld-ContribAuthor ">Feifei  Qin</span>, <span class="hlFld-ContribAuthor ">Yonghui  Zhang</span>, <span class="hlFld-ContribAuthor ">Leilei  Fu</span>, <span class="hlFld-ContribAuthor ">Gu  He</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>127 </em>, 997-1011. <a href="https://doi.org/10.1016/j.ejmech.2016.11.009" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.11.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.11.009%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIntegrated%252Bbioinformatics%25252C%252Bcomputational%252Band%252Bexperimental%252Bmethods%252Bto%252Bdiscover%252Bnovel%252BRaf%25252Fextracellular-signal%252Bregulated%252Bkinase%252B%252528ERK%252529%252Bdual%252Binhibitors%252Bagainst%252Bbreast%252Bcancer%252Bcells%26aulast%3DChen%26aufirst%3DYin%26date%3D2017%26volume%3D127%26spage%3D997%26epage%3D1011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Gaoyuan  Zhu</span>, <span class="hlFld-ContribAuthor ">Qing  Zhang</span>, <span class="hlFld-ContribAuthor ">Chunqi  Duan</span>, <span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhimin  Zhang</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhou</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Weifang  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2017,</strong> <em>15 </em>
                                    (16)
                                     , 3455-3465. <a href="https://doi.org/10.1039/C7OB00518K" title="DOI URL">https://doi.org/10.1039/C7OB00518K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB00518K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB00518K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DRational%252Bdesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252BPan-Raf%252Binhibitors%252Bto%252Bovercome%252Bresistance%26aulast%3DWang%26aufirst%3DLu%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D16%26spage%3D3455%26epage%3D3465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Antoine  Millet</span>, <span class="hlFld-ContribAuthor ">Anthony R.  Martin</span>, <span class="hlFld-ContribAuthor ">Cyril  Ronco</span>, <span class="hlFld-ContribAuthor ">Stéphane  Rocchi</span>, <span class="hlFld-ContribAuthor ">Rachid  Benhida</span>. </span><span class="cited-content_cbyCitation_article-title">Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2017,</strong> <em>37 </em>
                                    (1)
                                     , 98-148. <a href="https://doi.org/10.1002/med.21404" title="DOI URL">https://doi.org/10.1002/med.21404</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21404%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMetastatic%252BMelanoma%25253A%252BInsights%252BInto%252Bthe%252BEvolution%252Bof%252Bthe%252BTreatments%252Band%252BFuture%252BChallenges%26aulast%3DMillet%26aufirst%3DAntoine%26date%3D2017%26date%3D2016%26volume%3D37%26issue%3D1%26spage%3D98%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ha Linh  Vu</span>, <span class="hlFld-ContribAuthor ">Andrew E.  Aplin</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting mutant NRAS signaling pathways in melanoma. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2016,</strong> <em>107 </em>, 111-116. <a href="https://doi.org/10.1016/j.phrs.2016.03.007" title="DOI URL">https://doi.org/10.1016/j.phrs.2016.03.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2016.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2016.03.007%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DTargeting%252Bmutant%252BNRAS%252Bsignaling%252Bpathways%252Bin%252Bmelanoma%26aulast%3DVu%26aufirst%3DHa%2BLinh%26date%3D2016%26volume%3D107%26spage%3D111%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renzo  Rossi</span>, <span class="hlFld-ContribAuthor ">Marco  Lessi</span>, <span class="hlFld-ContribAuthor ">Chiara  Manzini</span>, <span class="hlFld-ContribAuthor ">Giulia  Marianetti</span>, <span class="hlFld-ContribAuthor ">Fabio  Bellina</span>. </span><span class="cited-content_cbyCitation_article-title">Achievement of regioselectivity in transition metal-catalyzed direct C–H (hetero)arylation reactions of heteroarenes with one heteroatom through the use of removable protecting/blocking substituents or traceless directing groups. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2016,</strong> <em>72 </em>
                                    (15)
                                     , 1795-1837. <a href="https://doi.org/10.1016/j.tet.2016.02.037" title="DOI URL">https://doi.org/10.1016/j.tet.2016.02.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2016.02.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2016.02.037%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DAchievement%252Bof%252Bregioselectivity%252Bin%252Btransition%252Bmetal-catalyzed%252Bdirect%252BC%2525E2%252580%252593H%252B%252528hetero%252529arylation%252Breactions%252Bof%252Bheteroarenes%252Bwith%252Bone%252Bheteroatom%252Bthrough%252Bthe%252Buse%252Bof%252Bremovable%252Bprotecting%25252Fblocking%252Bsubstituents%252Bor%252Btraceless%252Bdirecting%252Bgroups%26aulast%3DRossi%26aufirst%3DRenzo%26date%3D2016%26volume%3D72%26issue%3D15%26spage%3D1795%26epage%3D1837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shih-Hsun  Chen</span>, <span class="hlFld-ContribAuthor ">Youyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Robert D.  Van Horn</span>, <span class="hlFld-ContribAuthor ">Tinggui  Yin</span>, <span class="hlFld-ContribAuthor ">Sean  Buchanan</span>, <span class="hlFld-ContribAuthor ">Vipin  Yadav</span>, <span class="hlFld-ContribAuthor ">Igor  Mochalkin</span>, <span class="hlFld-ContribAuthor ">Swee Seong  Wong</span>, <span class="hlFld-ContribAuthor ">Yong Gang  Yue</span>, <span class="hlFld-ContribAuthor ">Lysiane  Huber</span>, <span class="hlFld-ContribAuthor ">Ilaria  Conti</span>, <span class="hlFld-ContribAuthor ">James R.  Henry</span>, <span class="hlFld-ContribAuthor ">James J.  Starling</span>, <span class="hlFld-ContribAuthor ">Gregory D.  Plowman</span>, <span class="hlFld-ContribAuthor ">Sheng-Bin  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">Oncogenic
              BRAF
              Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. </span><span class="cited-content_cbyCitation_journal-name">Cancer Discovery</span><span> <strong>2016,</strong> <em>6 </em>
                                    (3)
                                     , 300-315. <a href="https://doi.org/10.1158/2159-8290.CD-15-0896" title="DOI URL">https://doi.org/10.1158/2159-8290.CD-15-0896</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/2159-8290.CD-15-0896&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F2159-8290.CD-15-0896%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Discovery%26atitle%3DOncogenic%252BBRAF%252BDeletions%252BThat%252BFunction%252Bas%252BHomodimers%252Band%252BAre%252BSensitive%252Bto%252BInhibition%252Bby%252BRAF%252BDimer%252BInhibitor%252BLY3009120%26aulast%3DChen%26aufirst%3DShih-Hsun%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D3%26spage%3D300%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Biao  Lu</span>, <span class="hlFld-ContribAuthor ">Hu  Cao</span>, <span class="hlFld-ContribAuthor ">Jingsong  Cao</span>, <span class="hlFld-ContribAuthor ">Song  Huang</span>, <span class="hlFld-ContribAuthor ">Qiyue  Hu</span>, <span class="hlFld-ContribAuthor ">Dong  Liu</span>, <span class="hlFld-ContribAuthor ">Ru  Shen</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Shen</span>, <span class="hlFld-ContribAuthor ">Weikang  Tao</span>, <span class="hlFld-ContribAuthor ">Hong  Wan</span>, <span class="hlFld-ContribAuthor ">Dan  Wang</span>, <span class="hlFld-ContribAuthor ">Yinfa  Yan</span>, <span class="hlFld-ContribAuthor ">Liuqing  Yang</span>, <span class="hlFld-ContribAuthor ">Jiayin  Zhang</span>, <span class="hlFld-ContribAuthor ">Lei  Zhang</span>, <span class="hlFld-ContribAuthor ">Lianshan  Zhang</span>, <span class="hlFld-ContribAuthor ">Minsheng  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of EBI-907: A highly potent and orally active B-Raf V600E inhibitor for the treatment of melanoma and associated cancers. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (3)
                                     , 819-823. <a href="https://doi.org/10.1016/j.bmcl.2015.12.086" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.12.086</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.12.086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.12.086%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BEBI-907%25253A%252BA%252Bhighly%252Bpotent%252Band%252Borally%252Bactive%252BB-Raf%252BV600E%252Binhibitor%252Bfor%252Bthe%252Btreatment%252Bof%252Bmelanoma%252Band%252Bassociated%252Bcancers%26aulast%3DLu%26aufirst%3DBiao%26date%3D2016%26volume%3D26%26issue%3D3%26spage%3D819%26epage%3D823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meagan B.  Ryan</span>, <span class="hlFld-ContribAuthor ">Channing J.  Der</span>, <span class="hlFld-ContribAuthor ">Andrea  Wang-Gillam</span>, <span class="hlFld-ContribAuthor ">Adrienne D.  Cox</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting RAS -mutant Cancers: Is ERK the Key?. </span><span class="cited-content_cbyCitation_journal-name">Trends in Cancer</span><span> <strong>2015,</strong> <em>1 </em>
                                    (3)
                                     , 183-198. <a href="https://doi.org/10.1016/j.trecan.2015.10.001" title="DOI URL">https://doi.org/10.1016/j.trecan.2015.10.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.trecan.2015.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.trecan.2015.10.001%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Cancer%26atitle%3DTargeting%252BRAS%252B-mutant%252BCancers%25253A%252BIs%252BERK%252Bthe%252BKey%25253F%26aulast%3DRyan%26aufirst%3DMeagan%2BB.%26date%3D2015%26volume%3D1%26issue%3D3%26spage%3D183%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David E.  Uehling</span>, <span class="hlFld-ContribAuthor ">Philip A.  Harris</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress on MAP kinase pathway inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (19)
                                     , 4047-4056. <a href="https://doi.org/10.1016/j.bmcl.2015.07.093" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.07.093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.07.093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.07.093%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRecent%252Bprogress%252Bon%252BMAP%252Bkinase%252Bpathway%252Binhibitors%26aulast%3DUehling%26aufirst%3DDavid%2BE.%26date%3D2015%26volume%3D25%26issue%3D19%26spage%3D4047%26epage%3D4056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sheng-Bin  Peng</span>, <span class="hlFld-ContribAuthor ">James R.  Henry</span>, <span class="hlFld-ContribAuthor ">Michael D.  Kaufman</span>, <span class="hlFld-ContribAuthor ">Wei-Ping  Lu</span>, <span class="hlFld-ContribAuthor ">Bryan D.  Smith</span>, <span class="hlFld-ContribAuthor ">Subha  Vogeti</span>, <span class="hlFld-ContribAuthor ">Thomas J.  Rutkoski</span>, <span class="hlFld-ContribAuthor ">Scott  Wise</span>, <span class="hlFld-ContribAuthor ">Lawrence  Chun</span>, <span class="hlFld-ContribAuthor ">Youyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Robert D.  Van Horn</span>, <span class="hlFld-ContribAuthor ">Tinggui  Yin</span>, <span class="hlFld-ContribAuthor ">Xiaoyi  Zhang</span>, <span class="hlFld-ContribAuthor ">Vipin  Yadav</span>, <span class="hlFld-ContribAuthor ">Shih-Hsun  Chen</span>, <span class="hlFld-ContribAuthor ">Xueqian  Gong</span>, <span class="hlFld-ContribAuthor ">Xiwen  Ma</span>, <span class="hlFld-ContribAuthor ">Yue  Webster</span>, <span class="hlFld-ContribAuthor ">Sean  Buchanan</span>, <span class="hlFld-ContribAuthor ">Igor  Mochalkin</span>, <span class="hlFld-ContribAuthor ">Lysiane  Huber</span>, <span class="hlFld-ContribAuthor ">Lisa  Kays</span>, <span class="hlFld-ContribAuthor ">Gregory P.  Donoho</span>, <span class="hlFld-ContribAuthor ">Jennie  Walgren</span>, <span class="hlFld-ContribAuthor ">Denis  McCann</span>, <span class="hlFld-ContribAuthor ">Phenil  Patel</span>, <span class="hlFld-ContribAuthor ">Ilaria  Conti</span>, <span class="hlFld-ContribAuthor ">Gregory D.  Plowman</span>, <span class="hlFld-ContribAuthor ">James J.  Starling</span>, <span class="hlFld-ContribAuthor ">Daniel L.  Flynn</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell</span><span> <strong>2015,</strong> <em>28 </em>
                                    (3)
                                     , 384-398. <a href="https://doi.org/10.1016/j.ccell.2015.08.002" title="DOI URL">https://doi.org/10.1016/j.ccell.2015.08.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccell.2015.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccell.2015.08.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%26atitle%3DInhibition%252Bof%252BRAF%252BIsoforms%252Band%252BActive%252BDimers%252Bby%252BLY3009120%252BLeads%252Bto%252BAnti-tumor%252BActivities%252Bin%252BRAS%252Bor%252BBRAF%252BMutant%252BCancers%26aulast%3DPeng%26aufirst%3DSheng-Bin%26date%3D2015%26volume%3D28%26issue%3D3%26spage%3D384%26epage%3D398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. X-ray crystal structure of <b>3</b> bound to BRAF V600E.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. IVTI dose–response with compound <b>4</b> in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Xenograft efficacy of <b>4</b> in HT-29 tumors implanted in mice: (A) xenograft growth curve; (B) individual animal phospho-ERK Western blot tumor analysis after dosing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) X-ray crystal structure of <b>6</b> bound to BRAF V600E. (B) X-ray crystal structure of <b>13</b> bound to BRAF V600E.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Paradoxical activation of RAS-RAF-MEK signaling by vemurafenib (<b>1</b>), compound <b>6</b>, and <b>13</b> in <i>BRAF</i> WT HCT-116 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0008.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Mouse IVTI of <b>6</b> in A375 xenograft: (A) phospho-ERK dose response; (B) phospho-ERK concentration response; (C) Western blot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0009.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Compound <b>6</b> in vivo efficacy in mice dosed b.i.d. for 15 days in (A) A375 <i>BRAF</i> V600E and (B) HCT116 xenograft tumors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0010.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>13</b> in vivo efficacy in rat BRAF V600E ST019VR PDX model. Compound was dosed at 15 and 30 mg/kg b.i.d., respectively, for 28 days.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) For <b>6</b>, <b>9</b>, <b>10</b>: rt, 16 h, 52%; (b) EtOAc, Pd/C (10%), H<sub>2</sub> 1 atm, 16 h, 75%; (c) EtOH, KOH, 60 °C, 1 h, 60%. (d) For <b>7</b>: dioxane, K<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, 60 °C, 1 h, 84%. (e) <b>22</b>: NMP, 185 °C, 64 h, 43%. <b>23</b>: CH<sub>3</sub>NH<sub>2</sub> 30% EtOH, 120 °C microwave, 24 h, 98%; (f) EtOAc, H<sub>2</sub>0, rt, 1 h, 95%. (g) <b>26</b>: dioxane, RNH<sub>2</sub>, 60 °C, 4 h, carried on crude. <b>27</b>: dioxane, NMP, 80 °C, 16 h, 89%; (h) <b>26</b>, TFA, rt, 1 h, 53%.</p></p></figure><figure data-id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) acetone, KOH, rt, 10 min, carried on crude; (b) methylamine (33% in EtOH), 110 °C, 16 h, 65%, 2 steps; (c) MeCN, NBS, 0–5 °C 4 days, 31%; (d) NaOH, H<sub>2</sub>O, rt, 16 h, 56%; (e) pyridine, trifluoromethanesulfonic anhydride, 0 °C, 2 h, 70%; (f) DMF, glacial acetic acid, bleach, then methylamine (2.0 M in THF) 0 °C to rt, 2 h, 73%; (g) bis(pinacolato)diboron, KOAc, dioxane, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)–dichloromethane complex, 100 °C, 16 h, 85%; (h) EtOAC, aq NaHCO<sub>3</sub>, isopropenyl chloroformate, rt, 6 h, carried on crude; (i) 3,3-dimethylbutan-1-amine, NMP, dioxane, 75 °C, 16 h, 88% 2 steps. (j) From <b>34</b>: dioxane, NaHCO<sub>3</sub>, <b>38</b>, H<sub>2</sub>O, tetrakis(triphenylphosphine)palladium, 50 °C, 16 h, 77%.</p></p></figure><figure data-id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/medium/jm-2015-000678_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0013.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-10/acs.jmedchem.5b00067/20150521/images/large/jm-2015-000678_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b00067&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) MeCN, TEA, 180 °C microwave, 15 min, 24%; (b) <b>41</b>, dioxane, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, Pd(PPh<sub>3</sub>)<sub>4</sub>, 60 °C, 3 h, 80%; (c) isopropenyl chloroformate, EtOAc, aq NaHCO<sub>3</sub>, rt, 2 h, 99%; (d) NMP, THF, 65 °C, 4 h, 75%; (e) TFA, 0 °C to rt, 16 h, 81%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06065" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06065" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 27 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Vigil, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherfils, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rossman, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">RAS superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">842</span><span class="NLM_x">–</span> <span class="NLM_lpage">857</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1038%2Fnrc2960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=21102635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=842-857&author=D.+Vigilauthor=J.+Cherfilsauthor=K.+L.+Rossmanauthor=C.+J.+Der&title=RAS+superfamily+GEFs+and+GAPs%3A+validated+and+tractable+targets+for+cancer+therapy%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?</span></div><div class="casAuthors">Vigil, Dominico; Cherfils, Jacqueline; Rossman, Kent L.; Der, Channing J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">842-857</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  There is now considerable and increasing evidence for a causal role for aberrant activity of the Ras superfamily of small GTPases in human cancers.  These GTPases function as GDP-GTP-regulated binary switches that control many fundamental cellular processes.  A common mechanism of GTPase deregulation in cancer is the deregulated expression and/or activity of their regulatory proteins, guanine nucleotide exchange factors (GEFs) that promote formation of the active GTP-bound state and GTPase-activating proteins (GAPs) that return the GTPase to its GDP-bound inactive state.  In this Review, we assess the assocn. of GEFs and GAPs with cancer and their druggability for cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwbf8B7sLmb7Vg90H21EOLACvtfcHk0liAR6wDNIqwDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsbrM&md5=b7ad81f2fe0f7f7eaa5f015188f62e85</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2960%26sid%3Dliteratum%253Aachs%26aulast%3DVigil%26aufirst%3DD.%26aulast%3DCherfils%26aufirst%3DJ.%26aulast%3DRossman%26aufirst%3DK.%2BL.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DRAS%2520superfamily%2520GEFs%2520and%2520GAPs%253A%2520validated%2520and%2520tractable%2520targets%2520for%2520cancer%2520therapy%253F%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D842%26epage%3D857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Pylayeva-Gupta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabocka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bar-Sagi, D.</span><span> </span><span class="NLM_article-title">RAS oncogenes: weaving a tumorigenic web</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1038%2Fnrc3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=21993244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlSkur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=761-774&author=Y.+Pylayeva-Guptaauthor=E.+Grabockaauthor=D.+Bar-Sagi&title=RAS+oncogenes%3A+weaving+a+tumorigenic+web"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">RAS oncogenes: weaving a tumorigenic web</span></div><div class="casAuthors">Pylayeva-Gupta, Yuliya; Grabocka, Elda; Bar-Sagi, Dafna</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">761-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  RAS proteins are essential components of signalling pathways that emanate from cell surface receptors.  Oncogenic activation of these proteins owing to missense mutations is frequently detected in several types of cancer.  A wealth of biochem. and genetic studies indicates that RAS proteins control a complex mol. circuitry that consists of a wide array of interconnecting pathways.  In this Review, we describe how RAS oncogenes exploit their extensive signalling reach to affect multiple cellular processes that drive tumorigenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdHRt0jsiXtLVg90H21EOLACvtfcHk0liAR6wDNIqwDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlSkur7K&md5=d1be47023ab43a30cb81e71cb92bc0aa</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3106%26sid%3Dliteratum%253Aachs%26aulast%3DPylayeva-Gupta%26aufirst%3DY.%26aulast%3DGrabocka%26aufirst%3DE.%26aulast%3DBar-Sagi%26aufirst%3DD.%26atitle%3DRAS%2520oncogenes%253A%2520weaving%2520a%2520tumorigenic%2520web%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D761%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Inhibition of mutated, activated BRAF in metastatic melanoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">809</span><span class="NLM_x">–</span> <span class="NLM_lpage">819</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1056%2FNEJMoa1002011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=20818844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=809-819&author=K.+T.+Flahertyauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+J.+O%E2%80%99Dwyerauthor=R.+J.+Leeauthor=J.+F.+Grippoauthor=K.+Nolopauthor=P.+B.+Chapman&title=Inhibition+of+mutated%2C+activated+BRAF+in+metastatic+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mutated, activated BRAF in metastatic melanoma</span></div><div class="casAuthors">Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">809-819</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease.  Methods: We conducted a multicenter, phase 1, dose-escalation trial of PLX4032 (also known as RG7204), an orally available inhibitor of mutated BRAF, followed by an extension phase involving the max. dose that could be administered without adverse effects (the recommended phase 2 dose).  Patients received PLX4032 twice daily until they had disease progression.  Pharmacokinetic anal. and tumor-response assessments were conducted in all patients.  In selected patients, tumor biopsy was performed before and during treatment to validate BRAF inhibition.  Results: A total of 55 patients (49 of whom had melanoma) were enrolled in the dose-escalation phase, and 32 addnl. patients with metastatic melanoma who had BRAF with the V600E mutation were enrolled in the extension phase.  The recommended phase 2 dose was 960 mg twice daily, with increases in the dose limited by grade 2 or 3 rash, fatigue, and arthralgia.  In the dose-escalation cohort, among the 16 patients with melanoma whose tumors carried the V600E BRAF mutation and who were receiving 240 mg or more of PLX4032 twice daily, 10 had a partial response and 1 had a complete response.  Among the 32 patients in the extension cohort, 24 had a partial response and 2 had a complete response.  The estd. median progression-free survival among all patients was more than 7 mo.  Conclusions: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwq1fkvEjfyLVg90H21EOLACvtfcHk0liAR6wDNIqwDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVyksb3M&md5=80f70df0ac490828a42e6c7c0b40067f</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002011%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%2BF.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DInhibition%2520of%2520mutated%252C%2520activated%2520BRAF%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D809%26epage%3D819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BRIM-3 Study Group.</span><span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthurauthor=BRIM-3+Study+Group.&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0lhWM-ZK3zOfJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3D%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demidov, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutzmer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutkowski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blank, C. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. H.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaempgen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martín-Algarra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karaszewska, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiarion-Sileni, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haney, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mirakhur, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guckert, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span> </span><span class="NLM_article-title">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">380</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">365</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1016%2FS0140-6736%2812%2960868-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=22735384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2012&pages=358-365&author=A.+Hauschildauthor=J.+J.+Grobauthor=L.+V.+Demidovauthor=T.+Jouaryauthor=R.+Gutzmerauthor=M.+Millwardauthor=P.+Rutkowskiauthor=C.+U.+Blankauthor=W.+H.+Millerauthor=E.+Kaempgenauthor=S.+Mart%C3%ADn-Algarraauthor=B.+Karaszewskaauthor=C.+Mauchauthor=V.+Chiarion-Sileniauthor=A.+M.+Martinauthor=S.+Swannauthor=P.+Haneyauthor=B.+Mirakhurauthor=M.+E.+Guckertauthor=V.+Goodmanauthor=P.+B.+Chapman&title=Dabrafenib+in+BRAF-mutated+metastatic+melanoma%3A+a+multicentre%2C+open-label%2C+phase+3+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial</span></div><div class="casAuthors">Hauschild, Axel; Grob, Jean-Jacques; Demidov, Lev V.; Jouary, Thomas; Gutzmer, Ralf; Millward, Michael; Rutkowski, Piotr; Blank, Christian U.; Miller, Wilson H.; Kaempgen, Eckhart; Martin-Algarra, Salvador; Karaszewska, Boguslawa; Mauch, Cornelia; Chiarion-Sileni, Vanna; Martin, Anne-Marie; Swann, Suzanne; Haney, Patricia; Mirakhur, Beloo; Guckert, Mary E.; Goodman, Vicki; Chapman, Paul B.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">9839</span>),
    <span class="NLM_cas:pages">358-365</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dabrafenib, an inhibitor of mutated BRAF, has clin. activity with a manageable safety profile in studies of phase 1 and 2 in patients with BRAFV600-mutated metastatic melanoma.  We studied the efficacy of dabrafenib in patients with BRAFV600E-mutated metastatic melanoma.We enrolled patients in this open-label phase 3 trial between Dec 23, 2010, and Sept 1, 2011.  This report is based on a data cutoff date of Dec 19, 2011.  Patients aged 18 years or older with previously untreated, stage IV or unresectable stage III BRAFV600E mutation-pos. melanoma were randomly assigned (3:1) to receive dabrafenib (150 mg twice daily, orally) or dacarbazine (1000 mg/m2 i.v. every 3 wk).  Patients were stratified according to American Joint Committee on Cancer stage (unresectable III+IVM1a+IVM1b vs IVM1c).  The primary endpoint was investigator-assessed progression-free survival and was analyzed by intention to treat; safety was assessed per protocol.  This study is registered with ClinicalTrials.gov, no. NCT01227889.Of the 733 patients screened, 250 were randomly assigned to receive either dabrafenib (187 patients) or dacarbazine (63 patients).  Median progression-free survival was 5·1 mo for dabrafenib and 2·7 mo for dacarbazine, with a hazard ratio (HR) of 0·30 (95% CI 0·18-0·51; p<0·0001).  At data cutoff, 107 (57%) patients in the dabrafenib group and 14 (22%) in the dacarbazine group remained on randomized treatment.  Treatment-related adverse events (grade 2 or higher) occurred in 100 (53%) of the 187 patients who received dabrafenib and in 26 (44%) of the 59 patients who received dacarbazine.  The most common adverse events with dabrafenib were skin-related toxic effects, fever, fatigue, arthralgia, and headache.  The most common adverse events with dacarbazine were nausea, vomiting, neutropenia, fatigue, and asthenia.  Grade 3-4 adverse events were uncommon in both groups.Dabrafenib significantly improved progression-free survival compared with dacarbazine.GlaxoSmithKline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEDYPJULE5c7Vg90H21EOLACvtfcHk0ljuOTB7D55XAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xpt1SgtLg%253D&md5=5e8699780f47bd37e075d39636e0d809</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2812%2960868-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252812%252960868-X%26sid%3Dliteratum%253Aachs%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DDemidov%26aufirst%3DL.%2BV.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DBlank%26aufirst%3DC.%2BU.%26aulast%3DMiller%26aufirst%3DW.%2BH.%26aulast%3DKaempgen%26aufirst%3DE.%26aulast%3DMart%25C3%25ADn-Algarra%26aufirst%3DS.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DMauch%26aufirst%3DC.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DSwann%26aufirst%3DS.%26aulast%3DHaney%26aufirst%3DP.%26aulast%3DMirakhur%26aufirst%3DB.%26aulast%3DGuckert%26aufirst%3DM.%2BE.%26aulast%3DGoodman%26aufirst%3DV.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26atitle%3DDabrafenib%2520in%2520BRAF-mutated%2520metastatic%2520melanoma%253A%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25203%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D380%26spage%3D358%26epage%3D365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Heidorn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milagre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nourry, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhomen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hussain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reis-Filho, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">140</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&author=S.+J.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+Niculescu-Duvasauthor=N.+Dhomenauthor=J.+Hussainauthor=J.+S.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-dead+BRAF+and+oncogenic+RAS+cooperate+to+drive+tumor+progression+through+CRAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0ljuOTB7D55XAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescu-Duvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-dead%2520BRAF%2520and%2520oncogenic%2520RAS%2520cooperate%2520to%2520drive%2520tumor%2520progression%2520through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26spage%3D209%26epage%3D221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Poulikakos, P. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span> </span><span class="NLM_article-title">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">427</span><span class="NLM_x">–</span> <span class="NLM_lpage">430</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1038%2Fnature08902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=20179705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=427-430&author=P.+I.+Poulikakosauthor=C.+Zhangauthor=G.+Bollagauthor=K.+M.+Shokatauthor=N.+Rosen&title=RAF+inhibitors+transactivate+RAF+dimers+and+ERK+signalling+in+cells+with+wild-type+BRAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Zhang, Chao; Bollag, Gideon; Shokat, Kevan M.; Rosen, Neal</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">427-430</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumors with mutant BRAF are dependent on the RAF-MEK-ERK signaling pathway for their growth.  We found that ATP-competitive RAF inhibitors inhibit ERK signaling in cells with mutant BRAF, but unexpectedly enhance signaling in cells with wild-type BRAF.  Here we demonstrate the mechanistic basis for these findings.  We used chem. genetic methods to show that drug-mediated transactivation of RAF dimers is responsible for paradoxical activation of the enzyme by inhibitors.  Induction of ERK signaling requires direct binding of the drug to the ATP-binding site of one kinase of the dimer and is dependent on RAS activity.  Drug binding to one member of RAF homodimers (CRAF-CRAF) or heterodimers (CRAF-BRAF) inhibits one protomer, but results in transactivation of the drug-free protomer.  In BRAF(V600E) tumors, RAS is not activated, thus transactivation is minimal and ERK signaling is inhibited in cells exposed to RAF inhibitors.  These results indicate that RAF inhibitors will be effective in tumors in which BRAF is mutated.  Furthermore, because RAF inhibitors do not inhibit ERK signaling in other cells, the model predicts that they would have a higher therapeutic index and greater antitumor activity than mitogen-activated protein kinase (MEK) inhibitors, but could also cause toxicity due to MEK/ERK activation.  These predictions have been borne out in a recent clin. trial of the RAF inhibitor PLX4032 (refs 4, 5).  The model indicates that promotion of RAF dimerization by elevation of wild-type RAF expression or RAS activity could lead to drug resistance in mutant BRAF tumors.  In agreement with this prediction, RAF inhibitors do not inhibit ERK signaling in cells that coexpress BRAF(V600E) and mutant RAS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMlm9feupyNrVg90H21EOLACvtfcHk0ljuOTB7D55XAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFWjsrs%253D&md5=8323a558886ccbb8f7d85b22b9bfbc15</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnature08902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08902%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRosen%26aufirst%3DN.%26atitle%3DRAF%2520inhibitors%2520transactivate%2520RAF%2520dimers%2520and%2520ERK%2520signalling%2520in%2520cells%2520with%2520wild-type%2520BRAF%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D427%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaiswal, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0ligBlzOEQStZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D431%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Sanchez-Laorden, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saturno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turajlic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">ra30</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1126%2Fscisignal.2004815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=24667377" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=ra30&author=B.+Sanchez-Laordenauthor=A.+Virosauthor=M.+R.+Girottiauthor=M.+Pedersenauthor=G.+Saturnoauthor=A.+Zambonauthor=D.+Niculescu-Duvazauthor=S.+Turajlicauthor=A.+Hayesauthor=M.+Goreauthor=J.+Larkinauthor=P.+Loriganauthor=M.+Cookauthor=C.+Springerauthor=R.+Marais&title=BRAF+inhibitors+induce+metastasis+in+RAS+mutant+or+inhibitor-resistant+melanoma+cells+by+reactivating+MEK+and+ERK+signaling"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004815%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Laorden%26aufirst%3DB.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DGirotti%26aufirst%3DM.%2BR.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DTurajlic%26aufirst%3DS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DCook%26aufirst%3DM.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DBRAF%2520inhibitors%2520induce%2520metastasis%2520in%2520RAS%2520mutant%2520or%2520inhibitor-resistant%2520melanoma%2520cells%2520by%2520reactivating%2520MEK%2520and%2520ERK%2520signaling%26jtitle%3DSci.%2520Signaling%26date%3D2014%26volume%3D7%26spage%3Dra30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Blasco, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francoz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santamaria, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canamero, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubus, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charron, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">C-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">652</span><span class="NLM_x">–</span> <span class="NLM_lpage">663</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=652-663&author=R.+B.+Blascoauthor=S.+Francozauthor=D.+Santamariaauthor=M.+Canameroauthor=P.+Dubusauthor=J.+Charronauthor=M.+Baccariniauthor=M.+Barbacid&title=C-Raf%2C+but+not+B-Raf%2C+is+essential+for+development+of+K-Ras+oncogene-driven+non-small+cell+lung+carcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBlasco%26aufirst%3DR.%2BB.%26aulast%3DFrancoz%26aufirst%3DS.%26aulast%3DSantamaria%26aufirst%3DD.%26aulast%3DCanamero%26aufirst%3DM.%26aulast%3DDubus%26aufirst%3DP.%26aulast%3DCharron%26aufirst%3DJ.%26aulast%3DBaccarini%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DC-Raf%252C%2520but%2520not%2520B-Raf%252C%2520is%2520essential%2520for%2520development%2520of%2520K-Ras%2520oncogene-driven%2520non-small%2520cell%2520lung%2520carcinoma%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D652%26epage%3D663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Karreth, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frese, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeNicola, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baccarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span> </span><span class="NLM_article-title">C-Raf is required for the initiation of lung cancer by K-RasG12D</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">–</span> <span class="NLM_lpage">136</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=128-136&author=F.+A.+Karrethauthor=K.+K.+Freseauthor=G.+M.+DeNicolaauthor=M.+Baccariniauthor=D.+A.+Tuveson&title=C-Raf+is+required+for+the+initiation+of+lung+cancer+by+K-RasG12D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKarreth%26aufirst%3DF.%2BA.%26aulast%3DFrese%26aufirst%3DK.%2BK.%26aulast%3DDeNicola%26aufirst%3DG.%2BM.%26aulast%3DBaccarini%26aufirst%3DM.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26atitle%3DC-Raf%2520is%2520required%2520for%2520the%2520initiation%2520of%2520lung%2520cancer%2520by%2520K-RasG12D%26jtitle%3DCancer%2520Discovery%26date%3D2011%26volume%3D1%26spage%3D128%26epage%3D136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span> </span><span class="NLM_article-title">Conformation specific effects of Raf kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7332</span><span class="NLM_x">–</span> <span class="NLM_lpage">7341</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300613w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7332-7341&author=X.+Wangauthor=J.+Kim&title=Conformation+specific+effects+of+Raf+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm300613w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300613w%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DConformation%2520specific%2520effects%2520of%2520Raf%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7332%26epage%3D7341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Okaniwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirose, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yabuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchiyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sumita, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsutsumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tottori, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inui, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yano, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aertgeerts, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span> </span><span class="NLM_article-title">Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6478</span><span class="NLM_x">–</span> <span class="NLM_lpage">6494</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm400778d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2qsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6478-6494&author=M.+Okaniwaauthor=M.+Hiroseauthor=T.+Aritaauthor=M.+Yabukiauthor=A.+Nakamuraauthor=T.+Takagiauthor=T.+Kawamotoauthor=N.+Uchiyamaauthor=A.+Sumitaauthor=S.+Tsutsumiauthor=T.+Tottoriauthor=Y.+Inuiauthor=B.+C.+Sangauthor=J.+Yanoauthor=K.+Aertgeertsauthor=S.+Yoshidaauthor=T.+Ishikawa&title=Discovery+of+a+selective+kinase+inhibitor+%28TAK-632%29+targeting+pan-RAF+inhibition%3A+design%2C+synthesis%2C+and+biological+evaluation+of+C-7-substituted+1%2C3-benzothiazole+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives</span></div><div class="casAuthors">Okaniwa, Masanori; Hirose, Masaaki; Arita, Takeo; Yabuki, Masato; Nakamura, Akito; Takagi, Terufumi; Kawamoto, Tomohiro; Uchiyama, Noriko; Sumita, Akihiko; Tsutsumi, Shunichirou; Tottori, Tsuneaki; Inui, Yoshitaka; Sang, Bi-Ching; Yano, Jason; Aertgeerts, Kathleen; Yoshida, Sei; Ishikawa, Tomoyasu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6478-6494</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">With the aim of discovering a selective kinase inhibitor targeting pan-RAF kinase inhibition, we designed novel 1,3-benzothiazole derivs. based on our thiazolo[5,4-b]pyridine class RAF/VEGFR2 inhibitor and developed a regioselective cyclization methodol. for the C-7-substituted 1,3-benzothiazole scaffold utilizing meta-substituted anilines.  Eventually, we selected 7-cyano deriv. I (TAK-632) as a development candidate and confirmed its binding mode by cocrystal structure with BRAF.  Accommodation of the 7-cyano group into the BRAF-selectivity pocket and the 3-(trifluoromethyl)phenyl acetamide moiety into the hydrophobic back pocket of BRAF in the DFG-out conformation contributed to enhanced RAF potency and selectivity vs VEGFR2.  Reflecting its potent pan-RAF inhibition and slow off-rate profile, I demonstrated significant cellular activity against mutated BRAF or mutated NRAS cancer cell lines.  Furthermore, in both A375 (BRAFV600E) and HMVII (NRASQ61K) xenograft models in rats, I demonstrated regressive antitumor efficacy by twice daily, 14-day repetitive administration without significant body wt. loss.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2jcxKx47lWLVg90H21EOLACvtfcHk0ljsSHZKHBEKmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2qsrzL&md5=60ccb75bcf7d7772cdf21468e26c141f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm400778d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400778d%26sid%3Dliteratum%253Aachs%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DHirose%26aufirst%3DM.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DYabuki%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DSumita%26aufirst%3DA.%26aulast%3DTsutsumi%26aufirst%3DS.%26aulast%3DTottori%26aufirst%3DT.%26aulast%3DInui%26aufirst%3DY.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520kinase%2520inhibitor%2520%2528TAK-632%2529%2520targeting%2520pan-RAF%2520inhibition%253A%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520C-7-substituted%25201%252C3-benzothiazole%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6478%26epage%3D6494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Allgeier, M. C.; Flynn, D. L.; Kaufman, M. D.; Patel, P. J.; Wolfangel, C. D.</span><span> </span><span class="NLM_article-title">2-Amino, 6-phenyl substituted pyrido[2, 3-d]pyrimidine derivatives useful as raf kinase inhibitors</span>. WO2013134243,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+C.+Allgeier&author=D.+L.+Flynn&author=M.+D.+Kaufman&author=P.+J.+Patel&author=C.+D.+Wolfangel&title=2-Amino%2C+6-phenyl+substituted+pyrido%5B2%2C+3-d%5Dpyrimidine+derivatives+useful+as+raf+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllgeier%26aufirst%3DM.%2BC.%26atitle%3D2-Amino%252C%25206-phenyl%2520substituted%2520pyrido%255B2%252C%25203-d%255Dpyrimidine%2520derivatives%2520useful%2520as%2520raf%2520kinase%2520inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Peng, S.; Henry, J. R.; Kaufman, M. D.; Lu, W.; Smith, B. D.; Vogeti, S.; Wise, S.; Chun, L.; Buchanan, S.; Mochalkin, I.; Zhang, Y.; Van Horn, R.; Yin, T.; Zhang, X.; Yadav, V.; Chen, S.; Gong, X.; Ma, X.; Webster, Y.; Huber, L.; Kays, L.; Donoho, G.; Walgren, J.; McCann, D.; Patel, P.; Conti, I.; Plowman, G. D.; Starling, J. J.; Flynn, D. L.</span> Unpublished results.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Peng%2C+S.%3B+Henry%2C+J.+R.%3B+Kaufman%2C+M.+D.%3B+Lu%2C+W.%3B+Smith%2C+B.+D.%3B+Vogeti%2C+S.%3B+Wise%2C+S.%3B+Chun%2C+L.%3B+Buchanan%2C+S.%3B+Mochalkin%2C+I.%3B+Zhang%2C+Y.%3B+Van+Horn%2C+R.%3B+Yin%2C+T.%3B+Zhang%2C+X.%3B+Yadav%2C+V.%3B+Chen%2C+S.%3B+Gong%2C+X.%3B+Ma%2C+X.%3B+Webster%2C+Y.%3B+Huber%2C+L.%3B+Kays%2C+L.%3B+Donoho%2C+G.%3B+Walgren%2C+J.%3B+McCann%2C+D.%3B+Patel%2C+P.%3B+Conti%2C+I.%3B+Plowman%2C+G.+D.%3B+Starling%2C+J.+J.%3B+Flynn%2C+D.+L.+Unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DS." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Rohrs, B. R.</span><span> </span><span class="NLM_article-title">Biopharmaceutics modeling and the role of dose and formulation on oral exposure</span>. In  <span class="citation_source-book">Optimizing the “Drug-like” Properties of Leads in Drug Discovery</span>; <span class="NLM_contrib-group">Borchardt, R. T.; Kerns, E. H.; Hageman, M. J.; Thakker, D. R.; Stevens, J. L.</span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2006</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">IV</span>, pp  <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1007%2F978-0-387-44961-6_7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=151-166&author=B.+R.+Rohrsauthor=R.+T.+Borchardt&author=E.+H.+Kerns&author=M.+J.+Hageman&author=D.+R.+Thakker&author=J.+L.+Stevens&title=Optimizing+the+%E2%80%9CDrug-like%E2%80%9D+Properties+of+Leads+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1007%2F978-0-387-44961-6_7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-0-387-44961-6_7%26sid%3Dliteratum%253Aachs%26aulast%3DRohrs%26aufirst%3DB.%2BR.%26atitle%3DBiopharmaceutics%2520modeling%2520and%2520the%2520role%2520of%2520dose%2520and%2520formulation%2520on%2520oral%2520exposure%26btitle%3DOptimizing%2520the%2520%25E2%2580%259CDrug-like%25E2%2580%259D%2520Properties%2520of%2520Leads%2520in%2520Drug%2520Discovery%26aulast%3DBorchardt%26aufirst%3DR.%2BT.%26pub%3DSpringer%26date%3D2006%26volume%3DIV%26spage%3D151%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Oh, D.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curl, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amidon, G. L.</span><span> </span><span class="NLM_article-title">Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1023%2FA%3A1018947113238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=8456075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1SmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=264-270&author=D.-M.+Ohauthor=R.+L.+Curlauthor=G.+L.+Amidon&title=Estimating+the+fraction+dose+absorbed+from+suspensions+of+poorly+soluble+compounds+in+humans%3A+a+mathematical+model"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model</span></div><div class="casAuthors">Oh, Doo Man; Curl, Rane L.; Amidon, Gordon L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">264-70</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">A microscopic mass balance approach has been developed to predict the fraction dose absorbed of suspensions of poorly sol. compds.  The math. model includes four fundamental dimensionless parameters to est. the fraction dose absorbed: initial satn. (Is), absorption no. (An), dose no. (Do), and dissoln. no. (Dn).  The fraction dose absorbed (F) increases with increasing Is, An, and Dn and with decreasing Do.  At higher Dn and lower Do, the fraction dose absorbed reaches the maximal F, which depends only on An.  The dissoln. no. limit on F can appear at both lower Do and lower Dn.  It is shown that the extent fo drug absorption is expected to be highly variable when Dn and Do are approx. one.  Furthermore, by calcg. these dimensionless groups for a given compd., a formulation scientists can est. not only the extent of drug absorption but also the effect, if any, of particle size redn. on the extent of drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopaxhSvKyLwrVg90H21EOLACvtfcHk0liIrcUyIZT1lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1SmsLw%253D&md5=a83a50cd018fc09bd4b3142305199fa9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018947113238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018947113238%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DD.-M.%26aulast%3DCurl%26aufirst%3DR.%2BL.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DEstimating%2520the%2520fraction%2520dose%2520absorbed%2520from%2520suspensions%2520of%2520poorly%2520soluble%2520compounds%2520in%2520humans%253A%2520a%2520mathematical%2520model%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26spage%3D264%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Leuner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dressman, J. B.</span><span> </span><span class="NLM_article-title">Improving drug solubility for oral delivery using solid dispersions</span> <span class="citation_source-journal">Eur. J. Pharm. Biopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1016%2FS0939-6411%2800%2900076-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10840192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjslyju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2000&pages=47-60&author=C.+Leunerauthor=J.+B.+Dressman&title=Improving+drug+solubility+for+oral+delivery+using+solid+dispersions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Improving drug solubility for oral delivery using solid dispersions</span></div><div class="casAuthors">Leuner, C.; Dressman, J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutics and Biopharmaceutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">47-60</span>CODEN:
                <span class="NLM_cas:coden">EJPBEL</span>;
        ISSN:<span class="NLM_cas:issn">0939-6411</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 101 refs.  The soly. behavior of drugs remains one of the most challenging aspects in formulation development.  With the advent of combinatorial chem. and high throughput screening, the no. of poorly water sol. compds. has dramatically increased.  Although solid solns. have tremendous potential for improving drug soly., 40 yr of research have resulted in only a few marketed products using this approach.  With the introduction of new manufg. technologies such as hot melt extrusion, it should be possible to overcome problems in scale-up and for this reason solid solns. are enjoying a renaissance.  This article begins with an overview of the historical background and definitions of the various systems including eutectic mixts., solid dispersions and solid solns.  The remainder of the article is devoted to the prodn., the different carriers and the methods used for the characterization of solid dispersions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaO0ikKHQTgLVg90H21EOLACvtfcHk0liIrcUyIZT1lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjslyju7c%253D&md5=098a62ba5325f4cf33283bcec9421470</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS0939-6411%2800%2900076-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0939-6411%252800%252900076-X%26sid%3Dliteratum%253Aachs%26aulast%3DLeuner%26aufirst%3DC.%26aulast%3DDressman%26aufirst%3DJ.%2BB.%26atitle%3DImproving%2520drug%2520solubility%2520for%2520oral%2520delivery%2520using%2520solid%2520dispersions%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2000%26volume%3D50%26spage%3D47%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Janssens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Mooter, G.</span><span> </span><span class="NLM_article-title">Review: Physical chemistry of solid dispersions</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1571</span><span class="NLM_x">–</span> <span class="NLM_lpage">1586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1211%2Fjpp.61.12.0001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=19958579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFGqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=1571-1586&author=S.+Janssensauthor=G.+Van+den+Mooter&title=Review%3A+Physical+chemistry+of+solid+dispersions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Review: physical chemistry of solid dispersions</span></div><div class="casAuthors">Janssens, Sandrien; Van den Mooter, Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1571-1586</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Press</span>)
        </div><div class="casAbstract">A review.  With poorly sol. drug candidates emerging in the drug discovery pipeline, the importance of the solid dispersion formulation approach is increasing.  This strategy includes complete removal of drug crystallinity, and mol. dispersion of the poorly sol. compd. in a hydrophilic polymeric carrier.  The potential of this technique to increase oral absorption and hence bioavailability is enormous.  Nevertheless, some issues have to be considered regarding thermodn. instability, as well in supersatd. solns. that are formed upon dissoln. as in the solid state.  After a brief discussion on the historical background of solid dispersions and their current role in formulation, an overview will be given on the phys. chem. and stability of glass solns. as they form supersatd. solns., and during their shelf life.  Thorough understanding of these aspects will elicit conscious evaluation of carrier properties and eventually facilitate rational excipient selection.  Thus, full exploitation of the solid dispersion strategy may provide an appropriate answer to drug attrition due to low aq. soly. in later stages of development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2x4xN6QffoLVg90H21EOLACvtfcHk0lgAG-DiGiea_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFGqsr4%253D&md5=7c8c3efd9cf1fcc162e208ff8ffda813</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1211%2Fjpp.61.12.0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252Fjpp.61.12.0001%26sid%3Dliteratum%253Aachs%26aulast%3DJanssens%26aufirst%3DS.%26aulast%3DVan%2Bden%2BMooter%26aufirst%3DG.%26atitle%3DReview%253A%2520Physical%2520chemistry%2520of%2520solid%2520dispersions%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2009%26volume%3D61%26spage%3D1571%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Flynn, D. L.; Kaufman, M. D.; Patt, W. C.; Petillo, P. A.</span><span> </span><span class="NLM_article-title">Kinase inhibitors useful for the treatment of proliferative diseases</span>. WO2008034008,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=D.+L.+Flynn&author=M.+D.+Kaufman&author=W.+C.+Patt&author=P.+A.+Petillo&title=Kinase+inhibitors+useful+for+the+treatment+of+proliferative+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DKinase%2520inhibitors%2520useful%2520for%2520the%2520treatment%2520of%2520proliferative%2520diseases%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Flynn, D. L.; Kaufman, M. D.; Vogeti, L.; Wise, S. C.; Lu, W.; Smith, B. D.; Caldwell, T. M.; Patt, W. C.; Henry, J. R.; Hipskind, P. A.; Peng, S.</span><span> </span><span class="NLM_article-title">Raf inhibitor compounds</span>. WO2013134298,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=D.+L.+Flynn&author=M.+D.+Kaufman&author=L.+Vogeti&author=S.+C.+Wise&author=W.+Lu&author=B.+D.+Smith&author=T.+M.+Caldwell&author=W.+C.+Patt&author=J.+R.+Henry&author=P.+A.+Hipskind&author=S.+Peng&title=Raf+inhibitor+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DRaf%2520inhibitor%2520compounds%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Flynn, D. L.; Henry, J. R.; Hipskind, P. A.; Kaufman, M. D.; Lu, W.; Peng, S.; Smith, B. D.; Vogeti, L.; Wise, S. C.</span><span> </span><span class="NLM_article-title">2-Amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors</span>. WO2013134252,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=D.+L.+Flynn&author=J.+R.+Henry&author=P.+A.+Hipskind&author=M.+D.+Kaufman&author=W.+Lu&author=S.+Peng&author=B.+D.+Smith&author=L.+Vogeti&author=S.+C.+Wise&title=2-Amino%2C+6-phenyl+substituted+pyrido+%5B2%2C+3+-+d%5D+pyrimidine+derivatives+useful+as+raf+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3D2-Amino%252C%25206-phenyl%2520substituted%2520pyrido%2520%255B2%252C%25203%2520-%2520d%255D%2520pyrimidine%2520derivatives%2520useful%2520as%2520raf%2520kinase%2520inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Lavoie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thevakumaran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gavory, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padeganeh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiral, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duchaine, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouvier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicheri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therrien, M.</span><span> </span><span class="NLM_article-title">Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1038%2Fnchembio.1257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=23685672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=428-436&author=H.+Lavoieauthor=N.+Thevakumaranauthor=G.+Gavoryauthor=J.+J.+Liauthor=A.+Padeganehauthor=S.+Guiralauthor=J.+Duchaineauthor=D.+Y.+Maoauthor=M.+Bouvierauthor=F.+Sicheriauthor=M.+Therrien&title=Inhibitors+that+stabilize+a+closed+RAF+kinase+domain+conformation+induce+dimerization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization</span></div><div class="casAuthors">Lavoie, Hugo; Thevakumaran, Neroshan; Gavory, Gwenaelle; Li, John J.; Padeganeh, Abbas; Guiral, Sebastien; Duchaine, Jean; Mao, Daniel Y. L.; Bouvier, Michel; Sicheri, Frank; Therrien, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">428-436</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF kinases have a prominent role in cancer.  Their mode of activation is complex but critically requires dimerization of their kinase domains.  Unexpectedly, several ATP-competitive RAF inhibitors were recently found to promote dimerization and transactivation of RAF kinases in a RAS-dependent manner and, as a result, undesirably stimulate RAS/ERK pathway-mediated cell growth.  The mechanism by which these inhibitors induce RAF kinase domain dimerization remains unclear.  Here we describe bioluminescence resonance energy transfer-based biosensors for the extended RAF family that enable the detection of RAF dimerization in living cells.  Notably, we demonstrate the utility of these tools for profiling kinase inhibitors that selectively modulate RAF dimerization and for probing structural determinants of RAF dimerization in vivo.  Our findings, which seem generalizable to other kinase families allosterically regulated by kinase domain dimerization, suggest a model whereby ATP-competitive inhibitors mediate RAF dimerization by stabilizing a rigid closed conformation of the kinase domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhEtTJvsZ1FrVg90H21EOLACvtfcHk0lgAG-DiGiea_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvVSjtro%253D&md5=f866ae6da93c5e2d7fec53b8dc0e6f2a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1257%26sid%3Dliteratum%253Aachs%26aulast%3DLavoie%26aufirst%3DH.%26aulast%3DThevakumaran%26aufirst%3DN.%26aulast%3DGavory%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DPadeganeh%26aufirst%3DA.%26aulast%3DGuiral%26aufirst%3DS.%26aulast%3DDuchaine%26aufirst%3DJ.%26aulast%3DMao%26aufirst%3DD.%2BY.%26aulast%3DBouvier%26aufirst%3DM.%26aulast%3DSicheri%26aufirst%3DF.%26aulast%3DTherrien%26aufirst%3DM.%26atitle%3DInhibitors%2520that%2520stabilize%2520a%2520closed%2520RAF%2520kinase%2520domain%2520conformation%2520induce%2520dimerization%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D428%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Carnahan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babij, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonderfecht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagapudi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broome, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmontes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, T. L.</span><span> </span><span class="NLM_article-title">Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2399</span><span class="NLM_x">–</span> <span class="NLM_lpage">2410</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1158%2F1535-7163.MCT-10-0181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=20663930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2399-2410&author=J.+Carnahanauthor=P.+J.+Beltranauthor=C.+Babijauthor=Q.+Leauthor=M.+J.+Roseauthor=S.+Vonderfechtauthor=J.+L.+Kimauthor=A.+L.+Smithauthor=K.+Nagapudiauthor=M.+A.+Broomeauthor=M.+Fernandoauthor=H.+Khaauthor=B.+Belmontesauthor=R.+Radinskyauthor=R.+Kendallauthor=T.+L.+Burgess&title=Selective+and+potent+Raf+inhibitors+paradoxically+stimulate+normal+cell+proliferation+and+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth</span></div><div class="casAuthors">Carnahan, Josette; Beltran, Pedro J.; Babij, Carol; Le, Quynh; Rose, Mark J.; Vonderfecht, Steven; Kim, Joseph L.; Smith, Adrian L.; Nagapudi, Karthik; Broome, Martin A.; Fernando, Manory; Kha, Hue; Belmontes, Brian; Radinsky, Robert; Kendall, Richard; Burgess, Teresa L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2399-2410</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Raf inhibitors are under clin. investigation, specifically in patients with tumor types harboring frequent activating mutations in B-Raf.  Here, we show that cell lines and tumors harboring mutant B-Raf were sensitive to a novel series of Raf inhibitors (e.g., V600EB-Raf A375, IC50 on cells = 2 nmol/L; ED50 on tumor xenografts = 1.3 mg/kg).  However, in cells and tumors with wild-type B-Raf, exposure to Raf inhibitors resulted in a dose-dependent and sustained activation of mitogen-activated protein kinase signaling.  In some of these cell lines, Raf inhibition led to entry into the cell cycle, enhanced proliferation, and significantly stimulated tumor growth in vivo.  Inhibition with structurally distinct Raf inhibitors or isoform-specific small interfering RNA knockdown of Raf showed that these effects were mediated directly through Raf.  Either A-Raf or C-Raf mediated the Raf inhibitor-induced mitogen-activated protein kinase pathway activation in an inhibitor-specific manner.  These paradoxical effects of Raf inhibition were seen in malignant and normal cells in vitro and in vivo.  Hyperplasia of normal epithelial cells in the esophagus and the stomach was evident in mice with all efficacious Raf inhibitors (n = 8) tested.  An implication of these results is that Raf inhibitors may induce unexpected normal cell and tumor tissue proliferation in patients.  Mol Cancer Ther; 9(8); 2399-410.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN5Uws5uZF4rVg90H21EOLACvtfcHk0lgM5PVBFlGa4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D&md5=c2958b3c22d623571dea9bedf6835834</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0181%26sid%3Dliteratum%253Aachs%26aulast%3DCarnahan%26aufirst%3DJ.%26aulast%3DBeltran%26aufirst%3DP.%2BJ.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DLe%26aufirst%3DQ.%26aulast%3DRose%26aufirst%3DM.%2BJ.%26aulast%3DVonderfecht%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DNagapudi%26aufirst%3DK.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DKha%26aufirst%3DH.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DBurgess%26aufirst%3DT.%2BL.%26atitle%3DSelective%2520and%2520potent%2520Raf%2520inhibitors%2520paradoxically%2520stimulate%2520normal%2520cell%2520proliferation%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2399%26epage%3D2410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Yadav, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huber, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Horn, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starling, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckmann, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. B.</span><span> </span><span class="NLM_article-title">The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2253</span><span class="NLM_x">–</span> <span class="NLM_lpage">2263</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1158%2F1535-7163.MCT-14-0257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=25122067" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yisb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2253-2263&author=V.+Yadavauthor=T.+F.+Burkeauthor=L.+Huberauthor=R.+D.+Van+Hornauthor=Y.+Zhangauthor=S.+G.+Buchananauthor=E.+M.+Chanauthor=J.+J.+Starlingauthor=R.+P.+Beckmannauthor=S.+B.+Peng&title=The+CDK4%2F6+inhibitor+LY2835219+overcomes+vemurafenib+resistance+resulting+from+MAPK+reactivation+and+cyclin+D1+upregulation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation</span></div><div class="casAuthors">Yadav, Vipin; Burke, Teresa F.; Huber, Lysiane; Van Horn, Robert D.; Zhang, Youyan; Buchanan, Sean G.; Chan, Edward M.; Starling, James J.; Beckmann, Richard P.; Peng, Sheng-Bin</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2253-2263</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">B-RAF selective inhibitors, including vemurafenib, were recently developed as effective therapies for melanoma patients with B-RAF V600E mutation.  However, most patients treated with vemurafenib eventually develop resistance largely due to reactivation of MAPK signaling.  Inhibitors of MAPK signaling, including MEK1/2 inhibitor trametinib, failed to show significant clin. benefit in patients with acquired resistance to vemurafenib.  Here, we describe that cell lines with acquired resistance to vemurafenib show reactivation of MAPK signaling and upregulation of cyclin D1 and are sensitive to inhibition of LY2835219, a selective inhibitor of cyclin-dependent kinase (CDK) 4/6.  LY2835219 was demonstrated to inhibit growth of melanoma A375 tumor xenografts and delay tumor recurrence in combination with vemurafenib.  Furthermore, we developed an in vivo vemurafenib-resistant model by continuous administration of vemurafenib in A375 xenografts.  Consistently, we found that MAPK is reactivated and cyclin D1 is elevated in vemurafenib-resistant tumors, as well as in the resistant cell lines derived from these tumors.  Importantly, LY2835219 exhibited tumor growth regression in a vemurafenib-resistant model.  Mechanistic anal. revealed that LY2835219 induced apoptotic cell death in a concn.-dependent manner in vemurafenib-resistant cells whereas it primarily mediated cell-cycle G1 arrest in the parental cells.  Similarly, RNAi-mediated knockdown of cyclin D1 induced significantly higher rate of apoptosis in the resistant cells than in parental cells, suggesting that elevated cyclin D1 activity is important for the survival of vemurafenib-resistant cells.  Altogether, we propose that targeting cyclin D1-CDK4/6 signaling by LY2835219 is an effective strategy to overcome MAPK-mediated resistance to B-RAF inhibitors in B-RAF V600E melanoma.  Mol Cancer Ther; 13(10); 2253-63. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIfpmG0cDdI7Vg90H21EOLACvtfcHk0lgM5PVBFlGa4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yisb7M&md5=1dc6e49913933e10f0d9a27875e68705</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0257%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DBurke%26aufirst%3DT.%2BF.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DChan%26aufirst%3DE.%2BM.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DBeckmann%26aufirst%3DR.%2BP.%26aulast%3DPeng%26aufirst%3DS.%2BB.%26atitle%3DThe%2520CDK4%252F6%2520inhibitor%2520LY2835219%2520overcomes%2520vemurafenib%2520resistance%2520resulting%2520from%2520MAPK%2520reactivation%2520and%2520cyclin%2520D1%2520upregulation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2253%26epage%3D2263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Yadav, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrem, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henry, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starling, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. B.</span><span> </span><span class="NLM_article-title">Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">287</span><span class="NLM_x">, </span> <span class="NLM_fpage">28087</span><span class="NLM_x">–</span> <span class="NLM_lpage">28098</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=28087-28098&author=V.+Yadavauthor=X.+Zhangauthor=J.+Liuauthor=S.+Estremauthor=S.+Liauthor=X.+Q.+Gongauthor=S.+Buchananauthor=J.+R.+Henryauthor=J.+J.+Starlingauthor=S.+B.+Peng&title=Reactivation+of+mitogen-activated+protein+kinase+%28MAPK%29+pathway+by+FGF+receptor+3+%28FGFR3%29%2FRas+mediates+resistance+to+vemurafenib+in+human+B-RAF+V600E+mutant+melanoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DEstrem%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DGong%26aufirst%3DX.%2BQ.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DPeng%26aufirst%3DS.%2BB.%26atitle%3DReactivation%2520of%2520mitogen-activated%2520protein%2520kinase%2520%2528MAPK%2529%2520pathway%2520by%2520FGF%2520receptor%25203%2520%2528FGFR3%2529%252FRas%2520mediates%2520resistance%2520to%2520vemurafenib%2520in%2520human%2520B-RAF%2520V600E%2520mutant%2520melanoma%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D28087%26epage%3D28098" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Patricelli, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagannathan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aban, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okerberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herring, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nordin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weissig, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozarich, J. W.</span><span> </span><span class="NLM_article-title">In situ kinase profiling reveals functionally relevant properties of native kinases</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=10.1016%2Fj.chembiol.2011.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=21700206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotVejtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=699-710&author=M.+P.+Patricelliauthor=T.+K.+Nomanbhoyauthor=J.+Wuauthor=H.+Brownauthor=D.+Zhouauthor=J.+Zhangauthor=S.+Jagannathanauthor=A.+Abanauthor=E.+Okerbergauthor=C.+Herringauthor=B.+Nordinauthor=H.+Weissigauthor=Q.+Yangauthor=J.+D.+Leeauthor=N.+S.+Grayauthor=J.+W.+Kozarich&title=In+situ+kinase+profiling+reveals+functionally+relevant+properties+of+native+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases</span></div><div class="casAuthors">Patricelli, Matthew P.; Nomanbhoy, Tyzoon K.; Wu, Jiangyue; Brown, Heidi; Zhou, David; Zhang, Jianming; Jagannathan, Subadhra; Aban, Arwin; Okerberg, Eric; Herring, Chris; Nordin, Brian; Weissig, Helge; Yang, Qingkai; Lee, Jiing-Dwan; Gray, Nathanael S.; Kozarich, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">699-710</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Protein kinases are intensely studied mediators of cellular signaling, yet important questions remain regarding their regulation and in vivo properties.  Here, we use a probe-based chemoprotemics platform to profile several well studied kinase inhibitors against >200 kinases in native cell proteomes and reveal biol. targets for some of these inhibitors.  Several striking differences were identified between native and recombinant kinase inhibitory profiles, in particular, for the Raf kinases.  The native kinase binding profiles presented here closely mirror the cellular activity of these inhibitors, even when the inhibition profiles differ dramatically from recombinant assay results.  Addnl., Raf activation events could be detected on live cell treatment with inhibitors.  These studies highlight the complexities of protein kinase behavior in the cellular context and demonstrate that profiling with only recombinant/purified enzymes can be misleading.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopb21npuaC_rVg90H21EOLACvtfcHk0lj--L3XllGlEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotVejtbo%253D&md5=dda091b895850c95131f80c3aba9e8c7</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DPatricelli%26aufirst%3DM.%2BP.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJagannathan%26aufirst%3DS.%26aulast%3DAban%26aufirst%3DA.%26aulast%3DOkerberg%26aufirst%3DE.%26aulast%3DHerring%26aufirst%3DC.%26aulast%3DNordin%26aufirst%3DB.%26aulast%3DWeissig%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BD.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKozarich%26aufirst%3DJ.%2BW.%26atitle%3DIn%2520situ%2520kinase%2520profiling%2520reveals%2520functionally%2520relevant%2520properties%2520of%2520native%2520kinases%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D699%26epage%3D710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i53"><a href="/doi/suppl/10.1021/acs.jmedchem.5b00067">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_43433"></div></div></div></div></div><hr /></hr><p class="last">Synthetic procedures and analytical data for all compounds except for <b>13</b>. The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b00067">10.1021/acs.jmedchem.5b00067</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b00067/suppl_file/jm5b00067_si_001.pdf">jm5b00067_si_001.pdf (461.79 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-10%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b00067%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b00067" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679aa2cc8e6f3bfe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
